AI-Driven Drug Repurposing for Natural Products: Unlocking Hidden Therapeutic Potential

Abstract

This article explores the transformative role of Artificial Intelligence (AI) in repositioning natural products for new therapeutic uses. It examines the foundational value and unique challenges of natural products as a source for drug discovery. The article details key AI methodologies, including machine learning, deep learning, and network-based approaches, that are being applied to predict new indications. It addresses critical challenges such as data quality, model interpretability, and validation, offering strategies for optimization. Finally, the article presents validation frameworks, case studies across diseases like Alzheimer's and cancer, and a comparative analysis of leading AI platforms. Aimed at researchers and drug development professionals, it provides a comprehensive roadmap for integrating AI into natural product research to accelerate the development of safe, effective, and cost-efficient therapies[citation:1][citation:3][citation:8].

From Ancient Remedies to AI Pipelines: The Foundational Value of Natural Products in Drug Repurposing

The Historical Significance and Untapped Potential of Natural Products

For millennia, natural products (NPs) derived from plants, microbes, and other biological sources have formed the foundation of human pharmacotherapy. Their historical significance is profound, with early written records of herbal remedies dating back to ancient Egyptian (circa 1500 BCE), Chinese, and Sumerian civilizations [1]. This traditional knowledge has directly led to some of the most impactful medicines in the modern arsenal, including the analgesic morphine, the antimalarial artemisinin, and the anticancer agent paclitaxel [2] [1]. Approximately one-third of all FDA-approved small-molecule drugs over the past four decades are based on natural products or their direct derivatives, a statistic underscoring their irreplaceable role in treating critical areas like infectious diseases and oncology [2] [3].

Despite this legacy, the vast potential of nature's chemical library remains largely untapped. NPs exhibit unique structural complexity, biochemical specificity, and evolutionary optimization that make them privileged scaffolds for modulating human biology, particularly for challenging targets like protein-protein interactions [4] [3]. However, their very complexity has presented formidable challenges for modern, high-throughput drug discovery, leading to a decline in industrial pursuit from the 1990s onward [4].

Today, a transformative convergence is occurring. Advances in analytical chemistry, omics technologies, and—most critically—artificial intelligence (AI) are revitalizing NP research. This whitepaper posits that AI-driven drug repositioning represents a powerful and efficient strategy to unlock the latent therapeutic value of natural products. By applying machine learning (ML) and deep learning (DL) to decipher the polypharmacology of NPs, researchers can systematically identify new therapeutic indications for known natural compounds, accelerating the translation of nature's chemistry into novel treatments for unmet medical needs [5] [6].

Historical Legacy and Modern Challenges of Natural Product Drug Discovery

The Enduring Historical Impact

The historical journey of NPs from traditional medicine to modern drugs is marked by seminal discoveries. The 19th-century isolation of morphine from opium poppy established the paradigm of purifying single active ingredients from plants [1]. The 20th century witnessed the golden age of antibiotics from microbes (e.g., penicillin) and critical chemotherapeutics from plants (e.g., vinblastine, taxol) [2]. These successes are not historical artifacts; they demonstrate nature's ability to produce compounds with optimal bioactivity and drug-like properties. NPs typically possess greater molecular rigidity, more oxygen atoms, and higher stereochemical complexity compared to synthetic libraries, enabling them to interact with a broader swath of biological target space [4] [3].

Table 1: Representative Landmark Natural Product-Derived Drugs and Their Origins

Drug	Natural Source	Original/Primary Indication	Historical Significance
Morphine	Opium Poppy (Papaver somniferum)	Analgesia	One of the first pure plant isolates (1804); established the model for pharmacologically active compound isolation [1].
Quinine	Cinchona tree bark	Malaria	Early antimalarial; prototype for synthetic antimalarials [2] [1].
Penicillin	Penicillium mold	Bacterial Infections	First widely used antibiotic, revolutionizing medicine [2].
Artemisinin	Sweet Wormwood (Artemisia annua)	Malaria	Nobel Prize-winning discovery (2015); key for combating drug-resistant malaria [2] [1].
Paclitaxel (Taxol)	Pacific Yew tree (Taxus brevifolia)	Ovarian, Breast Cancer	Complex diterpene demonstrating efficacy in major cancers; spurred supply chain innovations [2] [1].
Dimethyl Fumarate	Derived from fumaric acid (found in Fumaria officinalis)	Psoriasis, Multiple Sclerosis	Example of a natural compound derivative successfully repositioned from psoriasis to MS [4].

Intrinsic Challenges in the Modern Pipeline

The transition to target-based, high-throughput screening in the late 20th century exposed key challenges in NP discovery:

• Technical Complexity: NP extracts are complex mixtures incompatible with standardized assays. Bioactivity-guided isolation is slow, and dereplication (avoiding rediscovery of known compounds) is difficult [4] [3].
• Supply and Synthesis: Sustainable sourcing and total synthesis of complex NPs are often non-trivial, hindering development [4].
• Intellectual Property (IP) and Access: Legal frameworks like the Nagoya Protocol create complexities regarding benefit-sharing and access to genetic resources [4].
• Mechanistic Deconvolution: NPs often act via polypharmacology or synergistic effects, making their precise molecular mechanisms of action (MoA) difficult to elucidate using reductionist approaches [2].

These challenges contributed to a waning of interest from major pharmaceutical companies. However, they also define the very opportunities that modern technologies, especially AI, are now poised to address.

The AI Revolution: A Framework for Natural Product Repositioning

AI, particularly ML and DL, provides a suite of tools to systematically analyze the complex, multi-dimensional data associated with NPs, thereby enabling rational drug repositioning. Repositioning existing NPs offers distinct advantages: known safety and pharmacokinetic profiles, reduced development costs (estimated at ~$300 million vs. $2.6 billion for de novo drugs), and a faster timeline to clinic (3-6 years on average) [6].

Table 2: Core AI/ML Methodologies for Natural Product Repositioning

Method Category	Key Techniques	Application in NP Repositioning	Key Advantage
Classical Machine Learning	Random Forest, Support Vector Machines (SVM), Logistic Regression [7] [6].	Building quantitative structure-activity relationship (QSAR) models to predict bioactivity or new targets for known NP structures.	Effective with smaller, curated datasets; good interpretability.
Deep Learning (DL)	Graph Neural Networks (GNNs), Convolutional Neural Networks (CNNs), Multilayer Perceptrons (MLPs) [5] [6] [8].	Directly learning from molecular graphs of NPs (e.g., SMILES, 2D/3D structure) to predict properties, targets, or disease associations.	Automates feature extraction; excels with large, complex data.
Network Pharmacology & Knowledge Graphs (KGs)	Heterogeneous network analysis, random walk algorithms, KG embedding (e.g., TransE, PairRE) [5] [6] [9].	Mapping NPs into multimodal networks linking herbs, ingredients, targets, pathways, and diseases to infer MoA and synergistic effects.	Captures system-level polypharmacology; ideal for multi-target NP actions.
Foundation Models & Zero-Shot Learning	Large-scale pre-trained models (e.g., TxGNN) on massive biomedical KGs [9].	Making predictions for diseases with no known treatments by transferring knowledge from biologically similar diseases.	Addresses the "cold-start" problem for rare/orphan diseases.

The Integrated AI-NP Repositioning Workflow

A state-of-the-art workflow for AI-driven NP repositioning integrates several steps, from data curation to experimental validation.

Title: AI-Driven Workflow for Natural Product Repositioning

• Data Integration & Curation: Diverse data on NPs (chemical structures, genomic, transcriptomic, bioactivity data) are aggregated from literature and databases. Knowledge Graphs (KGs) are constructed to link entities (drugs, targets, diseases, pathways) [5] [9].
• Model Development & Prediction: AI models are trained on this data. For instance, GNNs learn from the KG structure, while foundation models like TxGNN are pre-trained on vast biomedical networks to generate embeddings for drugs and diseases [8] [9].
• Candidate Ranking & Mechanistic Insight: Models score NP-disease pairs for potential activity. Network pharmacology approaches and explainable AI (XAI) modules (like TxGNN's Explainer) extract predictive rationales, such as key signaling pathways or target networks [5] [9].
• Experimental Validation: Top-ranked candidates undergo in silico validation (e.g., molecular docking) followed by in vitro and in vivo testing to confirm efficacy and proposed MoA [5] [10].

Case Studies & Experimental Validation of AI-Predicted Repurposing

Case Study 1: Network-Based Repurposing for Viral Infections

During the COVID-19 pandemic, AI demonstrated rapid repurposing potential. A knowledge graph approach identified baricitinib (an FDA-approved JAK1/2 inhibitor for rheumatoid arthritis) as a candidate for COVID-19. The model predicted its ability to inhibit host proteins (AAK1) involved in viral entry and its anti-inflammatory effect. This prediction was validated in vitro (reduced viral load in human liver spheroids) and later in clinical trials, leading to its emergency authorization [10].

Case Study 2: Unlocking the Therapeutic Potential of Broccoli – Sulforaphane

Sulforaphane, an isothiocyanate from broccoli, is a potent natural activator of the KEAP1/NRF2 pathway, a master regulator of cytoprotective and anti-inflammatory genes [4]. While its chemopreventive properties were known, AI and network analyses have helped systematically explore its repositioning potential for various conditions:

• Neurodevelopmental Disorders: Network pharmacology linking NRF2 activation to oxidative stress and inflammation pathways in autism spectrum disorder (ASD) provided a rationale. A subsequent placebo-controlled trial showed sulforaphane improved social responsiveness and behavior in young men with ASD [4].
• Oncology (Drug Resistance): AI-driven analysis of resistance pathways in estrogen receptor-positive (ER+) breast cancer identified NRF2 as a key node. This led to the development of SFX-01 (a stabilized sulforaphane formulation), which showed promise in phase II trials for reversing endocrine therapy resistance [4].
• Environmental Detoxification: Omics signatures of pollutant exposure guided trials in China, where sulforaphane-rich broccoli sprout extracts significantly increased the detoxification and excretion of airborne toxins like benzene [4].

Title: KEAP1/NRF2 Pathway: A Key Target for NP Repositioning

Detailed Experimental Protocol for Validating AI Predictions

Following AI-based prioritization, a tiered experimental validation protocol is essential.

Protocol: Multi-tier Validation of an AI-Predicted NP for a New Indication

Objective: To experimentally validate the predicted anti-inflammatory activity of a candidate NP (e.g., a flavonoid) for rheumatoid arthritis (RA).

Tier 1: In Silico and Biochemical Confirmation

• Molecular Docking & Dynamics: Perform docking of the NP into the predicted target (e.g., TNF-α, COX-2, or a kinase like JAK) using software like AutoDock Vina or Schrödinger Suite. Follow with molecular dynamics simulations to assess binding stability.
• Target-Based Biochemical Assay: Conduct a recombinant enzyme or protein-binding assay (e.g., ELISA, fluorescence polarization, kinase activity assay) to confirm direct interaction and measure IC₅₀.

Tier 2: In Vitro Phenotypic and Omics Analysis

• Cell-Based Assay: Treat relevant human cell lines (e.g., THP-1 macrophages or primary human synovial fibroblasts) with the NP. Measure the secretion of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) via ELISA or multiplex Luminex assay.
• Transcriptomics/Proteomics: Perform RNA-seq or quantitative proteomics on treated vs. untreated cells. Use pathway enrichment analysis (e.g., GSEA, Ingenuity Pathway Analysis) to verify if the NP's gene/protein signature reverses the disease-associated signature identified by the AI model.
• Network Pharmacology Validation: Construct a protein-protein interaction (PPI) network from omics-derived differentially expressed genes. Overlap this network with the AI model's predicted subnetwork to confirm key target nodes.

Tier 3: Ex Vivo and In Vivo Validation

• Ex Vivo Tissue Model: Test the NP on human RA synovial tissue explants in culture, assessing cytokine release and tissue viability.
• In Vivo Disease Model: Administer the NP in a standard murine collagen-induced arthritis (CIA) model. Monitor clinical scores (paw swelling), perform histopathological analysis of joints, and quantify systemic inflammatory markers.

Table 3: The Scientist's Toolkit: Key Reagents & Platforms for NP Repositioning Research

Research Reagent / Platform	Function & Application	Rationale
LC-HRMS (Liquid Chromatography-High Resolution Mass Spectrometry)	Metabolite profiling, dereplication, and characterization of NPs in complex extracts [4] [3].	Essential for ensuring compound identity, purity, and for annotating unknown analogues in bioactivity-guided fractionation.
NMR Spectroscopy	Definitive structural elucidation of novel NPs and confirmation of known structures [4].	Gold standard for determining the planar and stereochemical structure of complex natural products.
Knockout/Knockdown Cell Lines (CRISPR-Cas9)	Functional validation of AI-predicted molecular targets [4].	Confirms if the NP's bioactivity is dependent on the predicted target protein.
Multiplex Cytokine Assay Panels (Luminex/MSD)	High-throughput, quantitative profiling of inflammatory mediators in cell supernatants or serum [5].	Enables phenotypic validation of immunomodulatory NPs across multiple signaling pathways simultaneously.
Human iPSC-Derived Cells or Organoids	Phenotypic screening in disease-relevant human cell models [4].	Provides a more physiologically relevant in vitro system than immortalized cell lines for complex diseases.
Molecular Docking Software (e.g., AutoDock, Glide)	In silico prediction of NP binding poses and affinities to target proteins [10].	Provides a quick, cost-effective first pass for validating AI-predicted drug-target interactions.

The future of AI in NP repositioning lies in addressing current limitations and integrating emerging technologies. Key directions include:

• Overcoming Data Scarcity: Developing better "few-shot" and "zero-shot" learning models like TxGNN to make predictions for NPs or diseases with sparse data [9]. Creating standardized, minimal information (MI) standards for NP metadata (provenance, extraction, biological testing) is crucial for building high-quality datasets [5].
• Embracing Complexity: Moving beyond single-compartment models to micro-physiological systems (MPS) and digital twins that can model the synergistic, multi-target effects of NP formulations and their systemic pharmacokinetics [5].
• Generative AI for NP Optimization: Using generative models (e.g., GANs, VAEs) trained on NP chemical space to design optimized derivatives or novel scaffolds inspired by natural architectures, thereby overcoming synthesis or IP hurdles [5] [8].
• Explainable AI (XAI) for Trust and Discovery: Tools like TxGNN's Explainer, which reveals the multi-hop knowledge paths behind a prediction, are vital for building researcher trust and for generating novel biological hypotheses [9].

In conclusion, natural products possess an unparalleled historical significance and a vast, untapped reservoir of chemical diversity with direct therapeutic relevance. The integration of AI-driven drug repositioning strategies is poised to systematically mine this reservoir with unprecedented speed and precision. By transforming the discovery process from one of serendipity to one of prediction and rational design, this confluence of biology and computation holds the promise of unlocking a new generation of natural product-derived therapies for the most challenging human diseases.

Drug repositioning, the identification of new therapeutic uses for existing drugs, presents a strategic pathway to accelerate the development of treatments, particularly for diseases with limited options. This approach leverages existing safety and pharmacokinetic data, significantly reducing the time, cost, and risk associated with traditional drug development [6]. Artificial Intelligence (AI) has emerged as a transformative force in this field, capable of analyzing complex, high-dimensional biomedical datasets to predict novel drug-disease associations that are not immediately obvious [6].

The integration of AI is especially promising for the domain of Natural Product (NP) research. NPs, with their immense structural diversity and proven historical success as drug leads, represent a rich but notoriously challenging source for discovery. AI models are now being applied to predict the anticancer, anti-inflammatory, and antimicrobial activities of NPs, infer their mechanisms of action, and prioritize candidates for experimental validation [5].

However, the effective application of AI to NP-driven drug repositioning is hampered by three interrelated core challenges: the inherent chemical and biological complexity of NPs, the acute scarcity of high-quality, standardized data, and the pervasive irreproducibility of computational and experimental findings. This whitepaper provides an in-depth technical analysis of these challenges, framed within the AI drug repositioning paradigm, and offers detailed methodologies and solutions for researchers and drug development professionals.

Deconstructing the Core Challenges

The Multifaceted Complexity of Natural Products

The complexity of NPs is not a single barrier but a series of interconnected hurdles that complicate every stage of AI-driven analysis.

• Structural and Mixture Complexity: Unlike synthetic compound libraries, NPs are often isolated as complex mixtures. A single botanical extract contains hundreds of unique metabolites. This complexity confounds standard chemical representation methods (like SMILES strings) used in machine learning models and creates a "needle-in-a-haystack" problem for identifying the active constituent [5].
• Pharmacological Polyphony: NPs frequently exert therapeutic effects through polypharmacology—simultaneously modulating multiple biological targets and pathways. While this can be advantageous for treating complex diseases, it complicates the clear elucidation of a Mechanism of Action (MoA). AI models trained on single-target, single-pathway data may fail to capture or accurately predict these synergistic, network-wide effects [5].
• Provenance and Variability: The chemical profile of an NP is not static. It is influenced by a multitude of factors including plant genetics, growing conditions (soil, climate), harvest time, and post-harvest processing [11]. This batch-to-batch variability introduces significant noise into datasets, where the same species label may correspond to chemically distinct material, undermining model training and validation.

The following workflow diagram illustrates how this complexity propagates through a standard AI-driven NP discovery pipeline, creating points of ambiguity and uncertainty.

Diagram 1: Complexity in AI-NP Workflow. The diagram shows how inherent NP variability and chemical complexity introduce noise and uncertainty at multiple stages of the discovery pipeline.

The Critical Limitation of Data Scarcity

AI models are data-hungry. The performance of deep learning architectures, in particular, scales with the volume and quality of training data. NP research suffers from a severe data deficit, characterized by:

• Small and Imbalanced Datasets: High-quality, annotated bioactivity data for NPs is limited. Available datasets are often small and imbalanced, with many more known inactive compounds than active ones. This leads to models that are prone to overfitting and poor generalization to new chemical scaffolds [5].
• The "Long-Tail" Problem of Disease: A significant challenge for drug repositioning is addressing the "long tail" of diseases—those that are rare, complex, or poorly understood—which often have little to no approved therapies or associated research data. For example, approximately 92% of the 17,080 diseases in a large-scale medical knowledge graph had no FDA-approved drugs [9]. AI models struggle to make accurate predictions for these data-poor diseases.
• Heterogeneous and Non-Standardized Data: Existing NP data is scattered across publications, patents, and proprietary databases in inconsistent formats. Critical metadata regarding provenance, extraction methodology, and assay conditions is frequently missing, rendering data integration and model training difficult [11].

Table 1: Comparative Analysis of Drug Development Pathways

Development Metric	Traditional De Novo Drug Development	AI-Driven Drug Repositioning (General)	AI-Driven NP Repositioning (Current Challenge)
Average Cost	~$2.6 billion [6]	~$300 million [6]	Potentially lower, but data acquisition/standardization costs are high.
Development Timeline	10-15 years [6]	3-6 years [6]	Timeline extended by need for extensive NP characterization and validation.
Primary Data Challenge	High cost of generating novel compound & clinical data.	Integrating diverse, pre-existing biomedical datasets.	Extreme data scarcity, heterogeneity, and lack of standardized NP metadata [5].
Failure Risk in Late Stage	Very High	Reduced (known safety profile)	Uncertain: MoA for new indication may be complex/polypharmacological [5].

The Reproducibility Crisis in Computational NP Research

Reproducibility—the ability of an independent team to achieve the same results using the same data and methods—is a cornerstone of science. In AI-driven NP research, it is under severe threat from multiple angles [12].

• Computational Non-Determinism: Many AI models, especially complex deep learning architectures, have inherent non-determinism. Random factors in weight initialization, data shuffling, dropout regularization, and hardware-specific floating-point operations can lead to different outcomes across repeated training runs, even with identical code and data [12].
• Data Preprocessing Variability: Steps like normalization, feature selection, and handling missing data are often ad hoc and poorly documented. Applying different preprocessing pipelines to the same raw dataset can yield drastically different model inputs and, consequently, different predictions [12].
• Environment and Dependency Hell: Computational workflows depend on specific versions of software libraries, programming languages, and operating systems. A model that runs successfully in one environment may fail in another due to silent dependency conflicts, making long-term reproducibility nearly impossible without deliberate preservation efforts [13].

Table 2: Sources and Impacts of Irreproducibility in AI-NP Research

Source of Irreproducibility	Technical Description	Impact on NP Research
Model Non-Determinism	Stochastic elements in training (e.g., SGD, dropout, random seeds) lead to variable model parameters and outputs [12].	Different labs may validate different candidate rankings from the "same" AI screen, wasting resources.
Data Leakage	Information from the test set inadvertently influences the training process, inflating performance metrics [12].	Published models appear highly accurate but fail completely when applied to new NP libraries or biological assays.
Incomplete Data Documentation	Lack of detailed metadata on NP provenance, extraction, and assay conditions [11].	Impossible to recreate the exact training data conditions, preventing fair comparison or validation of published models.
Software & Environment Drift	Changes in underlying libraries or system architecture break computational workflows over time [13].	Landmark AI models for NP discovery become inoperable within a few years, halting follow-up research.

The diagram below maps the technical, data-centric, and human factors that converge to create the reproducibility crisis.

Diagram 2: Convergence to Irreproducibility. Multiple technical, data-centric, and human factors interact to undermine the reproducibility of AI-driven NP research.

Methodologies and Experimental Protocols for Addressing Challenges

Advanced AI Methodologies for Data-Scarce Environments

To overcome data scarcity, researchers must move beyond standard supervised learning.

• Protocol for Zero-Shot Learning with Foundation Models: Foundation models like TxGNN are pre-trained on massive, heterogeneous knowledge graphs (KGs) that integrate information on diseases, genes, pathways, and drugs [9]. For NP repositioning:

  • Knowledge Graph Construction: Integrate NP-specific data (structures, bioactivities, traditional uses) into a biomedical KG containing entities like genes, diseases, and approved drugs.
  • Model Pre-training: Use a Graph Neural Network (GNN) to learn embeddings for all entities and relationships in a self-supervised manner. The model learns to propagate information through the graph.
  • Zero-Shot Inference: To predict drugs for a disease with no known treatments, the model uses metric learning. It calculates a "disease signature" based on its neighboring entities in the KG (e.g., associated genes, phenotypes) and finds diseases with similar signatures. Knowledge is transferred from these similar, data-rich diseases to the target disease [9].
  • Explanation Generation: Employ an explainer module (e.g., GraphMask) to extract the subgraph of relationships (e.g., NP → modulates → Protein → involved_in → Disease) that contributed most to the prediction, providing a testable mechanistic hypothesis [9].

• Protocol for Few-Shot Learning with Transfer Learning:

  • Pre-train a Model on a Large, Source Domain: Train a deep learning model (e.g., a Graph Neural Network or Transformer) on a large, general-purpose chemical dataset with associated bioactivity (e.g., ChEMBL).
  • Feature Extraction or Fine-Tuning: For a small, target dataset of NP bioactivities:
    • Feature Extraction: Use the pre-trained model as a fixed feature extractor for the NP structures.
    • Fine-Tuning: Gently update the weights of the final layers (or the entire model) using the small NP dataset. Heavy regularization (e.g., dropout, weight decay) is critical to prevent overfitting [14].

Robust Experimental Validation Workflows

AI predictions are hypotheses that require rigorous biological validation. A reproducible validation protocol is essential.

• Candidate Prioritization & Orthogonal Confirmation:
  • Tiered Screening: Use AI to rank NP candidates. Subject the top-tier candidates to in silico docking or pharmacophore modeling for initial triaging.
  • Orthogonal Assay Design: Validate predicted activity using an assay method independent of the data used for training the AI model. For example, if the model was trained on gene expression data, validate with a cell viability assay or a protein-binding assay (e.g., SPR) [5].
  • Mechanistic "Add-Back" Experiments: If the AI model predicts a specific target or pathway, design experiments to confirm it (e.g., gene knockdown/overexpression, use of selective inhibitors). If the prediction is polypharmacological, attempt to reconstitute the full effect by combining selective modulators of the individual predicted targets [5].

Implementing Reproducible Computational Practices

Reproducibility must be engineered into the computational workflow from the start.

• Protocol for Containerized, Reproducible Analysis (e.g., using Neurodesk/Apptainer):

  • Environment Capture: At the beginning of a project, use a containerization tool (e.g., Apptainer, Docker) to define the exact software environment, including OS, library versions, and analysis tools.

  • Workflow Scripting: Write analysis scripts (in Python/R) that read data from a specified input directory and write results to an output directory. Avoid hard-coded paths.

  • Persistent Citation: Upload the finalized container to a repository like Zenodo or CodeOcean to obtain a Digital Object Identifier (DOI). Publish the analysis scripts and a "run.sh" master script in a version-controlled repository (e.g., GitHub) [13].
  • Peer Review & Replication: Reviewers or other researchers can download the container and the scripts, execute the "run.sh" file, and perfectly replicate the computational environment and results, regardless of their local system configuration [13].

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential Reagents and Resources for Reproducible NP Research

Item Category	Specific Item/Resource	Function & Importance for Reproducibility
NP Reference Standards & Controls	Certified Reference Materials (CRMs) from NIST, NIFDC, or USP. Commercially available, chemically pure compounds (e.g., curcumin, resveratrol).	Provide an unambiguous chemical benchmark for identity, purity, and quantitative analysis. Essential for calibrating instruments, validating extraction yields, and serving as positive/negative controls in bioassays [11].
Standardized Plant Extracts	Extracts with defined chemical fingerprints (e.g., via HPLC/UPLC), available from specialized suppliers (e.g., ChromaDex, Sigma-Aldrich's Extrasynthese).	Mitigate provenance and batch variability. Using the same characterized extract across labs allows for direct comparison of biological results. Critical for in vivo studies where chemical consistency is paramount [11].
Orthogonal Assay Kits	Cell-based reporter assay kits (e.g., luciferase-based NF-κB, AP-1). ELISA kits for cytokine detection. Commercial kinase or epigenetic enzyme panels.	Enable independent validation of AI-predicted mechanisms. Using a different methodological principle than the training data strengthens the evidence for a predicted bioactivity [5].
Metabolomics Standards	Stable isotope-labeled internal standards (e.g., 13C-labeled amino acids, lipids). MS/MS spectral libraries (e.g., GNPS, MassBank).	Ensure accurate quantification and identification of metabolites in complex NP mixtures. Labeled standards correct for instrument variability and recovery losses. Public spectral libraries aid in transparent compound annotation [5].
FAIR Data Repositories	GNPS for metabolomics [5]. PubChem for bioactivity. The Natural Products Atlas. GitHub/GitLab for code. Zenodo/Synapse for datasets.	Facilitate Findable, Accessible, Interoperable, and Reusable (FAIR) data and code sharing. Depositing raw data, processed features, and analysis code is non-negotiable for reproducible, collaborative science [13].
Computational Environment Tools	Containerization platforms (Apptainer, Docker). Workflow managers (Nextflow, Snakemake). Package managers (Conda, Pipenv).	Freeze the computational environment to guarantee that software dependencies and versions are preserved, eliminating "works on my machine" problems and ensuring long-term executable reproducibility [13].

A Strategic Roadmap for the Field

To advance AI-driven NP drug repositioning, a concerted effort across the community is required. The following integrated strategy addresses the tripartite challenge:

• Establish Minimal Information Standards: Develop and adopt community-agreed "Minimal Information for Natural Product AI (MINPAI)" standards. These should mandate reporting of critical metadata: precise biological source, extraction protocol, quantitative chemical characterization data (e.g., HPLC fingerprint, LC-MS feature table), and detailed assay conditions for any data used to train or validate AI models [5] [11].
• Create Curated, Benchmark Datasets: Funding agencies and consortia should sponsor the creation of publicly available, gold-standard benchmark datasets. These would include rigorously characterized NP libraries (physical or virtual) paired with standardized, multi-assay bioactivity profiles. They will serve as common ground for developing and fairly comparing AI algorithms [5].
• Mandate Reproducible Research Artifacts: Journals and funding bodies must strengthen mandates. Publication should require the sharing of both data and code within containerized, executable research objects that carry a DOI [13]. The computational peer review of these artifacts should be incentivized.
• Adopt Advanced AI Paradigms Institutionally: Research groups should prioritize investing expertise in next-generation AI methods specifically designed for data-scarce, complex scenarios. Mastery of foundation models, few-shot/zero-shot learning, and geometric deep learning (for graph-structured NP data) will be a key differentiator for impactful research [14] [9].
• Integrate Microphysiological Systems (MPS): To generate more predictive human-relevant data and tackle complexity, invest in MPS ("organ-on-a-chip") and their digital twin counterparts. These systems can model polypharmacology in tissue-level contexts and generate high-quality data for training next-generation AI models [5].

By systematically addressing complexity through rigorous characterization, combating data scarcity with innovative AI and shared resources, and engineering reproducibility into every step of the pipeline, the field of AI-driven natural product research can fully realize its potential to deliver novel, effective, and repurposed therapeutics to patients.

Drug repurposing (also known as drug repositioning, reprofiling, or retasking) is defined as the strategic identification and development of new therapeutic applications for existing drugs, whether they are approved, shelved, or in clinical investigation [15]. This approach stands in stark contrast to traditional de novo drug discovery, offering a compelling alternative that maximizes the therapeutic and commercial potential of known molecular entities [16]. The core value proposition lies in leveraging the extensive existing knowledge of a compound's safety, pharmacokinetics, and manufacturability, thereby bypassing many of the most resource-intensive and failure-prone stages of early development [17] [15].

The evolution of drug repurposing marks a transition from serendipitous discovery to a systematic, data-driven science [16]. Historic successes, such as sildenafil (from angina to erectile dysfunction) and thalidomide (from a sedative to a treatment for multiple myeloma), were often born from astute clinical observation [18] [16]. Today, the field is propelled by advances in computational biology, artificial intelligence (AI), and network pharmacology, enabling the rational prediction of new drug-disease associations [19] [20]. This whitepaper delineates the definitive economic and temporal advantages of drug repurposing over conventional discovery, framing the discussion within the transformative context of AI-driven repositioning of natural products.

Quantifying the Advantage: Economic and Temporal Efficiencies

The economic burden of traditional drug discovery has become a critical impediment to innovation. Analyses consistently show that developing a novel drug requires an investment ranging from $2 billion to $3 billion and a timeline spanning 10 to 17 years, from initial concept to market approval [19] [16]. This process is characterized by exceptionally high attrition, with only approximately 11% of candidates entering Phase I trials ultimately achieving approval [19].

Drug repurposing fundamentally alters this risk-reward calculus. By building upon established safety and manufacturing data, repurposing candidates can reach the market in 3 to 12 years, representing an average acceleration of 5 to 7 years [16] [15]. Financially, the mean development cost is estimated at $300 million, constituting a 50-60% reduction compared to de novo discovery [19] [15]. This efficiency stems primarily from bypassing or significantly de-risking preclinical through Phase I clinical stages [16]. Consequently, the probability of regulatory success for a repurposed drug that has passed Phase I is substantially higher, with estimates as high as 30% [16] [15].

Table 1: Comparative Analysis of De Novo Discovery vs. Drug Repurposing

Development Metric	De Novo Drug Discovery	Drug Repurposing	Advantage
Average Timeline	10–17 years [19] [16]	3–12 years [16] [15]	5–7 years faster [15]
Average Cost	$2–3 billion [19] [16]	~$300 million [19] [15]	50-60% cost reduction [15]
Typical Approval Rate (from Phase I)	~11% [19]	Up to 30% [16] [15]	~3x higher success rate
Key Risk Profile	High risk of failure due to unknown safety/toxicity [16]	Lower risk; established human safety profile [17]	Substantially de-risked

Mechanistic Approaches to Systematic Repurposing

Modern repurposing strategies have moved beyond chance observation to structured methodologies, which can be categorized by their starting point.

• Disease-Centric Approaches: Beginning with a specific medical condition, researchers analyze disease mechanisms, genetic signatures, and molecular pathways to identify existing drugs that could counteract pathological processes [20]. This approach is dominant in the market, holding a 43% revenue share due to its focused and efficient identification of drug-disease relationships [21].
• Target-Centric Approaches: This method focuses on a specific biological target (e.g., a protein or pathway) implicated in a disease and screens existing drug libraries for compounds that interact with it [20]. It is increasingly powered by advances in genomics, proteomics, and AI [21].
• Drug-Centric Approaches: Starting with a known compound, researchers explore its polypharmacology—its interactions with multiple biological targets—to predict new therapeutic applications based on its molecular structure or side-effect profile [20].
• Therapeutic Area Expansion: Repurposing within the same therapeutic area (e.g., from one cancer type to another) accounts for 68% of current activity, as shared disease biology reduces uncertainty [21]. Conversely, cross-therapeutic repurposing (e.g., from infectious disease to oncology) represents a significant growth frontier driven by AI [21].

The AI Revolution in Drug Repurposing

Artificial Intelligence has become the cornerstone of modern, systematic repurposing, capable of integrating and analyzing vast, heterogeneous biomedical datasets to generate testable hypotheses [6].

Core AI/ML Methodologies:

• Machine Learning (ML): Algorithms such as Random Forests, Support Vector Machines (SVM), and Logistic Regression are used to classify drug-disease associations and predict repurposing success based on features derived from chemical, biological, and clinical data [6] [20].
• Deep Learning (DL): Convolutional Neural Networks (CNNs) and Graph Neural Networks (GNNs) excel at processing complex molecular structures and biological interaction networks, uncovering non-obvious patterns [6] [20].
• Network-Based Approaches: These methods model biological systems as interconnected graphs (e.g., protein-protein, drug-target, disease-gene networks). Techniques like random walk algorithms quantify the proximity between drugs and disease modules within these networks to identify repurposing candidates [6].
• Literature Mining & Semantic Inference: Natural Language Processing (NLP) analyzes the vast corpus of scientific literature and clinical records to extract latent relationships between drugs, targets, and diseases that are not captured in structured databases [22] [20].

Table 2: Key AI/ML Algorithms in Drug Repurposing

Algorithm Category	Example Techniques	Primary Application in Repurposing	Typical Data Sources
Classical Machine Learning	Random Forest, SVM, Logistic Regression [6]	Classifying drug-disease pairs; ranking candidate likelihood [20]	Chemical descriptors, target profiles, clinical outcomes
Deep Learning	Convolutional Neural Networks (CNN), Graph Neural Networks (GNN) [6]	Predicting molecular binding affinity; analyzing heterogeneous biological networks [20]	Molecular graphs, omics data, protein structures
Network Analysis	Random Walk, Network Propagation [6]	Measuring drug-disease proximity in interactomes; identifying module perturbations [6]	Protein-protein interactions, drug-target maps, disease genes
Natural Language Processing (NLP)	Named Entity Recognition, Relation Extraction [22]	Mining novel associations from literature and clinical notes [20]	PubMed abstracts, electronic health records, patent texts

Diagram 1: AI-Driven Systematic Repurposing Workflow (100 chars)

AI-Driven Repositioning of Natural Products: A Thesis Framework

Natural products (NPs) and traditional medicine formulations represent an invaluable reservoir of chemical diversity with proven bioactivity but often ill-defined mechanisms of action. AI is uniquely positioned to unlock their repurposing potential, creating a powerful synergy between traditional knowledge and cutting-edge computation [5].

AI Applications in NP Repurposing:

• Activity and Target Prediction: Machine learning and deep learning models (e.g., graph neural networks) are trained to predict anticancer, anti-inflammatory, and antimicrobial activities of NP-derived compounds, guiding experimental validation [5].
• Mechanism Elucidation: Network pharmacology models construct herb-ingredient-target-pathway graphs to propose synergistic effects and plausible mechanisms for complex traditional formulations [5].
• Omics Integration: AI gates operational multi-omics data—such as transcriptomic signature reversal, proteome-scale target engagement, and metabolomic feature networking—to prioritize NP candidates for reproducible lab validation [5].

Critical Challenges & Thesis Focus: A thesis on this topic must address persistent field-wide barriers: the "small data" problem of unique NPs, batch variability, incomplete provenance, and data imbalance [5]. Proposed solutions include developing minimal information standards for NP metadata, applying scaffold and time-split benchmarks for model validation, and using uncertainty-aware AI models to gate experimental work [5]. This frames a critical research agenda for using AI to transition NP repurposing from retrospective analysis to prospectively validated, mechanistically grounded translation.

Diagram 2: AI-Powered Natural Product Repurposing Pipeline (96 chars)

The Scientist's Toolkit: Essential Research Reagents & Platforms

Transitioning from computational prediction to validated therapeutic hypothesis requires a suite of advanced experimental platforms.

Table 3: Research Reagent Solutions for Validation

Tool/Platform	Function in Repurposing Research	Key Application
High-Throughput/Content Screening (HTS/HCS)	Rapid phenotypic screening of drug libraries against disease-relevant cellular models [15].	Initial in vitro validation of AI-predicted candidates.
Organoids & Organ-on-a-Chip	Microphysiological systems that mimic human tissue and organ complexity for efficacy and toxicity testing [18] [15].	Translational bridge between cell assays and in vivo models.
CRISPR-Cas9 Screening	Genome-wide functional genomics to identify essential genes and validate drug mechanism of action [16].	Confirming on- and off-target effects of repurposed drugs.
Proteomics & Chemoproteomics	System-wide profiling of protein expression and drug-protein interactions [16].	Uncovering novel binding partners and polypharmacology.
Validated Reporter Cell Lines	Engineered cells with luminescent or fluorescent readouts for specific pathways (e.g., Wnt/β-catenin, NF-κB) [18].	Mechanistic validation of drug effects on signaling pathways.

Navigating Challenges and Future Directions

Despite its advantages, drug repurposing faces significant headwinds. Intellectual property (IP) protection for new uses of existing molecules, especially off-patent drugs, is complex and can undermine commercial incentives [17] [15]. Regulatory pathways, while flexible (e.g., FDA's 505(b)(2)), still require robust evidence for the new indication [17] [19]. Scientific challenges include the frequent lack of dose rationale for the new disease and the fact that pharmacological inhibition does not always phenocopy genetic target perturbation [17] [19].

The future market is poised for growth, projected to reach $59.30 billion by 2034 [21]. Key trends include the rising dominance of biologics repurposing (62% market share) due to their target specificity and the accelerated growth of target-centric approaches driven by AI [21]. The future of the field, particularly for NPs, hinges on creating collaborative networks that unite academia, industry, and regulators, alongside continued investment in explainable AI and standardized validation frameworks to translate computational promise into patient benefit [17] [5].

Drug repurposing definitively offers a faster, less costly, and de-risked alternative to de novo drug discovery. Its economic and temporal advantages are quantifiable and significant, reshaping pharmaceutical R&D strategy. The integration of advanced AI methodologies is transforming repurposing from a serendipitous endeavor into a predictive, systematic discipline. This is particularly transformative for the natural product domain, where AI can decode complex mechanisms and unlock vast, untapped therapeutic potential. As the field matures, overcoming translational, IP, and data-quality challenges through collaborative innovation will be crucial to fully realizing the promise of repurposing for addressing unmet medical needs.

The convergence of artificial intelligence (AI) and natural product (NP) science represents a foundational shift in drug discovery. Natural products, with their unparalleled structural diversity and proven biological relevance, have historically been a prolific source of therapeutics. However, their modern repurposing for new diseases has been hampered by complexity, data fragmentation, and the serendipity of traditional methods [5] [23]. AI emerges as the critical catalyst to systematically unlock this potential, transforming repurposing from a low-probability endeavor into a high-throughput, rational pipeline.

The economic and temporal imperative is clear. Traditional de novo drug development costs approximately $2.6 billion and spans 10-15 years, while repurposing an existing compound can cost around $300 million and take 3-6 years [6]. For natural products, which often have established safety profiles from traditional use or prior investigation, this advantage is magnified. The global drug repurposing market, valued at $34.08 billion in 2024, is projected to grow to $53.69 billion by 2033, driven significantly by AI and big data integration [24]. This whitepaper delineates the technical architecture of AI-driven natural product repurposing, providing researchers with a roadmap to harness these transformative tools.

Foundational AI Methodologies for Repurposing

AI in drug repurposing is not a monolithic tool but a suite of complementary methodologies, each suited to different aspects of the prediction and validation pipeline. Understanding their operational principles is essential for experimental design.

Core Machine Learning (ML) Frameworks

ML algorithms learn patterns from data to make predictions without explicit programming [6]. Their application in NP repurposing is varied:

• Supervised Learning: Used for quantitative structure-activity relationship (QSAR) models and bioactivity classification. Algorithms like Random Forest (RF) and Support Vector Machines (SVM) are trained on labeled datasets (e.g., compounds with known "active" or "inactive" status against a target) to predict the activity of new NPs [6].
• Unsupervised Learning: Applied to explore the chemical space of natural products, identify novel clusters, or detect patterns in untargeted metabolomics data. Principal Component Analysis (PCA) is fundamental for dimensionality reduction and visualization [6].
• Semi-supervised Learning: Crucial for leveraging the vast amounts of unlabeled NP data (e.g., uncharacterized spectral features) alongside smaller, labeled datasets to build more robust models [6].

Deep Learning (DL) and Advanced Architectures

DL, a subset of ML based on deep artificial neural networks, excels at processing high-dimensional, unstructured data [6].

• Graph Neural Networks (GNNs): This is a pivotal architecture for NPs. GNNs directly operate on molecular graphs where atoms are nodes and bonds are edges, natively learning structural and topological features that are critical for NP bioactivity [5].
• Convolutional Neural Networks (CNNs): While known for image analysis, CNNs can be applied to spectral data (e.g., mass spectrometry, NMR) or 2D molecular grid representations to extract diagnostic features for classification [6].
• Natural Language Processing (NLP) & Large Language Models (LLMs): These tools mine vast scientific literature and unstructured biomedical databases to extract hidden drug-disease associations, standardize herbal medicine information, and generate testable hypotheses [5] [23].

Network-Based & Multimodal Approaches

These methods move beyond the single molecule to model complex biological systems.

• Network Pharmacology: Constructs "herb–ingredient–target–pathway–disease" graphs to propose mechanisms and synergistic effects of complex NP mixtures [5].
• Heterogeneous Knowledge Graph Mining: Integrates multimodal data (chemical, genomic, phenotypic) into a unified graph structure. Algorithms then perform link prediction to infer novel, non-obvious relationships between a natural product node and a disease node [6] [23]. The TxGNN model, for example, uses this approach to predict drug candidates for rare diseases [24].

Table 1: Core AI/ML Approaches in Natural Product Repurposing

Approach Category	Key Algorithms/Models	Primary Application in NP Repurposing	Typical Input Data
Classical Machine Learning	Random Forest (RF), SVM, PCA	Bioactivity classification, QSAR, chemical space exploration	Structural fingerprints, assay data, physicochemical descriptors
Deep Learning (DL)	Graph Neural Networks (GNNs), CNNs, Multilayer Perceptrons (MLPs)	Molecular property prediction, spectral data analysis, advanced QSAR	Molecular graphs, mass/NMR spectra, 3D conformers
Natural Language Processing	Transformer-based LLMs (e.g., BERT, GPT variants)	Literature mining, hypothesis generation, data curation	Scientific text, patents, electronic health records
Network & Knowledge-Based	Network propagation, Graph embedding, Link prediction	Mechanism inference, polypharmacology, predicting novel indications	Protein-protein interaction networks, omics data, biomedical knowledge graphs

Data Integration: The Critical Path from Fragmentation to Knowledge

The single greatest technical challenge in AI-driven NP research is data modality and fragmentation [23]. NP data is inherently multimodal—encompassing genomic (BGCs), spectroscopic (MS, NMR), structural (2D/3D), and phenotypic (assay) information—and is scattered across specialized, non-interoperable repositories.

The Knowledge Graph as a Unifying Solution

A Natural Product Science Knowledge Graph (NP-KG) is proposed as the essential data infrastructure to overcome this barrier [23]. Unlike a traditional database, a KG represents entities (e.g., a compound, a gene, a disease) as nodes and the relationships between them (e.g., "binds to," "inhibits," "is associated with") as edges. This structure natively captures the complexity and interconnectedness of biological systems.

• Construction: An NP-KG integrates diverse data: chemical structures from COCONUT or NPASS, spectral libraries from GNPS, genomic data from MIBiG, and bioactivity data from ChEMBL, linked via standardized ontologies [23].
• Function: It enables sophisticated causal inference and reasoning. An AI model can traverse the graph to answer complex queries like, "Which NPs with a xanthone scaffold that target kinase X are also predicted to modulate pathway Y implicated in disease Z?"

Diagram 1: Structure of a multimodal Natural Product Knowledge Graph (NP-KG).

The AI-Driven Repurposing Workflow

An integrated workflow leverages the NP-KG and AI models to systematically identify repurposing candidates.

Diagram 2: Integrated AI workflow for natural product repurposing.

Experimental Validation: From AI Prediction to Bench Verification

AI predictions are hypotheses requiring rigorous biological validation. A tiered experimental protocol is essential.

Protocol for Validating AI-Predicted NP-Target Interactions

Objective: To confirm the binding and functional activity of an AI-predicted natural product against a novel target protein.

• Compound Acquisition & Preparation: Source the predicted NP (e.g., from commercial libraries, in-house collections, or custom synthesis). Prepare a 10 mM stock solution in DMSO, with serial dilutions for assays. Critical Control: Include a well-characterized inhibitor/activator of the target as a positive control.
• Primary Binding Assay: Employ a surface plasmon resonance (SPR) or microscale thermophoresis (MST) assay to measure direct binding affinity (KD). Perform experiments in triplicate across a minimum of six compound concentrations.
• Functional Enzymatic/Cellular Assay: Based on target biology, perform a functional assay (e.g., kinase activity, receptor antagonism/agonism). Use a cell line engineered with a reporter (e.g., luciferase) under the control of the target pathway. Data Analysis: Generate dose-response curves to calculate IC50/EC50 values.
• Specificity Screening: Counter-screen against a panel of related targets (e.g., kinase panel) to assess selectivity and validate the AI model's precision.
• Phenotypic Confirmation in Complex Models: Test the NP in a disease-relevant ex vivo or micro-physiological system (e.g., patient-derived organoid). Measure downstream phenotypic endpoints (e.g., cytokine secretion, cell viability, biomarker expression) to confirm the predicted therapeutic effect [5].

The Scientist's Toolkit: Key Research Reagent Solutions

Table 2: Essential Research Tools for AI-Driven NP Repurposing Validation

Reagent/Material Category	Specific Examples	Function in Validation Pipeline
AI-Prioritized Compound Libraries	NPCARE, NORMAN, In-house NP fraction libraries	Source of physical compounds for testing AI-generated hypotheses.
High-Content Screening Assays	Multiparameter imaging, High-content cytometers (e.g., ImageStream)	Enable phenotypic screening in complex cell models, generating rich data for AI model feedback.
Multi-Omics Analysis Kits	RNA-Seq kits, Phosphoproteomic arrays, Untargeted metabolomics platforms	Generate mechanistic data (transcriptomic signature reversal, proteomic engagement) to confirm AI-predicted MOA [5].
Biosensor-Enabled Systems	SPR chips (Biacore), MST-capable systems, Label-free cellular impedance systems	Provide quantitative, real-time binding and functional data for target validation.
Advanced Cell Culture Models	Patient-derived organoids (PDOs), 3D spheroids, Organ-on-a-chip microfluidic systems	Provide physiologically relevant models for confirming therapeutic efficacy and safety predictions.

Market Landscape, Challenges, and Strategic Future

Economic and Regional Landscape

The AI-driven repurposing market is growing dynamically, with distinct regional drivers [24] [25].

Table 3: Global Drug Repurposing Market Landscape and Projections

Region	Market Size (2025E)	Projected CAGR (2025-2033)	Key Growth Drivers
North America	Dominant Share (38.7%) [24] ~$280.9M [25]	13.4% [25]	Strong R&D investment, AI biotech hubs, high rare disease prevalence.
Europe	~29% Share [24] ~$220.2M [25]	13.9% [25]	EU-funded initiatives (e.g., REMEDi4ALL), adaptive EMA regulations.
Asia-Pacific	~24% Share [24] ~$182.2M [25]	17.6% (Fastest) [25]	Rising healthcare investment, government incentives, expanding CRO sector.
Global Total	$35.84B (2025) [24] / $759.2M (2025) [25]	5.18% [24] / 15.6% [25]	Note: Size disparity due to different study scopes (total market vs. segment).

Persistent Challenges and Technical Hurdles

Despite progress, significant barriers remain:

• Data Quality & Bias: NP datasets are often small, imbalanced, and suffer from "batch effect" variability, leading to model overfitting and poor generalizability [5] [23].
• Interpretability & Causality: Many complex AI models are "black boxes." Explaining why a prediction was made is critical for scientific acceptance and mechanism-driven research [5].
• IP and Regulatory Pathways: Repurposing off-patent NPs presents commercial challenges. Regulatory agencies are developing pathways like the FDA's 505(b)(2), but clarity is still evolving [24].

Future Directions: The Road to Autonomous Discovery

The field is evolving towards more integrated and intelligent systems:

• Generative AI for NP Design: Using models like Generative Adversarial Networks (GANs) to design optimized, synthetically tractable NP analogs with desired properties [5] [6].
• Self-Driving Experimentation: Coupling AI prediction with automated robotic synthesis and screening platforms for closed-loop, iterative discovery.
• Prospective Clinical Validation: Implementing "AI clinical trials" using real-world data and digital twins to simulate trial outcomes and optimize patient stratification for repurposed NP therapies [5].

The confluence of AI and natural product science is not merely an incremental improvement but a necessary modernization. By providing the computational power to integrate fragmented data, discern hidden patterns, and generate testable, mechanistic hypotheses, AI is the key that unlocks the vast, untapped repurposing potential of the natural world. The path forward requires collaborative efforts to build standardized knowledge infrastructures, develop interpretable models, and establish clear translational pipelines. For researchers and drug developers, mastering this confluence is no longer optional—it is the cornerstone of the next generation of efficient, rational, and impactful therapeutic discovery.

The AI Toolkit: Methodologies Powering Natural Product Repurposing Predictions

Disease-Centric, Target-Centric, and Drug-Centric Computational Strategies

This technical guide provides a comprehensive analysis of the three principal computational strategies driving modern drug repositioning: disease-centric, target-centric, and drug-centric approaches. Framed within the urgent need to accelerate and de-risk drug discovery—particularly for natural products—these methodologies leverage artificial intelligence (AI) and vast biomedical datasets to identify new therapeutic uses for existing compounds. The guide details the core principles, quantitative performance, and experimental protocols for each strategy, supported by structured data comparisons and workflow visualizations. It further explores the transformative integration of AI and network pharmacology in overcoming historical challenges in natural product research, such as chemical complexity and limited data. The synthesis of these computational paradigms offers a systematic, data-driven framework to harness the untapped therapeutic potential of known molecules, thereby addressing critical unmet medical needs.

The traditional de novo drug discovery pipeline is notoriously inefficient, characterized by extended timelines of 10-15 years, exorbitant costs averaging $2-3 billion, and high failure rates exceeding 90% [26] [27]. In this context, drug repurposing (or repositioning) has emerged as a strategic alternative, seeking new therapeutic indications for existing drugs, investigational compounds, or, as is increasingly relevant, characterized natural products [26] [28]. This approach capitalizes on established safety and pharmacokinetic profiles, dramatically reducing development risk, cost (estimated at ~$300 million), and time to market (approximately 6 years) [26] [6]. Approximately 30% of newly marketed drugs in the U.S. now result from repurposing strategies, underscoring its clinical and commercial significance [26] [27].

The evolution from serendipitous discovery—epitomized by cases like sildenafil—to systematic, computational-driven methods marks a paradigm shift [26]. This shift is powered by the explosion of multi-omics data, sophisticated AI algorithms, and expansive biomedical knowledge graphs [8] [29]. For natural products, which are a prolific source of novel pharmacophores but are hindered by complexities of mixtures, limited scalability, and incomplete annotation, AI-driven computational repositioning offers a revolutionary path forward [5]. AI tools can predict bioactivity, infer mechanisms of action, and prioritize natural compounds for experimental validation, thereby integrating these complex entities into mainstream drug development pipelines [5].

This guide details the three foundational computational strategies—disease-centric, target-centric, and drug-centric—that form the backbone of systematic repurposing. Each approach offers distinct advantages and is suited to different research questions and data landscapes. The following sections dissect their methodologies, provide comparative analysis, and outline integrated workflows tailored for the unique challenges and opportunities presented by natural product-based drug discovery.

Core Repositioning Strategies: Definitions and Data-Driven Comparison

Systematic computational repositioning is categorized into three primary approaches based on the starting point of the investigation: the disease, the biological target, or the drug itself [28]. A large-scale analysis of over 100 repurposed drugs revealed a clear distribution in their application, highlighting the prevailing trends in the field [28].

Table 1: Prevalence and Characteristics of Core Computational Repositioning Strategies

Strategy	Primary Starting Point	Core Hypothesis	Prevalence in Reported Cases [28]	Typical Data Inputs
Disease-Centric	A specific disease or pathological phenotype.	Drugs effective for a related or phenotypically similar disease may be effective for the new disease.	>60%	Clinical data, disease omics (genomics, transcriptomics), electronic health records (EHRs), phenotypic screens.
Target-Centric	A specific protein or molecular pathway implicated in disease.	A drug known to modulate a particular target may treat any disease where that target is dysregulated.	~30%	Protein 3D structures, protein-protein interaction networks, pathway databases, target-based assay data.
Drug-Centric	A specific drug molecule or compound.	A drug’s polypharmacology (action on multiple targets) may yield therapeutic benefits in unforeseen disease contexts.	<10%	Drug chemical structure (e.g., SMILES), side-effect profiles, drug-induced gene expression signatures, binding assays.

Disease-Centric Strategy

The disease-centric approach begins with a deep characterization of a disease’s molecular and phenotypic signature. The goal is to identify existing drugs that can reverse or counteract this signature [26] [27]. This is often operationalized through the "signature reversion" principle, where computational tools search for drugs whose gene expression profiles inversely correlate with the disease profile [27]. For natural products, this involves constructing detailed herb–ingredient–target–pathway graphs from multi-omics data to model synergistic effects and propose repurposing candidates for complex diseases like cancer or neurodegeneration [5].

Target-Centric Strategy

This approach is rooted in molecular biology and structural chemistry. It starts with a validated disease target and screens for compounds, including natural product libraries, that can modulate its activity [26] [28]. The key advantage is the ability to screen virtually any compound with a known structure against a target of interest. However, it is inherently limited to known biology and cannot identify novel, off-target mechanisms [26] [27]. Advanced structure-based methods, such as molecular docking and binding-site similarity analysis, are central to this strategy [28] [29].

Drug-Centric Strategy

The drug-centric strategy explores the principle of polypharmacology. It starts with a single compound and aims to comprehensively map its interaction profile across the proteome to predict novel therapeutic indications [28]. This approach is particularly powerful for natural products with complex bioactivities but poorly defined mechanisms. AI models can predict a natural compound's binding affinities to hundreds of targets, generating new, testable hypotheses for its use [5]. Despite its potential, it remains the least utilized approach, in part due to the complexity of fully characterizing a compound's mechanistic landscape [28].

Methodological Foundations and Experimental Protocols

The execution of each repositioning strategy relies on a suite of computational and experimental protocols. The following workflows and detailed methodologies outline the step-by-step processes.

Disease-Centric Workflow & Protocol

The disease-centric pipeline translates clinical and omics observations into candidate drug hypotheses.

Disease-Centric Computational-Experimental Protocol

• Disease Profiling:

  • Input: Collect and integrate multi-omics data (e.g., differential gene expression from RNA-seq of patient tissues) and phenotypic data from electronic health records (EHRs) [27].
  • Computation: Use bioinformatic tools (e.g., GSEA, pathway enrichment analysis) to define a robust disease-specific molecular signature.

• Signature Reversal Screening:

  • Input: Access large-scale drug perturbation databases like the Connectivity Map (CMap), which contains gene expression profiles from cell lines treated with thousands of compounds [27].
  • Computation: Employ pattern-matching algorithms (e.g., Kolmogorov-Smirnov statistics, cosine similarity) to rank drugs whose perturbation signatures most strongly negatively correlate with the disease signature.

• Candidate Prioritization & Validation:

  • Computation: Integrate additional data layers (drug pharmacokinetics, structural similarity, literature evidence) to filter and rank candidates.
  • Experimental Validation: Top candidates proceed to in vitro validation using disease-relevant cell models (e.g., patient-derived cells) to assess efficacy in reversing pathological phenotypes [26].

Target-Centric Workflow & Protocol

This protocol focuses on identifying ligands for a specific protein target, often through structural bioinformatics.

Target-Centric Computational-Experimental Protocol

• Target Preparation:

  • Input: Obtain a high-resolution 3D structure of the target protein from PDB or via homology modeling. For natural product targets, this may include plant or microbial enzymes [29].
  • Computation: Define the binding pocket and generate a pharmacophore model describing essential interaction features (e.g., hydrogen bond donors/acceptors, hydrophobic regions).

• Ultra-Large Virtual Screening:

  • Input: Prepare a virtual compound library. For natural products, this includes libraries of characterized metabolites (e.g., ZINC Natural Products) [29].
  • Computation: Employ high-throughput molecular docking software (e.g., AutoDock Vina, Glide) to screen billions of compounds. Advanced iterative screening combines fast deep learning-based pre-screening with precise physics-based docking to maximize efficiency [29].

• Hit Identification & Validation:

  • Computation: Rank compounds based on docking scores (binding energy estimates) and analyze predicted binding poses.
  • Experimental Validation: Synthesize or procure top-ranking compounds for in vitro binding assays (e.g., Surface Plasmon Resonance) and functional enzyme/cell-based assays to confirm target engagement and biological activity [28].

Drug-Centric Workflow & Protocol

This protocol builds a comprehensive interaction network for a given drug to reveal novel indications.

Drug-Centric Computational-Experimental Protocol

• Comprehensive Drug Profiling:

  • Input: Aggregate all available data on the compound: chemical structure (SMILES), known protein targets, adverse event reports, and drug-induced omics signatures [28].

• Predictive Modeling of Interactions:

  • Computation: Apply machine learning models trained on known drug-target interaction databases. Graph neural networks (GNNs) are particularly effective, learning from the relational structure of biomedical knowledge graphs to predict novel interactions for the query drug [8].

• Network-Based Indication Discovery:

  • Computation: Integrate predicted new targets into a heterogeneous network linking drugs, targets, and diseases. Use network algorithms (e.g., random walk, network proximity measures) to identify disease modules that are topologically "close" to the drug's target profile [6] [27].
  • Hypothesis Generation: Diseases whose molecular networks are significantly impacted by the drug's multi-target profile are nominated as new indication hypotheses.

• Experimental Deconvolution:

  • Experimental Validation: Use chemoproteomic techniques (e.g., affinity chromatography coupled with mass spectrometry) to experimentally validate predicted novel targets. Follow with functional assays in disease models relevant to the newly hypothesized indications [5].

Validation, Integration, and The Scientist's Toolkit

Validation Frameworks

Computational predictions require rigorous validation [26].

• Computational Validation: Use metrics like Area Under the ROC Curve (AUROC) and Area Under the Precision-Recall Curve (AUPRC) via cross-validation on held-out datasets. For advanced AI models like the Unified Knowledge-Enhanced deep learning framework for Drug Repositioning (UKEDR), performance in "cold-start" scenarios (predicting for entirely new entities) is a critical benchmark [26] [8].
• Experimental Validation: A tiered approach is essential:
  • In vitro binding and functional assays confirm target engagement.
  • In vitro phenotypic assays in disease-relevant cell models assess functional efficacy.
  • In vivo studies in animal models evaluate physiological impact and pharmacokinetics.
  • Retrospective analysis of real-world patient data (EHRs) can provide supporting clinical evidence [26].

Integrated AI Frameworks

Modern platforms integrate the three strategies into unified AI systems. For example, the UKEDR framework combines knowledge graph embedding (capturing relational data between drugs, targets, diseases), pre-trained attribute representations (e.g., from molecular structures and disease descriptions), and an attention-based recommendation system to make accurate predictions, even for novel natural compounds not in the original knowledge graph [8]. This addresses the critical "cold-start" problem prevalent in natural product research.

Table 2: Key Resources for Computational Drug Repositioning Research

Category	Resource/Solution	Description & Function
Compound Libraries	ZINC20, ChEMBL, NPC (Natural Product Atlas), In-house natural product libraries.	Curated databases of purchasable or characterized compounds for virtual and experimental screening [29].
Bioactivity & Omics Data	Connectivity Map (CMap), LINCS, GEO (Gene Expression Omnibus).	Databases of drug-induced gene expression profiles and disease omics signatures for signature-based screening [27].
Target & Pathway Data	PDB (Protein Data Bank), STRING, KEGG, Reactome.	Sources of protein structures, protein-protein interactions, and curated pathway maps for target-centric and network analysis [28] [29].
AI/ML Platforms & Tools	DeepChem, PyTorch Geometric, TensorFlow, Schrödinger Suite, OpenEye Toolkits.	Software libraries and platforms for building deep learning models (e.g., GNNs), and for molecular docking and simulation [8] [29].
Knowledge Graphs	Hetionet, DRKG (Drug Repurposing Knowledge Graph), Integrated biomedical KGs from PubMed.	Large-scale graphs integrating millions of relationships between biomedical entities to fuel network-based and KG-driven prediction models [8].
Validation Assay Kits	ADP-Glo Kinase Assay, CellTiter-Glo Viability Assay, Proteomics & Metabolomics Kits.	Standardized biochemical, cell-based, and omics assay kits for experimental validation of computational predictions.

Therapeutic Applications and Case Studies

Computational repositioning strategies have demonstrated significant impact across diverse therapeutic areas:

• Oncology & Rare Diseases: Dominant areas for repurposing due to high unmet need and complex biology. Disease-centric approaches using patient genomic data have identified novel uses for existing drugs in specific cancer subtypes [30].
• Neurodegenerative Diseases: Target-centric approaches have proposed kinase inhibitors (e.g., nilotinib, originally for cancer) for Parkinson's disease based on shared target pathways (e.g., ABL1 kinase) [28].
• Infectious Diseases: The COVID-19 pandemic served as a catalyst, with AI-driven drug-centric and target-centric screens rapidly identifying candidates like baricitinib (an anti-inflammatory) for clinical testing [26] [6].

Future Directions: AI and Natural Product Synergy

The convergence of advanced AI with natural product research defines the future frontier [5]:

• Overcoming Data Scarcity: Developing federated learning and few-shot learning techniques to build predictive models from small, imbalanced natural product datasets.
• Mechanistic Deconvolution: Using explainable AI (XAI) to interpret model predictions and illuminate the complex, polypharmacological mechanisms of natural product mixtures.
• Generative AI for Optimization: Employing generative models to design optimized, synthetically accessible analogs of complex natural product scaffolds, balancing efficacy and drug-like properties.
• Digital Twins: Creating patient- or system-specific in silico models ("digital twins") to simulate the effects of natural product interventions, enabling personalized repositioning hypotheses.

Disease-centric, target-centric, and drug-centric strategies provide complementary and powerful frameworks for systematic drug repositioning. The integration of these approaches within unified AI architectures, such as knowledge graph-enhanced deep learning models, is dramatically increasing the scale, accuracy, and translational potential of predictions. For the rich yet challenging domain of natural products, these computational strategies are indispensable. They offer a path to systematically decode complex bioactivities, predict novel indications, and accelerate the integration of these historically important compounds into the next generation of precision therapeutics. As data resources continue to expand and algorithms evolve, computational repositioning will solidify its role as a cornerstone of efficient, intelligent, and patient-centric drug discovery.

Drug repositioning, the identification of new therapeutic uses for existing drugs, represents a paradigm shift in pharmaceutical research [6]. By leveraging compounds with established safety and pharmacokinetic profiles, this strategy significantly reduces the time, cost, and risk associated with traditional de novo drug discovery [31]. The conventional drug development pipeline is notoriously prolonged, spanning 10–15 years with costs averaging $2.6 billion, while repurposing can bring a drug to a new market in approximately 3–6 years for about $300 million [6]. Artificial Intelligence (AI), particularly machine learning (ML) and deep learning (DL), has emerged as a transformative force in this field. These technologies can analyze complex, high-dimensional biological data—including genomic, transcriptomic, and chemical structures—to predict novel and non-obvious drug-disease associations that elude conventional methods [6] [8].

The application of AI in repositioning natural products is especially promising. Natural products, derived from plants, microbes, and marine organisms, possess unparalleled chemical diversity and have been the source of a significant proportion of all approved drugs [32] [33]. However, their complex structures and often unknown or multi-faceted mechanisms of action present unique challenges. AI models, from classical Random Forests to advanced Graph Neural Networks (GNNs), are uniquely suited to decode this complexity. They can model the intricate relationships between the structural features of natural compounds and their polypharmacological effects on biological networks, thereby systematically uncovering new therapeutic indications [5] [34]. This technical guide explores the evolution and application of these computational approaches within the specific context of repositioning natural products.

Foundational Machine Learning Models in Drug Repositioning

Before the rise of deep learning, classical machine learning algorithms provided the first computational framework for systematic drug repositioning. These models treat the task primarily as a binary classification or link prediction problem, aiming to determine the likelihood of an association between a drug (e.g., a natural product) and a disease target.

Table 1: Key Machine Learning Algorithms and Their Applications in Drug Repositioning

Algorithm Category	Example Algorithms	Key Characteristics	Typical Application in Repositioning
Supervised Learning	Logistic Regression (LR), Support Vector Machine (SVM), Random Forest (RF)	Learns from labeled input-output pairs; requires features representing drugs and diseases.	Predicting binary drug-disease associations using features like chemical descriptors and genomic signatures [6] [8].
Ensemble Learning	Random Forest (RF), Gradient Boosting	Combines multiple base models (e.g., decision trees) to improve robustness and accuracy.	Integrating diverse data types (e.g., chemical, phenotypic, side-effect) for more reliable prediction [6].
Network-Based Methods	Random Walk with Restart (RWR), Network Propagation	Utilizes graph topology of biological networks (protein-protein, drug-target).	Prioritizing drugs based on their proximity to disease modules in molecular interaction networks [6].

Random Forest (RF) is a particularly impactful ensemble method. It operates by constructing a multitude of decision trees during training, where each tree is built on a random subset of data samples and features. For repositioning, features may include molecular fingerprints (e.g., Extended Connectivity Fingerprints - ECFP), which encode the presence of chemical substructures within a compound [35]. The model's output is the class (e.g., "associated" or "not associated") selected by the majority of trees. Key advantages include resistance to overfitting and the ability to handle high-dimensional data, making it suitable for the complex feature spaces derived from natural product chemistry and omics data [8].

The experimental protocol for an ML-based repositioning study typically follows a structured pipeline:

• Data Curation: Collect known drug-disease associations from databases (e.g., DrugBank, RepoDB). Represent natural products using features like molecular fingerprints or simplified molecular-input line-entry system (SMILES)-derived descriptors.
• Feature Engineering & Selection: Generate and select the most informative features to represent drugs and diseases. For diseases, this might involve gene expression profiles or phenotypic data.
• Model Training & Validation: Split data into training and test sets. Train the ML model (e.g., Random Forest) on the training set to learn the mapping between features and associations. Optimize hyperparameters (e.g., number of trees in RF, maximum depth) via cross-validation.
• Prediction & Prioritization: Apply the trained model to a library of natural products to score their potential association with a target disease. The highest-scoring candidates are prioritized for in vitro or in silico validation [8] [34].

While powerful, these traditional ML models have limitations. They often rely on hand-crafted features (e.g., fingerprints) that may not fully capture the complex, hierarchical structural information of natural products. Furthermore, they struggle with the inherent "cold-start" problem—making predictions for entirely novel compounds or diseases absent from the training data [8].

The Deep Learning Revolution: From Molecular Representation to Prediction

Deep Learning (DL) has overcome many limitations of classical ML by automatically learning optimal feature representations from raw data. In drug repositioning, DL architectures are designed to process the native structural format of molecules and integrate heterogeneous biological data.

Molecular Representation: The choice of input representation is critical. While SMILES strings and molecular fingerprints are common, they have drawbacks: SMILES lacks spatial awareness, and fingerprints lose structural connectivity information [35]. Molecular graphs have emerged as the superior representation, where atoms are nodes and bonds are edges, naturally preserving the complete topological and chemical information of a compound [35].

Core Deep Learning Architectures:

• Convolutional Neural Networks (CNNs): Initially adapted from image processing, CNNs can be applied to SMILES strings (as 1D text) or molecular graphs. They learn local chemical patterns through convolutional filters but are not inherently designed for non-Euclidean graph data [35].
• Multilayer Perceptrons (MLPs): Used as final prediction layers or to process non-graph features (e.g., gene expression vectors from disease models) [35].
• Graph Neural Networks (GNNs): This specialized class of DL models operates directly on graph-structured data, making them ideal for molecules. The core operation is message passing, where each node (atom) aggregates feature information from its neighboring nodes (connected atoms) to build a contextualized representation of its local chemical environment. After several layers of message passing, a global pooling step aggregates all atom representations into a single vector that encapsulates the entire molecule. This graph-derived embedding can then be used for property prediction, such as binding affinity or therapeutic activity [35] [36].

A significant advancement in feature learning for GNNs is the Circular Atomic Feature Computation algorithm, inspired by ECFP fingerprints [35]. This method dynamically generates node features that encode increasingly larger chemical environments, providing the GNN with rich, sub-structure-aware information from the outset.

Diagram: Circular Atom Feature Computation Workflow (94 characters)

Table 2: Experimental Datasets and Protocols for AI-Driven Repositioning

Study / Model	Primary Data Sources	Key Preprocessing Steps	Experimental Protocol Summary
XGDP Model [35]	GDSC (drug response), CCLE (gene expression), PubChem (SMILES).	Combined GDSC & CCLE by cell line; filtered to 956 landmark genes; converted SMILES to molecular graphs via RDKit.	Trained GNN (drug) + CNN (cell line) with cross-attention; used Integrated Gradients for interpretation; benchmarked against tCNN, GraphDRP.
UKEDR Framework [8]	RepoAPP, RepoDB, Cdataset (drug-disease associations).	Fine-tuned BioBERT on disease text for DisBERT; used CReSS model for drug spectra; constructed knowledge graphs.	Systematic ablation of KG embedding & recommender modules; evaluated on cold-start splits; validated via clinical trial simulation.
Natural Product Study [34]	Phytochemical isolation, public bioactivity databases.	Isolated compounds from Gynura procumbens; conducted in vitro assays for antioxidant, cytotoxic, anti-diabetic activity.	Used experimental bioactivity results to validate computational predictions of multi-target therapeutic potential.

Graph Neural Networks: The State-of-the-Art for Network Pharmacology

GNNs represent the cutting edge for drug repositioning because they can model not just single molecules, but entire biological systems as interconnected networks. This aligns perfectly with the polypharmacological nature of many natural products, which often exert effects by modulating multiple targets within a disease network [5] [34].

Heterogeneous Knowledge Graphs (KGs): The most powerful applications embed diverse entities (drugs, diseases, proteins, pathways, side effects) and their relations into a massive graph. Models like Relational Graph Convolutional Networks (R-GCN) perform message passing that is conditioned on the type of relation (e.g., "binds-to," "treats," "causes"), learning embeddings that capture the complex semantic and topological structure of biomedical knowledge [8].

The UKEDR Framework: A state-of-the-art example addresses two key challenges: cold-start (predicting for new entities) and integrating intrinsic attributes. UKEDR first uses pre-trained models (e.g., a language model fine-tuned on disease text, a neural network trained on molecular spectra) to generate attribute embeddings for any drug or disease, even unseen ones. It then integrates these with relational embeddings from a knowledge graph using an Attentive Factorization Machine (AFM) recommender system. This allows it to make accurate predictions for novel natural products not present in the original knowledge graph [8].

Diagram: UKEDR Framework for Cold-Start Prediction (86 characters)

Interpretability with GNNExplainer: A critical advantage of GNNs like those in the XGDP model is explainability. Tools like GNNExplainer can identify which sub-graph (molecular substructure) and which node features (genes in a cell line profile) were most influential for a prediction. This provides a mechanistic hypothesis, suggesting that a specific functional group in a natural product may interact with a particular gene pathway, which can guide experimental validation [35].

Implementation Guide: From Theory to Practice

Implementing a GNN-based repositioning pipeline for natural products involves several concrete steps, leveraging modern software libraries and curated datasets.

1. Data Preparation:

• Compound Library: Obtain SMILES representations of natural products from sources like COCONUT, NPASS, or PubChem. Use the RDKit library to convert each SMILES into a molecular graph object [35].
• Biological Knowledge Graph: Integrate relationships from databases like DrugBank, Hetionet, or STITCH. A platform like DeepDR provides a pre-integrated KG with over 5.9 million edges [37].
• Bioactivity Data: For supervised training, use labels from databases like GDSC for cell-line response or ChEMBL for target binding affinities [35].

2. Model Building with PyTorch Geometric:

• This library simplifies GNN implementation. Define a GNN model by stacking graph convolution layers (e.g., GCNConv, GATConv).

3. Training and Validation:

• Split data carefully (e.g., scaffold split for molecules) to avoid artificial inflation of performance.
• Use appropriate loss functions (e.g., Mean Squared Error for regression, Binary Cross-Entropy for classification).
• Employ attribution methods like Integrated Gradients post-training to interpret model predictions and highlight crucial molecular substructures [35].

Table 3: Performance Comparison of AI Models in Repositioning Studies

Model	Architecture	Key Dataset	Reported Performance (AUC/Other)	Key Advantage for Natural Products
Random Forest [8]	Ensemble of Decision Trees	RepoDB, Cdataset	AUC: ~0.85-0.89 (benchmark)	Robust with small, imbalanced datasets; handles diverse fingerprints.
XGDP [35]	GNN + CNN + Cross-Attention	GDSC/CCLE	Improves RMSE over predecessors (tCNN, GraphDRP)	Explainable; identifies key substructures and gene interactions.
UKEDR [8]	KG Embedding + Pre-training + AFM Recommender	RepoAPP, Cold-Start Splits	AUC: ~0.95-0.96; +39.3% in clinical trial sim.	Solves cold-start; integrates molecular and textual attributes.
DeepDR [37]	Integrated Deep Learning Platform	6 DBs, 5.9M-edge KG	Web server with high accuracy per user task	Provides accessible, comprehensive platform for hypothesis generation.

Case Studies: Repositioning Natural Products with AI

Case Study 1: Eudesmin as an Epigenetic Modulator A transcriptomics-driven study repositioned eudesmin, a natural lignan, as a modulator of the Polycomb Repressive Complex 2 (PRC2). Computational analysis of gene expression changes predicted eudesmin's influence on PRC2 target genes. This prediction was experimentally validated, showing eudesmin increased PRC2 occupancy and repressive histone marks on the DKK1 gene promoter, implicating it in stem cell pluripotency regulation [34]. This demonstrates how AI can move from predictive signature to mechanistic insight.

Case Study 2: Phenolic Esters as Antifungal Agents An in silico screening coupled with in vitro validation identified prenylated cinnamic esters and ethers as effective against clinical Fusarium spp. AI models helped prioritize these natural compounds based on chemical similarity and predicted activity, leading to the discovery of new antifungal chemotypes [34]. This showcases a successful bioactivity-driven repositioning pipeline.

Case Study 3: Multi-Target Activity of Gynura procumbens Compounds Phytochemical investigation of Gynura procumbens led to the isolation of compounds like lupeol and stigmasterol. Subsequent in vitro testing revealed a range of bioactivities—antioxidant, cytotoxic, thrombolytic, and anti-diabetic—for different fractions [34]. This polypharmacological profile is ideal for AI models that can integrate multiple activity endpoints to predict which compounds might be repositioned for complex diseases like diabetes with comorbidities.

Table 4: The Scientist's Toolkit: Essential Research Reagents & Resources

Item / Resource	Function / Purpose	Example / Source
Chemical Databases	Provide SMILES, structures, and bioactivity data for natural products.	COCONUT, NPASS, PubChem, ChEMBL [35] [32].
Bioactivity Databases	Supply labeled data for model training (drug-target, drug-response).	GDSC, DrugBank, RepoDB [35] [8].
Omics Data Repositories	Provide disease-state molecular profiles (genomic, transcriptomic).	CCLE, TCGA, GEO [35].
Software Libraries (Chemistry)	Convert representations, calculate descriptors, handle molecular graphs.	RDKit (SMILES to graph), DeepChem (featurization) [35] [36].
Software Libraries (Deep Learning)	Build, train, and deploy GNN and DL models.	PyTorch Geometric, DGL, TensorFlow [36].
Integrated Platforms	User-friendly web servers for prediction without extensive coding.	DeepDR (for repositioning) [37].
Interpretation Tools	Explain model predictions and identify critical features.	GNNExplainer, Integrated Gradients [35].

The field of AI-driven drug repositioning for natural products is rapidly evolving. Future directions include:

• Generative AI: Using models like Generative Adversarial Networks (GANs) or Geometric Deep Learning to design optimized natural product derivatives or novel scaffolds inspired by natural pharmacophores [6] [5].
• Multimodal and Temporal Models: Integrating time-series omics data (e.g., from patient-derived organoids) and real-world evidence from electronic health records to capture dynamic treatment responses and patient heterogeneity.
• Causal Inference: Moving beyond correlation to infer causal relationships between drug exposure and disease modification, strengthening the rationale for repositioning [5].
• Federated Learning: Addressing data privacy concerns by training models across multiple, decentralized datasets (e.g., from different research institutes or biobanks) without sharing raw data.

In conclusion, the journey from Random Forests to Graph Neural Networks marks a significant evolution in computational capability for drug repositioning. For the rich yet complex world of natural products, GNNs offer an unparalleled framework to model their intricate structures within the broad context of biological systems knowledge graphs. By transforming natural products into graph data and leveraging sophisticated message-passing architectures, researchers can systematically decode their polypharmacology, generate mechanistic hypotheses, and prioritize candidates for experimental validation. This synergy between ancient medicinal sources and cutting-edge AI technology is poised to accelerate the discovery of new therapeutic uses from nature's chemical treasury, making the drug development process more efficient and targeted [5] [32] [33].

The convergence of network pharmacology and artificial intelligence (AI) is catalyzing a profound transformation in the study and application of natural products for modern therapeutics [5]. This paradigm moves beyond the conventional "one drug, one target" model to embrace the inherent complexity of both diseases and traditional herbal medicines, which are characterized by multi-component formulations designed for systemic effects [38] [39]. The core challenge and opportunity lie in systematically deciphering the intricate web of interactions between herbal compounds, their protein targets, and the downstream biological pathways they modulate.

Within the broader thesis of AI-driven drug repositioning, network pharmacology provides the foundational framework. It conceptualizes the biological system as an interconnected network, where perturbations by drug compounds can be mapped and their therapeutic outcomes predicted [6] [40]. For natural products, this approach is particularly powerful. It offers a mechanistic bridge between the holistic tenets of traditional medicine and the molecular-level understanding required by modern drug development [38] [41]. By constructing comprehensive, semantically rich knowledge graphs (KGs) that encode relationships between herbs, ingredients, targets, and diseases, researchers can unlock new avenues for identifying synergistic combinations, elucidating mechanisms of action, and efficiently repositioning herbal compounds for new therapeutic indications [5] [6] [41].

Foundational Concepts: From Herbal Formulae to Network Models

Traditional herbal medicine, such as Traditional Chinese Medicine (TCM), relies on the principle of herb compatibility, where formulae comprising multiple herbs are believed to achieve maximum therapeutic effect through synergistic interactions [38]. The pharmacological effect is an emergent property of the complex system, not attributable to a single ingredient. Network pharmacology directly addresses this complexity by applying graph theory to model these relationships [42] [40].

A fundamental hypothesis in network-based drug discovery is that therapeutic compounds, including herbal ingredients, tend to target proteins that are topologically close within the human protein-protein interaction (PPI) network, or "interactome" [38] [6]. Studies have shown that frequently used, effective herb pairs exhibit shorter network distances (e.g., closest, shortest, or center distances) between their respective target sets compared to random herb pairs [38]. This suggests that synergistic herb combinations likely function by cooperatively perturbing a localized neighborhood in the interactome.

Key computational frameworks like Visual Network Pharmacology (VNP) enable the interactive exploration of these complex relationships among diseases, targets, and drugs, providing intuitive visual hypotheses for mechanisms and repurposing opportunities [42].

Table 1: Core Entities and Relationships in Herb-Focused Knowledge Graphs

Entity Type	Description	Example (from HerbKG) [41]
Herb	A medicinal plant or its parts used for therapy.	Salvia officinalis (Sage), Ginkgo biloba
Chemical/Ingredient	A bioactive compound extracted from a herb.	Cinnamaldehyde, Quercetin, Berberine
Gene/Protein Target	A macromolecule (typically a protein) with which an ingredient interacts.	CASP3 (Caspase-3), TNF, EGFR
Disease	A specific pathological condition.	Hyperlipidemia, Alzheimer's disease, NSCLC
Relation: HHC	Herb Has Compound. Links a herb to its constituent chemicals.	Cinnamomum cassia → Cinnamaldehyde
Relation: CAG	Chemical Associates with Gene. Indicates a biochemical interaction.	Cinnamaldehyde → CASP3
Relation: GID	Gene Influences Disease. Connects a target's function to a pathology.	CASP3 → Apoptosis-related diseases

Constructing the Knowledge Graph: Data Integration and Ontology

A robust, AI-ready knowledge graph requires a structured ontology and scalable methods for data extraction and integration [41].

3.1 Ontology Definition The ontology defines the schema of the KG. For herb-focused research, a core ontology includes the entity types listed in Table 1 and their permissible relationships (e.g., HerbHasCompound, ChemicalAssociatesGene, GeneInfluencesDisease) [41]. This formal schema ensures data consistency and enables complex, semantically-aware queries.

3.2 Data Sourcing and Curation Data is aggregated from multiple specialized databases:

• Herb and Compound Databases: TCMSP, TCMID, and HERB provide curated information on herbs, their chemical constituents, and pharmacokinetic properties like oral bioavailability (OB) and drug-likeness (DL) [38] [43].
• Target and Interaction Databases: STITCH, ChEMBL, and DrugBank offer experimentally validated and predicted drug-target interactions [38] [40]. The STRING database is a primary source for PPIs [43].
• Disease and Pathway Databases: GeneCards, DisGeNET, CTD, KEGG, and GO are used to link genes to diseases and biological pathways [39] [43].

A critical challenge is the variable quality and consistency across these sources. A systematic evaluation is essential, as the choice of database significantly impacts the resulting network topology and mechanistic predictions [39].

3.3 Automated Knowledge Graph Construction Manual curation is unsustainable at scale. Automated frameworks like HerbKG employ Natural Language Processing (NLP) and machine learning to extract entities and relations from vast biomedical literature (e.g., PubMed abstracts) [41].

• Named Entity Recognition (NER): Identifies and classifies text mentions of herbs, chemicals, genes, and diseases.
• Relation Extraction (RE): Determines the specific semantic relationship between identified entity pairs (e.g., an "inhibits" relationship between a chemical and a gene). State-of-the-art models fine-tuned on biomedical corpora, such as BioBERT, can achieve high accuracy (F1 scores >95%) in this task [41].

Analytical Methodologies: From Network Construction to AI Prediction

4.1 Core Network Construction Workflow A standard analytical pipeline involves several key stages [43]:

• Bioactive Ingredient Screening: Filter compounds from an herb or formula based on ADME properties (e.g., OB ≥ 30%, DL ≥ 0.18) [43].
• Target Prediction: Identify putative protein targets for each ingredient using similarity search, reverse docking, or machine learning models [44] [40].
• Disease Target Collection: Aggregate genes known to be associated with the disease of interest from public databases.
• Network Integration:
  • Construct a Herb-Ingredient-Target-Disease network.
  • Build a Protein-Protein Interaction (PPI) subnet using the overlapping targets as seeds.
  • Perform enrichment analysis (GO, KEGG) on the core target set to identify affected biological processes and pathways [43].

4.2 Key Network Metrics and AI-Driven Analysis

• Topological Analysis: Identifying central nodes (targets) using metrics like Degree, Betweenness, and Closeness Centrality is crucial for pinpointing key therapeutic targets [40] [43]. Tools like CytoNCA in Cytoscape facilitate this analysis.
• Modularity and Community Detection: Algorithms can identify densely connected clusters within the network, which often correspond to functional modules or synergistic ingredient groups [38].
• AI and Machine Learning Applications:
  • Predictive Modeling: Graph Neural Networks (GNNs) and other ML models trained on the KG can predict novel herb-target or drug-disease associations for repurposing [5] [6].
  • Synergy Prediction: Network-based distances (e.g., separation between two herbs' target sets in the PPI network) can be used as features in models predicting synergistic herb or drug combinations [38].
  • Pathway Perturbation Modeling: Tools like SmartGraph enable the simulation of network perturbations, allowing researchers to trace the potential effects of an ingredient through the interactome and generate mechanistic hypotheses [40].

Experimental Validation and Case Studies

Computational predictions must be anchored in experimental validation. A typical multi-stage validation protocol proceeds from in vitro to in vivo models [39] [43].

5.1 In Vitro Validation Protocol

• Objective: To confirm direct target engagement and primary biological activity of predicted core ingredients.
• Methods:
  • Cell-based Assays: Treat relevant cell lines (e.g., cancer, inflamed endothelial cells) with the core ingredient(s).
  • Viability/Activity Assays: Measure effects using MTT, CCK-8, or apoptosis assays (Annexin V/PI staining).
  • Target Protein Validation:
    • Western Blotting: Quantify expression levels of predicted core target proteins (e.g., IL-6, TNF-α, CASP3) [43].
    • qRT-PCR: Measure mRNA expression of target genes.
  • Pathway Analysis: Use phospho-specific antibodies in Western Blots or pathway reporter assays to validate perturbation of predicted signaling pathways (e.g., MAPK, NF-κB) [44] [43].

5.2 In Vivo Validation Protocol

• Objective: To assess the holistic therapeutic efficacy and systemic impact of the herb or formula in a disease model.
• Methods:
  • Animal Model Induction: Establish a disease model (e.g., hyperlipidemia induced by Triton WR-1339 or high-fat diet in mice [43]).
  • Group Administration: Divide animals into control, model, positive drug, and treatment (herb/formula) groups.
  • Efficacy Endpoints:
    • Collect serum for biochemical analysis (e.g., TC, TG, LDL-C in hyperlipidemia) [43].
    • Harvest tissue organs (liver, heart) for histopathological examination (H&E staining).
    • Analyze gene and protein expression in tissues via qRT-PCR and Western Blot, confirming in vitro findings in vivo.

Table 2: Case Study: Network Analysis of Bushao Tiaozhi Capsule (BSTZC) for Hyperlipidemia [43]

Analysis Stage	Key Findings	Validation Outcome
Ingredient Screening	Identified 36 bioactive ingredients from BSTZC meeting OB/DL criteria.	N/A (Computational)
Target Prediction & Network Analysis	Mapped 209 gene targets. Identified quercetin, kaempferol, wogonin as core ingredients via network centrality.	N/A (Computational)
PPI & Pathway Enrichment	Identified IL6, TNF, VEGFA, CASP3 as core targets. Pathways enriched: MAPK, TNF, IL-17 signaling.	N/A (Computational)
In Vivo Validation	BSTZC treatment in HLP mice significantly reduced serum TC, TG, LDL-C levels.	Confirmed lipid-lowering efficacy.
Molecular Validation	BSTZC regulated mRNA expression of predicted core targets (Il6, Tnf, Casp3) in liver tissue.	Experimentally validated network-predicted targets.

Table 3: The Scientist's Toolkit: Essential Resources for Network Pharmacology

Resource Type	Name & Examples	Primary Function
Database	TCMSP, TCMID, HERB	Provides curated data on herbs, chemical ingredients, and ADME properties.
Database	STITCH, ChEMBL, DrugBank	Sources for drug/compound-target interaction data.
Database	STRING, BioGRID	Provides protein-protein interaction (PPI) data for network construction.
Database	KEGG, Gene Ontology (GO)	For pathway mapping and functional enrichment analysis.
Software/Platform	Cytoscape (with plugins)	Network visualization, construction, and topological analysis.
Software/Platform	SmartGraph, VNP	Integrated platforms for network exploration, perturbation modeling, and hypothesis generation [42] [40].
AI/ML Framework	BioBERT, GNN Libraries (PyTorch Geometric)	For NLP tasks on literature and graph-based predictive modeling [5] [41].
Experimental Reagent	Triton WR-1339	Used to induce acute hyperlipidemia in animal validation models [43].
Experimental Reagent	Core Ingredient Standards (e.g., Quercetin, Berberine)	Pure compounds for in vitro and in vivo mechanistic validation [43].

Future Directions and Challenges

The field is rapidly evolving, driven by advances in AI and systems biology. Key future directions include:

• Dynamic and Multi-Omics KGs: Integrating temporal, spatial, and multi-omics data (transcriptomics, proteomics, metabolomics) to create dynamic models of herb action [5] [39].
• Advanced AI Reasoning: Employing graph representation learning and causal inference on KGs to move beyond association to discovering causal mechanisms of action [5] [6].
• Microphysiological Systems (MPS) and Digital Twins: Using "organ-on-a-chip" data to refine network models and creating digital twins of disease states for in silico therapy testing [5].

Significant challenges remain, including data quality and heterogeneity, the need for standardized protocols for network construction and validation, and the interpretability and translational gap between complex network predictions and clinical applications [5] [6] [39]. Addressing these requires continued interdisciplinary collaboration among computational scientists, pharmacologists, and traditional medicine experts.

The Conceptual Framework of Multi-Omics Integration in Drug Discovery

The integration of transcriptomics, proteomics, and metabolomics data represents a paradigm shift in systems biology, moving beyond single-layer analysis to a holistic view of biological systems. In the context of drug repositioning for natural products, this multi-omics approach is particularly powerful. It enables researchers to decipher the complex mechanisms of action of natural compounds, map their effects across multiple molecular layers, and identify novel therapeutic indications with greater precision and speed [45] [5].

The biological information flow from genes to metabolites forms a causal cascade. Transcriptomics measures RNA expression levels, providing an indirect view of DNA activity. Proteomics identifies and quantifies the proteins and enzymes that execute cellular functions. Metabolomics profiles the small-molecule end products and regulators of metabolic reactions [45]. Natural products can intervene at any point in this cascade, and their full effect can only be captured by integrating data across all three levels. This integration reveals how a compound modulates gene expression, alters protein networks, and ultimately reshapes the metabolic phenotype of a cell or tissue, thereby illuminating new therapeutic pathways for existing natural compounds [5] [46].

Table 1: Core Multi-Omics Layers and Their Role in Understanding Natural Product Action

Omics Layer	Measured Entities	Scale/Size	Key Insight for Drug Repositioning
Transcriptomics	RNA transcripts (mRNA, non-coding RNA)	Varies	Identifies gene expression networks and upstream regulatory pathways targeted by a natural product [45].
Proteomics	Proteins and post-translational modifications	Typically > 2 kDa	Reveals functional effectors, enzymatic activities, and signaling proteins modulated by the compound [45] [47].
Metabolomics	Metabolites (e.g., amino acids, lipids, sugars)	≤ 1.5 kDa	Captures the final biochemical phenotype and metabolic pathway alterations induced by treatment [45] [48].

Diagram 1: Multi-omics information flow and natural product intervention (760x380px).

Methodological Strategies for Multi-Omics Data Integration

Integrating heterogeneous omics data requires strategic computational approaches. These methods can be broadly categorized based on the stage of integration and the underlying statistical or machine learning principles [45] [49]. The choice of strategy is critical for applications like identifying a natural product's multi-omics signature and linking it to a new disease context.

Correlation-based integration is a foundational strategy. It involves calculating statistical associations (e.g., Pearson correlation) between features across omics layers, such as linking the expression of a gene with the abundance of a metabolite [45]. Network-based methods extend this by constructing interaction graphs (e.g., gene-metabolite networks) to visualize and analyze these relationships, often using tools like Cytoscape [45]. Concatenation-based early integration simply merges datasets from different omics for unified analysis, though it can be challenged by differing scales and data structures [50].

More advanced machine learning (ML) and deep learning (DL) approaches are now central to the field. Unsupervised methods like Multi-Omics Factor Analysis (MOFA+) identify hidden factors that explain variation across all datasets [49]. Supervised models are trained to predict an outcome (e.g., drug response) from integrated omics data. A cutting-edge development is the use of graph-based deep learning models, such as Multi-view Multi-level Contrastive Graph Convolutional Networks (MCGCN). These models excel at learning both shared patterns and omics-specific information from complex data, making them highly effective for tasks like patient or disease subtyping, which is a key step in repositioning [51].

Table 2: Comparison of Multi-Omics Integration Strategies

Integration Strategy	Core Methodology	Typical Use-Case	Key Consideration
Early (Concatenation)	Direct merging of data matrices for joint analysis.	Exploratory analysis when sample alignment is perfect.	Highly sensitive to differing scales, noise, and dimensionality across omics [49] [50].
Intermediate (Transformation)	Data transformed into a joint lower-dimension space (e.g., via ML).	Identifying latent factors or generating integrated embeddings for prediction.	Balances data specificity and integration; choice of model (PCA, CCA, DNN) is critical [51] [50].
Late (Model/Decision)	Separate models are built per omics and results are combined.	When omics data are not perfectly matched or are highly distinct.	Preserves data structure but may miss complex cross-omics interactions [50].
Network-Based	Construction of correlation or interaction networks (e.g., gene-metabolite).	Visualizing and analyzing system-wide molecular relationships.	Relies on prior knowledge (pathway DBs) or high-quality correlation metrics [45] [46].
Machine/Deep Learning	Use of algorithms (Random Forest, VAEs, GCNs) to learn complex patterns.	High-dimensional prediction, subtyping, and biomarker discovery.	Requires significant computational resources and careful tuning to avoid overfitting [5] [51] [6].

Diagram 2: Computational strategies for multi-omics data integration (760x300px).

Experimental Protocols for Generating Integrative Multi-Omics Data

Robust data generation is the foundation of any successful integration study. A key principle is ensuring sample-matched multi-omics profiling, where different molecular layers are analyzed from the same biological sample or subject cohort [48] [50]. For natural product studies, this typically involves treating a cell line, animal model, or collecting patient samples, followed by parallel extraction and analysis of RNA, proteins, and metabolites.

Transcriptomic Profiling via RNA-Sequencing: High-quality total RNA is extracted (RIN > 8). After library preparation (e.g., poly-A selection), samples are sequenced on a platform like Illumina NovaSeq to a depth of 20-30 million reads per sample. Reads are aligned to a reference genome (e.g., GRCm38 for mouse), and gene expression is quantified (e.g., using featureCounts). Differential expression analysis (using tools like DESeq2) identifies genes significantly altered by natural product treatment, with results filtered by a log2 fold change threshold (e.g., ≥1) and adjusted p-value (e.g., <0.05) [48].

Proteomic Profiling via LC-MS/MS: Proteins are extracted, digested with trypsin, and resulting peptides are analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). A data-independent acquisition (DIA) strategy is preferred for reproducibility in quantification across many samples. Proteins are identified and quantified using spectral library matching. Differential analysis, often involving linear models and moderated t-tests, highlights proteins with significant abundance changes [47].

Metabolomic & Lipidomic Profiling via LC-MS/GC-MS: Metabolites are extracted using a solvent like methanol/water. For broad coverage, both liquid chromatography-MS (LC-MS) and gas chromatography-MS (GC-MS) are employed. LC-MS captures a wide range of lipids and polar metabolites, while GC-MS offers high reproducibility for volatile compounds. Data processing includes peak picking, alignment, and compound identification against standard libraries. Univariate and multivariate statistics (e.g., PCA, PLS-DA) reveal discriminatory metabolites [48] [47].

Table 3: Experimental Design & Platform Selection for Multi-Omics

Study Component	Recommended Platform/Technique	Key Quality Control Step	Consideration for Natural Product Studies
Transcriptomics	RNA-Sequencing (Illumina platform).	RNA Integrity Number (RIN) > 8.0.	Choose model system (in vitro/vivo) relevant to hypothesized new indication.
Proteomics	Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) with Data-Independent Acquisition (DIA).	Use of stable isotope-labeled internal standards for quantification.	Consider profiling post-translational modifications (phosphoproteomics) to capture signaling events.
Metabolomics	Combined LC-MS (broad coverage) and GC-MS (high reproducibility).	Pooled quality control samples analyzed throughout the batch.	Employ both untargeted (discovery) and targeted (validation) metabolomics.
Sample Design	Split-sample or source-matched study design [50].	All omics assays performed on aliquots from the same biological sample.	Include multiple time points to capture dynamic, system-wide responses to treatment.
Data Preprocessing	Platform-specific pipelines followed by cross-omics normalization (e.g., quantile).	Batch effect correction using ComBat or similar tools [47].	Ensure metadata accurately captures treatment dose, duration, and sample provenance.

AI-Driven Computational Workflow for Repositioning Natural Products

The integrated multi-omics data serves as the fuel for an AI-driven pipeline to systematically reposition natural products. This workflow moves from data harmonization to generating testable hypotheses about novel therapeutic uses.

The initial step is data harmonization and feature engineering. Processed datasets from transcriptomics, proteomics, and metabolomics are aligned by sample ID. Features are normalized, scaled, and subjected to batch-effect correction. For network-based AI models, features are further structured as graphs, where nodes represent molecules (genes, proteins, metabolites) and edges represent known interactions or significant correlations [51] [46].

Next, integrative analysis and signature generation takes place. Unsupervised integration methods, such as MOFA+ or the multi-view contrastive learning in MCGCN, are applied to derive a unified representation of the multi-omics profile induced by the natural product [51] [49]. This profile, or "multi-omics signature," encapsulates the compound's systems-level effect. Simultaneously, supervised models can be trained to classify samples based on treatment, identifying the most discriminatory cross-omics features as potential multi-omics biomarkers.

The core repositioning step involves signature matching and network pharmacology. The natural product's multi-omics signature is computationally compared to extensive reference databases of disease signatures (e.g., from LINCS L1000, TCGA, or GEO) [5] [46]. The search is for diseases where the natural product signature is anti-correlated with the disease signature, suggesting a potential reversal of the disease state. Furthermore, network analysis connects the natural product's modulated molecules (e.g., key dysregulated metabolites and their upstream protein regulators) to established disease pathways via knowledge graphs, strengthening the mechanistic hypothesis for the new indication [5] [6].

Diagram 3: AI workflow for natural product repositioning using multi-omics (760x500px).

Table 4: Research Reagent Solutions & Essential Resources

Category	Item/Resource	Function/Description	Example/Source
Sample Prep & QC	RNA Stabilization Reagent (e.g., RNAlater)	Preserves RNA integrity immediately upon sample collection for transcriptomics.	Thermo Fisher Scientific [48].
	BCA or Bradford Assay Kit	Quantifies total protein concentration for proteomics sample normalization.	Various commercial suppliers [47].
	Internal Standard Mixtures (Stable Isotope Labeled)	Enables accurate absolute quantification in metabolomics and proteomics.	Cambridge Isotope Laboratories; Sigma-Aldrich [47].
Data Generation	Next-Gen Sequencing Platform	Generates high-throughput transcriptomic (RNA-seq) data.	Illumina NovaSeq [48].
	High-Resolution Mass Spectrometer	Core instrument for proteomic and metabolomic profiling.	Thermo Fisher Orbitrap Eclipse; SCIEX TripleTOF [47].
	Chromatography Columns (C18, HILIC)	Separates peptides or metabolites prior to MS detection.	Waters, Agilent [47].
Computational Tools	Multi-Omics Integration Software	Statistical and ML frameworks for joint analysis.	MOFA+ (factor analysis), MixOmics (multivariate stats), xMWAS (network integration) [47] [46].
	Network Analysis & Visualization	Constructs and visualizes biological interaction networks.	Cytoscape [45].
	Deep Learning Libraries	Implements advanced models like GCNs for integration.	PyTorch, TensorFlow, with libraries like PyTorch Geometric [51].
Reference Databases	Public Multi-Omics Data Repositories	Sources of disease signatures for comparative analysis.	TCGA (cancer), METABRIC (breast cancer), OmicsDI (general) [46].
	Pathway & Interaction Databases	Provides prior knowledge for network construction and interpretation.	KEGG, Reactome, STITCH (chemical-protein interactions) [48] [46].

Application in Drug Repositioning: A Practical Synthesis

The ultimate application of this integrated approach is to efficiently identify new therapeutic uses for natural products. For instance, a multi-omics study on a natural compound might reveal that it upregulates genes in a specific anti-inflammatory pathway (transcriptomics), increases the abundance of key detoxifying enzymes (proteomics), and lowers the levels of pro-inflammatory leukotrienes (metabolomics). An AI model integrates these signals into a coherent signature.

This signature is then matched against a database of disease profiles and finds a strong anti-correlation with the multi-omics signature of a specific autoimmune disease like rheumatoid arthritis in public repositories [46]. Concurrently, network pharmacology analysis shows the compound's targets are centrally located in a protein-metabolite network associated with that disease [45] [5]. This convergent computational evidence generates a high-confidence hypothesis: the natural product could be repositioned for rheumatoid arthritis. This hypothesis, rooted in systems-level evidence, can then be prioritized for validation in relevant preclinical models, significantly derisking and accelerating the repositioning pipeline [6].

Alzheimer's Disease (AD) represents one of the most significant and costly global health challenges, affecting an estimated 50 million people worldwide and resulting in 28.8 million disability-adjusted life-years [52]. The traditional drug development pipeline is ill-equipped to address this crisis, requiring approximately $2.6 billion and 10-15 years to bring a single new drug to market, with a high failure rate particularly in complex neurodegenerative diseases [52] [6]. In contrast, drug repurposing—identifying new therapeutic uses for existing approved drugs—offers a promising strategic alternative. Repurposed candidates can potentially reach patients in 3-6 years at a cost near $300 million, leveraging existing safety and pharmacokinetic data to de-risk development [6].

The current therapeutic landscape for AD is severely limited. Only six drugs and one two-drug combination are approved by the FDA, primarily comprising acetylcholinesterase inhibitors (Donepezil, Galantamine, Rivastigmine) and an NMDA receptor antagonist (Memantine) [52]. A systematic meta-analysis indicates these treatments offer symptomatic relief for cognitive scores but do not address underlying neurodegeneration or neuropsychiatric symptoms, highlighting a critical unmet need for disease-modifying therapies [52].

This context frames the emergence of DeepDrug, a novel expert-guided AI framework for multi-drug repurposing in AD. Moving beyond single-target approaches, DeepDrug embodies a paradigm shift towards systems pharmacology, designed to identify synergistic drug combinations that concurrently modulate the multiple pathological pathways driving AD progression [52]. Its development aligns with a broader thesis on leveraging artificial intelligence to unlock the therapeutic potential of complex interventions, including natural products, by modeling their polypharmacology within sophisticated biological networks [5].

Table 1: Economic and Clinical Rationale for Drug Repurposing in Alzheimer's Disease

Metric	Traditional Drug Development	Drug Repurposing	Data Source
Average Cost	~$2.6 billion	~$300 million	[52] [6]
Development Timeline	10-15 years	3-6 years	[6]
Approved AD Drugs	6 drugs, 1 combination	N/A (Therapeutic Goal)	[52]
Therapeutic Scope	Primarily symptomatic	Aims for disease modification	[52]

Core Methodology: The Four Pillars of the DeepDrug Framework

The DeepDrug framework is architecturally defined by four interconnected methodological innovations that integrate deep domain expertise with advanced graph machine learning [52].

Expert-Guided Biological Knowledge Integration

DeepDrug moves beyond standard gene lists by incorporating specialized AD domain knowledge into its candidate target selection. This includes:

• Long Genes: Genes particularly vulnerable to age-related transcriptional stress and implicated in neurodegeneration.
• Immunological & Aging Pathways: Curated pathways reflecting the central role of neuroinflammation and cellular senescence in AD.
• Somatic Mutation Markers: Genetic variants identified in both brain tissue and blood samples associated with AD pathology [52].

This expert curation ensures the model is grounded in the multi-factorial biology of AD, covering key hallmarks often missed by conventional, data-driven target discovery approaches.

Construction of a Signed, Directed, and Weighted Biomedical Graph

The framework's core is a signed directed heterogeneous biomedical graph. This complex network synthesizes diverse biological entities and their nuanced relationships:

• Node Types: Includes drugs, proteins/genes, diseases, pathways, and gene ontology terms.
• Edge Types: Captures relationships such as protein-protein interactions (PPI), drug-target binding (activation/inhibition), and disease-gene associations.
• Key Innovations:
  • Edge Direction & Sign: Edges have direction (e.g., Drug A → Target B) and a sign (positive for activation, negative for inhibition), capturing causal and inhibitory biological logic.
  • Node/Edge Weighting: Entities and relationships are weighted (e.g., by binding affinity or evidence strength), allowing the model to prioritize more robust biological information [52].

This graph structure provides a computationally tractable representation of AD pathophysiology, superior to previous graphs used in repurposing which lacked these weighted and signed attributes [52].

Graph Neural Network Encoding and Embedding

The constructed knowledge graph is processed using a signed directed Graph Neural Network (GNN). The GNN performs nonlinear dimensionality reduction, learning to map each node (e.g., a drug or protein) into a lower-dimensional, continuous vector space (an "embedding") [52].

• Message Passing: The GNN algorithm propagates information across the graph's edges, allowing the embedding for a drug node to be informed by the features of its protein targets, their associated pathways, and related diseases.
• Capturing Granular Relationships: This process generates embeddings that encapsulate high-order, multi-hop relationships within the graph. Consequently, drugs with similar network neighborhoods (i.e., targeting similar biological processes) will have similar embeddings, even if they are structurally dissimilar [52].

Systematic Identification of High-Order Drug Combinations

The final pillar addresses the combinatorial challenge of multi-drug therapy. DeepDrug employs a diminishing return-based thresholding algorithm to systematically search for synergistic combinations from the top-ranked single drugs. This method prioritizes combinations where the added therapeutic benefit of each new drug outweighs the complexity it introduces, moving efficiently beyond pairwise drug analysis to identify optimal 3-to-5 drug cocktails with maximal predicted synergy against the AD network [52].

Table 2: Core Components of the DeepDrug Expert-Guided Biomedical Graph

Component	Description	Role in Model
Expert-Guided Nodes	Long genes, aging/immune pathways, somatic markers	Seeds the graph with biologically relevant AD targets.
Signed Directed Edges	Relationships with direction (→) and sign (+/-)	Encodes causal & inhibitory biological logic (e.g., drug inhibits protein).
Node/Edge Weights	Numerical scores (e.g., binding affinity, p-value)	Quantifies relationship strength, informing GNN's learning priority.
Heterogeneous Types	Drugs, proteins, diseases, pathways, GO terms	Enables multi-scale reasoning from molecular to systems level.

Experimental Protocols & Validation

Graph Construction and Data Curation Protocol

• Entity Collection: Compile lists of FDA-approved drugs from sources like DrugBank, AD-associated genes from genomic studies (GWAS, sequencing), and pathway definitions from KEGG and Reactome.
• Expert Curation: A panel of neuroscientists and geneticists reviews and augments the gene list to include long genes, key immunological/aging pathways (e.g., NF-κB, mTOR), and reported somatic mutation markers from AD cohorts.
• Relationship Annotation: For each drug-target pair, annotate the interaction type (agonist, antagonist, inhibitor) from databases like STITCH and ChEMBL, assigning direction and sign. Protein-protein interactions are sourced from STRING or BioGRID.
• Weight Assignment: Assign confidence weights to edges based on experimental evidence (e.g., Ki values for drug-target pairs, combined scores for PPIs). Disease-gene associations are weighted by genetic evidence scores [52].

GNN Model Training and Embedding Generation Protocol

• Graph Representation: Formalize the curated data as a graph G = (V, E, W), where V is the set of nodes, E the set of signed, directed edges, and W the set of corresponding weights.
• Model Architecture: Implement a signed directed GNN. For a node v, its embedding h_v at layer (l+1) is updated via a signed message-passing function: h_v^(l+1) = σ( Σ_(u∈N+(v)) W_+^l h_u^l + Σ_(u∈N-(v)) W_-^l h_u^l + W_self^l h_v^l ) where N+(v) and N-(v) denote neighbors connected by positive and negative edges, respectively, W are trainable weight matrices, and σ is a non-linear activation [52].
• Training Objective: Train the model using a link prediction task. Randomly mask a subset of known edges (e.g., drug-target links) and task the model with predicting their existence and sign. This self-supervised objective forces the GNN to learn meaningful node embeddings that capture the graph's topological and semantic structure.
• Embedding Extraction: After training, perform a forward pass to generate the final latent vector (embedding) for each drug and disease node in the graph.

Drug Scoring and Combination Optimization Protocol

• Single Drug Scoring: Calculate a drug-AD association score. This is typically derived from the proximity (e.g., cosine similarity or distance) between a drug's embedding and the embedding of the "Alzheimer's disease" node or a composite of key AD gene embeddings in the latent space.
• Ranking & Thresholding: Rank all drugs by their association score. Apply a diminishing returns function to determine a cutoff threshold. This function models the marginal utility of adding lower-ranked drugs and selects the top k candidates for combination analysis.
• Combinatorial Search: Systematically evaluate the predicted efficacy of combinations (from pairs up to 5-drug sets) derived from the top k candidates. The synergy score can be modeled as a function of the combined embeddings and their collective network proximity to the AD pathology module.
• Lead Combination Selection: Select the combination that maximizes the predicted synergy score while adhering to practical constraints (e.g., number of drugs, avoiding known adverse interactive effects) [52].

Key Output: The DeepDrug Lead Combination for AD

Applying this framework, DeepDrug identified a five-drug lead combination predicted to synergistically modulate converging AD pathways [52]:

• Tofacitinib & Baricitinib: JAK/STAT inhibitors that target neuroinflammation, a core driver of neuronal damage.
• Niraparib: A PARP inhibitor that addresses mitochondrial dysfunction and oxidative stress.
• Empagliflozin: An SGLT2 inhibitor shown to improve glucose metabolism, addressing cerebral bioenergetic deficits.
• Doxercalciferol: A vitamin D analog with potential neuroprotective and immunomodulatory properties.

This combination exemplifies the systems pharmacology approach, designed to concurrently hit multiple pathological axes—inflammation, metabolism, and oxidative stress—rather than a single target [52].

Table 3: Research Reagent Solutions for GNN-Driven Drug Repurposing

Reagent / Resource	Function in the Workflow	Example Sources / Tools
Biomedical Knowledge Bases	Provide structured data on entities (drugs, genes, diseases) and their relationships for graph construction.	DrugBank, STITCH, STRING, DisGeNET, KEGG, Reactome [52]
Genomic & Transcriptomic Datasets	Source for identifying AD-associated genes, long genes, and somatic mutation markers for expert-guided node selection.	AD GWAS studies, brain tissue RNA-seq datasets (e.g., from ROSMAP), blood-based biomarker studies [52]
GNN Software Frameworks	Libraries for building, training, and evaluating the signed directed graph neural network model.	PyTorch Geometric (PyG), Deep Graph Library (DGL), Spektral [52]
High-Performance Computing (HPC) / Cloud GPU	Computational infrastructure required for processing large heterogeneous graphs and training deep GNN models.	Local GPU clusters, AWS EC2 (P3/G4 instances), Google Cloud AI Platform, Azure ML [52]
Drug-Target Interaction Predictors	Tools to supplement experimental data and predict novel or weak binding interactions for edge weighting.	SwissTargetPrediction, SuperPred, SEAR [52] [5]
Network Visualization & Analysis Suites	Software for visualizing the constructed biomedical graph and conducting topological analysis.	Cytoscape, Gephi, NetworkX [52]

Visualizing the DeepDrug Framework and Pathways

The following diagrams, generated using Graphviz DOT language, illustrate the core workflow of DeepDrug and the biological rationale for its predicted drug combination.

Diagram 1: DeepDrug AI Repurposing Workflow (Max 760px)

Diagram 2: DeepDrug Combo Targets Key AD Pathways (Max 760px)

Discussion and Future Directions within AI for Natural Product Repurposing

The DeepDrug framework demonstrates the transformative potential of expert-guided GNNs in decoding complex diseases for drug repurposing. Its success provides a template applicable to natural product research, a field characterized by unparalleled chemical diversity and polypharmacology but hampered by mechanistic ambiguity [5].

Future integrations could involve:

• Incorporating Natural Product Libraries: Expanding the graph's "drug" nodes to include characterized natural compounds (e.g., from Traditional Chinese Medicine databases or marine/fungal metabolite libraries).
• Modeling Synergistic Herbal Formulations: Using the GNN's combination optimization engine to predict effective multi-herb formulations, moving beyond reductionist single-compounder approaches [5].
• Linking to Multi-Omic Validation Gates: Connecting AI predictions to experimental validation pipelines, such as transcriptomic signature reversal assays or feature-based molecular networking in untargeted metabolomics, to create a closed-loop discovery system [5].

Persistent challenges such as data quality, batch variability in natural products, and model interpretability remain. Addressing these will require minimal information standards for natural product metadata, robust benchmark datasets, and advanced explainable AI (XAI) techniques for GNNs [5]. As these frameworks mature, the convergence of expert knowledge, biomedicine-centric AI, and systematic experimentation holds the promise of accelerating the discovery of effective, multi-target therapies for Alzheimer's disease and beyond.

Navigating the Challenges: Data, Design, and Translation in AI-Driven NP Repurposing

The repositioning of natural products using artificial intelligence (AI) represents a frontier in accelerating drug discovery. This approach promises to systematically uncover new therapeutic applications for complex natural compounds, leveraging their historical use and bioactivity [5]. However, the transformative potential of AI is constrained by significant data challenges intrinsic to the field. Natural product research often grapples with small, imbalanced datasets due to the complexity and cost of characterizing novel metabolites. Furthermore, the "cold start" problem—the inability of models to make predictions for entirely new compounds or diseases absent from training data—severely limits real-world applicability [5] [8]. This technical guide frames these data hurdles within the broader thesis of AI-driven drug repositioning for natural products. It provides researchers and drug development professionals with an in-depth analysis of the problems, surveys state-of-the-art methodological solutions, and outlines practical experimental protocols and toolkits to advance the field toward mechanistically grounded and prospectively validated translation [5].

The Core Data Challenges in Detail

The efficacy of AI and machine learning (ML) models is fundamentally dependent on the volume, quality, and balance of training data. In natural product research, the data landscape is particularly fraught.

• Small and Imbalanced Datasets: Experimental data on natural products—covering isolation, structure elucidation, and bioactivity—is notoriously scarce and expensive to generate. This results in datasets that are orders of magnitude smaller than those available for synthetic compound libraries [5]. Furthermore, these datasets are typically highly imbalanced; for a given therapeutic area (e.g., antimicrobial activity), the number of confirmed active compounds is vastly outnumbered by inactive or untested ones. Models trained on such data risk poor generalization, high false-positive rates, and bias toward predicting the majority class (e.g., "inactive") [8].
• The Cold Start Problem: This is a critical limitation for dynamic and expanding fields. In drug repositioning, the cold start problem manifests in two primary scenarios: 1) Drug-centric: Predicting therapeutic potential for a newly discovered or synthesized natural product with no prior association data. 2) Disease-centric: Identifying candidate compounds for a novel disease target or a rare disease with limited molecular profiling data [8]. Traditional network-based and graph models fail in these scenarios because their predictions are reliant on the existing connections within a knowledge graph; a completely new entity has no connections, making prediction impossible [8]. This creates a significant barrier to deploying AI for truly novel discovery.

Table 1: Impact and Characteristics of Core Data Challenges in AI for Natural Products

Challenge	Primary Cause in Natural Product Research	Impact on AI/ML Models	Common in Silico Manifestation
Small Datasets	High cost & complexity of metabolite characterization; limited high-throughput screening data [5].	High variance, overfitting, poor generalization, unreliable performance metrics.	Training sample size < 1,000 for specific bioactivity classes.
Imbalanced Datasets	Most screened compounds are inactive for any given target; positive hits are rare [5].	Model bias toward majority class (inactivity); low recall for active compounds; inflated accuracy metrics.	Class ratio (negative:positive) of 100:1 or greater.
Cold Start (Drug)	Discovery of novel phytochemicals or engineered analogs with no prior biological data [8].	Inability of graph-based models to generate embeddings or predictions for unseen molecular nodes.	New natural product entity absent from all training networks/knowledge graphs.
Cold Start (Disease)	Research into rare diseases or novel pathogenic mechanisms with sparse molecular data [8].	Lack of a disease node feature vector or network links for model inference.	New disease entity without known drug associations or detailed omics signatures.

Technical Solutions and Methodological Advances

To overcome these hurdles, the field is evolving beyond classical machine learning toward integrated frameworks that combine multiple data modalities and learning paradigms.

3.1 Overcoming Data Scarcity and Imbalance Technical strategies focus on enhancing model robustness and expanding limited data.

• Data Augmentation and Synthetic Data: Generating realistic synthetic data is a promising approach. For molecules, this can involve validated in silico simulations of molecular properties or bioactivity spectra. Techniques like Generative Adversarial Networks (GANs) can create synthetic molecular structures or biological activity profiles to augment training sets, though they require careful validation to ensure biological relevance [53] [6].
• Advanced Modeling Techniques: Models must be explicitly designed for imbalance. Cost-sensitive learning algorithms assign a higher penalty for misclassifying the rare, active class, forcing the model to pay more attention to it. Ensemble methods, like balanced random forests, which under-sample the majority class during the creation of multiple model trees, are also effective [8]. The UKEDR framework demonstrated strong robustness on highly imbalanced datasets by leveraging rich pre-trained feature representations and attention-based recommendation systems [8].
• Transfer and Multi-Task Learning: These paradigms mitigate data scarcity by leveraging knowledge from related, data-rich domains. A model pre-trained on a large corpus of synthetic drug-target interactions can be fine-tuned on a small dataset of natural product activities, effectively transferring learned chemical and biological patterns [5] [6].

3.2 Solving the Cold Start Problem State-of-the-art solutions move from pure graph-based inference to hybrid systems that incorporate intrinsic entity attributes.

• Semantic Similarity and Proxy Mapping: For a new natural product (cold-start drug), one approach is to find its closest analogs in a pre-trained chemical space based on molecular fingerprints or embeddings from SMILES strings. The relational embeddings of these similar, known compounds can then serve as a proxy to map the new compound into the prediction framework [8].
• Unified Knowledge-Enhanced Frameworks: The UKEDR model exemplifies this advanced approach. It integrates several key components to address cold starts [8]:
  • Attribute-Specific Pre-training: It uses domain-specific pre-trained models to generate intrinsic feature vectors for any drug or disease. For drugs, this involves contrastive learning on molecular SMILES and spectral data. For diseases, a fine-tuned language model (e.g., DisBERT, fine-tuned from BioBERT) generates embeddings from textual descriptions [8].
  • Knowledge Graph Embedding: It learns relational representations from existing biomedical knowledge graphs using scalable methods like PairRE.
  • Hybrid Recommendation System: An Attentional Factorization Machine (AFM) acts as the prediction engine, intelligently combining the pre-trained attribute features and the relational graph embeddings. This allows UKEDR to make predictions for entities entirely absent from the original knowledge graph by using their pre-trained attribute features alongside proxy relational information [8].

Table 2: Performance Comparison of AI Models in Standard vs. Cold-Start Scenarios

Model Type	Representative Model	AUC on Standard Benchmark	AUC on Drug-Cold-Start	Key Advantage	Primary Limitation
Classical ML	Random Forest, SVM	Moderate (~0.75-0.85)	Very Low (<0.60)	Simplicity, interpretability for small features.	Cannot handle unseen features; poor on imbalanced data.
Network-Based	Heterogeneous Graph Network (e.g., DRHGCN)	High (>0.90)	Fails (Cannot run)	Excellent with rich network data.	Fails completely on new graph nodes [8].
Knowledge Graph + RS	UKEDR (PairRE_AFM configuration)	Very High (0.95) [8]	High (0.88-0.92) [8]	Handles cold-start via attributes & similarity; robust to imbalance.	Higher complexity; requires diverse pre-training data.

3.3 Integrated AI Workflow for Natural Products A cohesive pipeline addresses these challenges systematically. The workflow begins with multi-omics data acquisition (genomics, metabolomics) from natural sources, followed by curation and enrichment using chemical and taxonomic databases. The core analytical phase employs the hybrid AI models described above to predict bioactivity and repositioning potential. High-confidence predictions are then validated experimentally in iterative cycles, with the resulting new data feeding back to refine the AI models, creating a virtuous cycle of discovery [5].

Diagram 1: Conceptual flow from data challenges to AI solutions in natural product research.

Experimental Protocols and Validation

Translating AI predictions into credible biological insights requires rigorous experimental validation. Below is a detailed protocol for validating AI-predicted natural product-disease associations, integrating in silico and in vitro steps.

4.1 Protocol for Validating AI-Predicted Repurposing Candidates

• Step 1: In Silico Prioritization & Compound Sourcing
  • Input: AI model generates a ranked list of natural product-disease associations with confidence scores (e.g., UKEDR output) [8].
  • Action: Select top candidates (e.g., top 10-20) considering confidence score, commercial/generative availability, and chemical diversity. Source compounds from commercial vendors, in-house natural product libraries, or initiate extraction/isolation based on taxonomic information.
  • Quality Control: Perform LC-MS or NMR on sourced compounds to verify identity and purity (>95%).

• Step 2: In Vitro Bioactivity Screening

  • Cell-Based Assay Design: Select a disease-relevant cell line (e.g., cancer cell line for an oncology prediction). Develop an assay measuring a key phenotypic endpoint (e.g., cell viability via MTT, apoptosis via caspase-3 activation, or cytokine release for inflammation).
  • Experimental Setup: Treat cells with a dose range of the natural product candidate (e.g., 0.1 µM to 100 µM). Include a positive control (known effective drug for the disease) and negative control (vehicle-only). Perform experiments in triplicate.
  • Data Analysis: Calculate IC₅₀ or EC₅₀ values. A candidate is considered initially validated if it shows a dose-dependent effect on the target endpoint with a potency (IC₅₀/EC₅₀) in a biologically relevant range (typically low µM or better).

• Step 3: Target Engagement and Mechanistic Deconvolution

  • Target Identification: For candidates with confirmed bioactivity, employ techniques to probe mechanism. Use cellular thermal shift assay (CETSA) to confirm physical binding to the predicted protein target in a cellular context.
  • Pathway Analysis: Perform phospho-proteomics or RNA-seq on treated vs. untreated cells. Analyze differential expression/activation to determine if the treatment modulates the predicted signaling pathway (e.g., reversal of disease-associated gene signature) [5].
  • Functional Rescue ("Add-Back") Experiments: To establish causality, genetically or pharmacologically inhibit the predicted target/pathway. If the natural product's effect is abolished, it strongly supports the predicted mechanism [5].

• Step 4: Specificity and Early Toxicity Assessment

  • Counter-Screening: Test the compound in a panel of unrelated cell-based assays to assess selectivity and rule out non-specific cytotoxic effects.
  • Therapeutic Index Estimation: Determine the cytotoxic concentration (CC₅₀) in healthy primary cell lines (e.g., human fibroblasts). Compare with the therapeutic EC₅₀ to calculate a preliminary selectivity index.

Diagram 2: Experimental validation workflow for AI-predicted natural product repositioning.

The Scientist's Toolkit: Essential Research Reagents and Solutions

Successfully navigating the AI-driven repositioning pipeline requires a combination of computational tools and wet-lab reagents. The following toolkit is essential for implementing the strategies and protocols described.

Table 3: Research Reagent Solutions for AI-Driven Natural Product Repositioning

Tool/Reagent Category	Specific Example / Product	Primary Function in Workflow	Key Consideration for Use
AI/Computational Tools	UKEDR-like framework (integrating PairRE, AFM) [8]; DisBERT/BioBERT [8]; Graph neural network libraries (PyTorch Geometric, DGL).	Generate predictions, create molecular/disease embeddings, manage knowledge graphs.	Ensure interpretability and applicability domain assessment to avoid "black box" predictions [5].
Chemical & Metabolite Standards	Commercially available pure natural compounds (e.g., from Sigma-Aldrich, Cayman Chemical); In-house purified natural product libraries.	Provide physical material for in vitro validation of AI predictions.	Critical to verify purity and identity (via LC-MS, NMR) prior to biological testing [5].
Bioactivity Assay Kits	Cell viability/cytotoxicity (MTT, CellTiter-Glo); Apoptosis (Caspase-3/7 glo); Phospho-kinase array kits; Pathway-specific reporter assays.	Perform the initial functional validation of predicted bioactivity in disease-relevant models.	Select assays that match the predicted mechanism of action (e.g., anti-inflammatory, cytotoxic).
Target Engagement Reagents	Cellular Thermal Shift Assay (CETSA) kits; Target-specific antibodies for Western blot or immunofluorescence; siRNA/shRNA for target knockdown.	Confirm physical interaction with the predicted molecular target and establish mechanistic causality.	Requires prior high-confidence target prediction from the AI model or integrated network analysis.
Omics & Profiling Services	RNA-seq transcriptomics; Untargeted mass spectrometry-based metabolomics; Proteomics services.	Enable mechanistic deconvolution (pathway analysis) and generate systems-level data for model feedback [5].	Data analysis expertise is required to interpret results and link them back to the AI prediction.
Specialized Cell Models	Disease-relevant immortalized cell lines; Primary patient-derived cells; Induced pluripotent stem cell (iPSC)-derived lineages; Micro-physiological systems ("organ-on-a-chip") [5].	Provide biologically relevant contexts for validation, moving beyond simple cell lines to more translational models.	Increased biological relevance often comes with higher cost, complexity, and variability.

Addressing the dual hurdles of small/imbalanced data and the cold start problem is paramount for realizing the potential of AI in natural product repositioning. As demonstrated by integrated frameworks like UKEDR, the solution lies in hybrid architectures that combine knowledge graph reasoning with rich, pre-trained attribute representations from diverse data modalities (text, molecular structure, omics) [8]. This enables models to generalize beyond their initial training set. The future of the field depends on creating virtuous data cycles: AI predictions must flow into standardized, reproducible experimental validation pipelines, and the resulting high-quality biological data must feed back to retrain and refine the AI models [5] [54]. Closing this loop requires concerted effort in data stewardship—adopting minimal information standards for natural product metadata, performing cross-laboratory replication studies, and implementing uncertainty quantification [5]. By embracing these technical solutions and collaborative practices, researchers can transform natural product libraries into validated leads for unmet medical needs with unprecedented efficiency.

Whitepaper Context This whitepaper addresses the critical challenge of model overfitting within the specific domain of AI-driven drug repositioning for natural products. The repositioning paradigm—finding new therapeutic uses for existing drugs or natural compounds—offers a faster, lower-cost alternative to traditional drug development [6]. Artificial Intelligence (AI) and Machine Learning (ML) are pivotal in analyzing complex biological datasets to predict novel drug-disease associations [6]. However, the success of these models hinges on their reliability and ability to generalize beyond the data they were trained on. Overfitting, where a model learns noise and spurious patterns from limited or biased training data, is a fundamental threat to this goal, potentially leading to failed experimental validation and wasted resources [55]. This guide details robust validation techniques and mitigation strategies to build trustworthy AI models that can accelerate the discovery of new therapies from natural products.

The Overfitting Challenge in Drug Repositioning AI

In AI for drug repositioning, overfitting manifests when a model memorizes specific, non-generalizable patterns in the training data—such as coincidental correlations in high-throughput screening data or biases in historical compound libraries—instead of learning the underlying biological principles governing drug-target interactions. This risk is exacerbated by several field-specific factors:

• Small, Imbalanced Datasets: High-quality experimental data on natural product bioactivity is often limited and costly to produce, leading to small datasets. Furthermore, confirmed active compounds are typically far outnumbered by inactive ones, creating severe class imbalance [5].
• High-Dimensional, Noisy Data: Models integrate diverse data types (e.g., chemical structures, omics profiles, clinical outcomes), resulting in a vast number of features relative to samples. This "curse of dimensionality" increases the risk of finding chance correlations [55].
• Data Leakage and Bias: Improper handling of data where information from the "future" (e.g., a drug's later-discovered side effect) leaks into features predicting an earlier-stage property can create deceptively accurate but non-generalizable models [56].

An overfitted model may perform exceptionally well on its training data but will fail to accurately predict the activity of novel, unseen natural products or their efficacy against new disease targets, thereby invalidating its translational utility [8].

Core Concepts: Bias, Variance, and Model Generalization

Understanding the bias-variance tradeoff is essential for diagnosing and addressing model reliability.

• Bias: The error from erroneous assumptions in the learning algorithm. High bias (underfitting) causes the model to miss relevant relationships, leading to poor performance on both training and test data. An example is using a linear model to capture complex, non-linear structure-activity relationships.
• Variance: The error from sensitivity to small fluctuations in the training set. High variance (overfitting) causes the model to model the random noise in the training data, leading to excellent training performance but poor test performance [55].
• Generalization: The primary goal is to build a model with low generalization error, meaning it performs reliably on new, unseen data drawn from the same underlying distribution. The ideal model balances bias and variance to capture the true signal without the noise [57].

Table 1: Model Performance Profiles Indicating Fit Quality

Model Profile	Training Accuracy	Validation/Test Accuracy	Indication	Likely Cause in Drug Repositioning Context
Underfit	Low	Low	High Bias	Model is too simple (e.g., insufficient model capacity, inadequate features to capture pharmacology).
Well-Fit	High	Similarly High (slight drop expected)	Good Generalization	Optimal balance. Model has learned generalizable patterns of drug-disease association.
Overfit	Very High (e.g., >99%)	Significantly Lower	High Variance	Model is too complex, has trained on noise, or has leaked data (e.g., memorized batch effects in screening data) [56] [55].

The distinction between a well-fit and overfit model is not merely a performance gap but a measure of how much less accurate the model is on unseen data [56].

Foundational Validation Techniques

Robust validation is the first line of defense against overfitting. It provides an unbiased estimate of model performance on unseen data.

• Train-Validation-Test Split: The dataset is partitioned into three subsets. The model is trained on the training set, its hyperparameters are tuned on the validation set, and its final performance is evaluated on the held-out test set, which should only be used once to avoid bias. In time-series or clinical trial data, splits must be chronological to prevent leakage from future data [57].

• K-Fold Cross-Validation (CV): A gold standard technique where the data is split into k equal folds. The model is trained k times, each time using a different fold as the validation set and the remaining k-1 folds as the training set. The final performance is the average across all k trials. This maximizes data use and provides a more reliable performance estimate, especially for small natural product datasets [55]. For temporal data, a forward-chaining (rolling window) approach must be used.

• Performance Metrics for Imbalanced Data: Accuracy is a misleading metric when positive cases (e.g., active compounds) are rare. Superior metrics include:

  • Area Under the Precision-Recall Curve (AUPR): More informative than ROC-AUC for severe class imbalance, as it focuses on the performance on the positive (minority) class [56].
  • F1-Score: The harmonic mean of precision and recall, providing a single measure of a model's accuracy on the minority class [56].

Advanced Strategies to Mitigate Overfitting

Beyond validation, specific techniques can be applied during model development to improve generalization.

• Regularization: Techniques that penalize model complexity to discourage over-reliance on any single feature.
  • L1 (Lasso): Adds a penalty equal to the absolute value of feature coefficients, which can drive some coefficients to zero, performing feature selection [56] [55].
  • L2 (Ridge): Adds a penalty equal to the square of the magnitude of coefficients, shrinking all coefficients proportionally [56].
• Ensemble Methods: Combining predictions from multiple diverse models (e.g., Random Forests, Gradient Boosting) averages out errors and reduces variance. This is a core strength of many top-performing methods in computational biology [55].
• Dropout (for Neural Networks): Randomly "dropping out" (ignoring) a proportion of neurons during training prevents complex co-adaptations and forces the network to learn more robust, redundant features [55].
• Early Stopping: Halting the training process when performance on the validation set stops improving and begins to degrade, preventing the model from over-optimizing to the training noise [55].
• Data Augmentation & Synthetic Data: Artificially expanding the training set by creating modified copies of existing data (e.g., small molecular transformations that preserve activity) can improve robustness, though care must be taken to maintain biological validity [55].

Table 2: Summary of Overfitting Mitigation Techniques

Technique	Primary Mechanism	Best Suited For	Key Consideration in Drug Repositioning
L1/L2 Regularization	Penalizes complex coefficient weights.	Linear models, Logistic Regression, Neural Networks.	Helps identify the most predictive molecular descriptors or genomic features.
Ensemble Learning (e.g., Random Forest)	Averages predictions from multiple base models.	Most data types, especially structured/tabular data.	Improves robustness against noise in high-throughput screening data.
Dropout	Randomly ignores neurons during training.	Deep Neural Networks (DNNs), Graph Neural Networks (GNNs).	Crucial for large networks analyzing complex knowledge graphs of drug-target-disease relationships [8].
Early Stopping	Stops training when validation error increases.	Iterative models like DNNs and GNNs.	Requires a clean validation set not used for hyperparameter tuning.
Data Augmentation	Increases effective training data size.	Image-based assays, molecular property prediction.	Must be scientifically plausible (e.g., valid stereochemistry, ring alterations).

Experimental Protocol: A Case Study in Robust AI for Repositioning

The following protocol is inspired by the Unified Knowledge-Enhanced deep learning framework for Drug Repositioning (UKEDR), which exemplifies the integration of advanced techniques to ensure reliability and handle cold-start problems for novel natural products [8].

Objective: To predict novel therapeutic associations for natural product compounds by integrating heterogeneous biological knowledge while rigorously avoiding overfitting.

1. Data Curation & Preprocessing:

• Data Sources: Integrate data from knowledge graphs (e.g., DRKG), including drug-target, target-disease, and drug-disease associations. Include intrinsic attributes: molecular SMILES strings for drugs and textual disease descriptions from medical ontologies [8].
• Splitting Strategy: Implement a time-split or cold-start split for the test set. For example, hold out all associations involving drugs or diseases approved/added after a specific date. This simulates real-world prediction scenarios and prevents temporal leakage [8].
• Addressing Imbalance: Use techniques like AUC-weighted loss functions or oversampling of minority classes during training. The model should be evaluated using AUPR and AUC-ROC [56].

2. Model Architecture (UKEDR-inspired):

• Feature Representation:
  • Drugs: Use a pre-trained model (e.g., CReSS) to convert molecular SMILES into fixed-dimensional feature vectors via contrastive learning on spectral data [8].
  • Diseases: Fine-tune a biomedical language model (e.g., BioBERT) on disease text corpora (DisBERT) to generate semantic feature vectors [8].
• Relational Learning: Embed the heterogeneous knowledge graph using a translational model (e.g., PairRE) to capture multi-relation patterns (e.g., "binds," "inhibits," "treats") [8].
• Prediction Engine: Fuse the intrinsic (pre-trained) and relational (graph) embeddings using an Attentional Factorization Machine (AFM). The attention mechanism learns which feature interactions are most important for the prediction, moving beyond simple dot products and improving generalization [8].
• Regularization: Apply dropout within the AFM layers and use L2 regularization on all trainable parameters.

3. Training & Validation Workflow:

• Perform 5-fold cross-validation on the training/validation portion of the data to tune hyperparameters (learning rate, dropout rate, regularization strength).
• Implement early stopping with a patience parameter (e.g., 10 epochs) based on the cross-validation AUPR score.
• The final model is retrained on the entire training/validation set with the optimal hyperparameters and evaluated once on the held-out cold-start test set.

Diagram: Robust Validation Workflow for AI Drug Repositioning

4. Performance Benchmarking:

• Compare the model against classical baselines (e.g., Random Forest, Logistic Regression) and state-of-the-art graph-based methods (e.g., DeepDR, KGNN) [8].
• Critical Analysis: Report performance degradation between CV validation scores and the final test score. A large gap indicates potential overfitting to the validation tuning process. Analyze model performance specifically on the "cold-start" entities to validate real-world utility [8].

The Scientist's Toolkit: Key Research Reagents & Solutions

Item/Category	Function in AI Model Validation	Example/Note
Knowledge Graph Databases	Provide structured, relational biological data for training and benchmarking.	DRKG, Hetionet, PrimeKG. Essential for network-based and GNN approaches [8].
Pre-trained Molecular Encoders	Convert chemical structure (e.g., SMILES) into informative numerical features, addressing data scarcity.	CReSS (for spectral data), ChemBERTa, GROVER. Transfers knowledge from large unlabeled chemical corpora [8].
Pre-trained Biomedical Language Models	Generate semantic feature vectors for diseases, targets, or pathways from text.	DisBERT (fine-tuned BioBERT), BlueBERT. Captures contextual biological knowledge [8].
Hyperparameter Optimization Frameworks	Automate the search for optimal model settings to maximize performance and generalization.	Optuna, Ray Tune, scikit-learn's GridSearchCV. Integrated with CV to prevent overfitting.
Model Interpretation Libraries	Provide post-hoc explanations for predictions, helping to identify biological plausibility vs. learned artifacts.	SHAP, Captum, GNNExplainer. Critical for validating that models learn meaningful biology.

Diagram: UKEDR Model Architecture for Robust Predictions

Ensuring model reliability through robust validation and overfitting mitigation is not a secondary step but the core of developing translatable AI for natural product drug repositioning. As exemplified by frameworks like UKEDR, the integration of rigorous splitting (cold-start), advanced regularization, and fusion of complementary data representations (intrinsic and relational) sets a new standard for generalization [8].

Future advancements will likely focus on:

• Quantifying Prediction Uncertainty: Developing models that output confidence intervals for their predictions, allowing researchers to prioritize high-certainty candidates for costly experimental validation [5].
• AI-Guided Experimental Design: Creating active learning loops where model predictions directly inform which natural products or assays should be tested next, optimizing resource allocation to reduce data imbalance and bias [58].
• Standardized Benchmarking and Governance: The establishment of community-wide, biologically realistic benchmarks with prospective validation, alongside evolving regulatory frameworks for AI/ML in drug development, will be crucial for translating reliable models into clinical impact [5] [58].

By adhering to the principles and practices outlined in this guide, researchers can build AI systems that genuinely accelerate the discovery of new therapeutic uses for natural products, moving from serendipitous finds to systematic, reliable prediction.

The integration of Artificial Intelligence (AI) into drug repositioning, particularly for natural products, represents a paradigm shift in pharmaceutical research, promising to reduce development timelines from over a decade to potentially under eight years and cut costs by up to 75% [59] [60]. However, the inherent "black-box" nature of advanced AI models, such as deep learning and graph neural networks, creates a significant interpretability gap. This gap hinders the translation of computational predictions into actionable biological insight and trustworthy therapeutic hypotheses [61] [62]. Explainable AI (XAI) emerges as the critical discipline bridging this gap, offering methodologies to make AI's reasoning transparent, auditable, and biologically meaningful [61]. This technical guide details how XAI strategies—from feature attribution to counterfactual explanations—can be deployed within AI-driven frameworks for repositioning natural products. These strategies are essential for validating predictions, uncovering novel mechanisms of action, mitigating data bias, and ultimately building the trust required for adoption in high-stakes drug development [62] [63]. The following sections provide a comprehensive analysis of the interpretability challenge, present a technical overview of relevant AI models, outline practical XAI methodologies, and propose an integrated workflow for experimental validation.

The Interpretability Imperative in AI-Driven Drug Repositioning

The traditional drug discovery pipeline is notoriously inefficient, typically requiring 12–15 years and over $2.5 billion per approved therapy, with a failure rate exceeding 90% [8] [60]. Drug repositioning, which identifies new therapeutic uses for existing drugs or compounds, offers a faster, cheaper, and de-risked alternative [64]. Natural products, which form the basis of approximately 50% of all FDA-approved small-molecule drugs, are a prime candidate source for repositioning due to their unique structural complexity and proven bioactivity [65]. AI accelerates repositioning by analyzing vast, interconnected datasets—including genomic, proteomic, clinical, and chemical information—to predict novel drug-disease associations [66] [60].

However, the complexity of the models that enable these predictions (e.g., deep neural networks, knowledge graph embeddings) obscures the reasoning behind their outputs [61]. In a regulatory and scientific context, a high-accuracy prediction is insufficient without a clear, biologically plausible rationale. The interpretability gap manifests in several critical challenges:

• Loss of Biological Insight: A model may correctly associate a natural product with a disease but based on latent statistical patterns that do not correspond to a verifiable biological pathway, leading to dead-end hypotheses [66].
• Amplification of Bias: AI models can perpetuate and amplify biases present in training data. For instance, datasets underrepresented in specific demographics may lead to skewed efficacy predictions [62]. XAI is necessary to audit and identify these biases.
• Regulatory and Trust Barriers: Regulatory frameworks, such as the EU AI Act, increasingly demand transparency for AI used in high-risk areas, including healthcare. A "black-box" model is a significant barrier to regulatory acceptance and clinician trust [62] [63].

Table 1: Quantitative Impact of AI and the Interpretability Challenge in Drug Development

Metric	Traditional Process	AI-Accelerated Process (Potential)	Role of XAI
Development Timeline	12-15 years [8] [60]	~8 years [59]	Reduces validation time by providing testable hypotheses.
Cost per Approved Drug	>$2.5 billion [60]	Up to 75% reduction [59]	Prevents costly late-stage failures by enabling early vetting of AI predictions.
Clinical Trial Success Rate	~10% [8]	Significantly improved [60]	Builds trust in AI-selected candidates for trial design and patient recruitment.
Data Points for Target ID	N/A	10,000–15,000 entries for specific targets (e.g., Mpro, hERG) [60]	Explains which data features (e.g., genetic variants, protein interactions) drove the target selection.

AI Model Architectures for Natural Product Repositioning and Their Opacity

Several AI architectures are central to modern drug repositioning efforts. Understanding their structure is the first step in devising strategies to explain them.

• Knowledge Graph Embedding Models: These models represent biomedical knowledge as a network of entities (e.g., Natural Product, Gene, Disease, Side Effect) and relationships (e.g., binds_to, treats, causes). Models like TransE, PairRE, and others embed these entities into a continuous vector space [8]. While they capture complex relational logic, the resulting embeddings are not human-interpretable, making it unclear why a new link is predicted between a product and a disease.
• Graph Neural Networks (GNNs): GNNs operate directly on graph structures. In frameworks like UKEDR (Unified Knowledge-Enhanced deep learning framework for Drug Repositioning), GNNs aggregate information from a node's neighbors to create rich representations [8]. The "message-passing" mechanism, while powerful, diffuses information across the graph in ways that are difficult to trace back to the original source data.
• Hybrid Deep Learning Frameworks: State-of-the-art systems like UKEDR combine multiple modules: knowledge graph embedding, attribute representation learning (using language models for diseases or molecular encoders for drugs), and a recommendation system (e.g., Attentional Factorization Machines) [8]. The final prediction is a product of interacting subsystems, each contributing to the opacity. For example, UKEDR's superior performance (e.g., AUC > 0.95 on benchmark datasets) comes from this integration, but explaining a specific prediction requires disentangling each module's contribution [8].

Table 2: Performance Benchmarks of AI Repositioning Models (Illustrative)

Model / Approach	Dataset	Key Performance Metric	Interpretability Status
UKEDR (PairRE_AFM configuration) [8]	RepoAPP, RepoDB, PREDICT	AUC: 0.95, AUPR: 0.96	Low. High performance but complex hybrid architecture.
Classical ML (e.g., SVM, Random Forest) [66]	Various	Varies; generally lower than DL	Moderate. Feature importance scores can be generated.
Network-Based Methods (e.g., MBiRW) [8]	Drug-Disease Networks	Varies	Moderate. Relies on network topology which can be visualized.
KGCNH (Knowledge Graph CNN) [8]	Biomedical KG	Good performance	Low. Graph convolutions obscure reasoning paths.

The following diagram illustrates the flow of information and opacity in a sophisticated hybrid AI repositioning framework.

Diagram 1: Opacity in a Hybrid AI Repositioning Framework (UKEDR)

XAI Strategies to Bridge the Gap: From Output to Insight

To extract biological insight from models like the one above, specific XAI techniques must be applied at different stages.

1. Feature Attribution and Importance Analysis: This class of methods assigns a contribution score to each input feature for a given prediction.

• SHAP (SHapley Additive exPlanations): A game-theoretic approach that provides consistent and locally accurate feature importance values. In the context of a natural product repositioning model, SHAP can reveal which molecular descriptors (e.g., presence of a specific functional group, logP, molecular weight) or which disease ontology terms most strongly influenced the positive association prediction [61].
• LIME (Local Interpretable Model-agnostic Explanations): Approximates the complex "black-box" model locally around a specific prediction with a simple, interpretable model (e.g., linear regression). LIME can answer: "What minimal set of features in this natural product's profile is driving its predicted activity against this specific cancer subtype?" [61]

2. Counterfactual Explanations: This powerful strategy involves generating "what-if" scenarios. It modifies input features in a minimal way to change the model's prediction [62]. For a predicted active natural product, a counterfactual explanation could show: "If the glycosylation moiety on this flavonoid were removed, the model would predict a loss of activity. This suggests the glycosyl group is critical for the predicted effect." This directly points medicinal chemists toward structure-activity relationships.

3. Attention Mechanism Visualization: Models using attention (like the AFM in UKEDR or Transformer-based encoders) learn to "pay attention" to different parts of the input when making a decision. Visualizing attention weights can show, for instance, which words in a disease description or which atoms in a molecular graph the model focused on most, offering a glimpse into its internal reasoning process [8].

4. Knowledge Graph Path Reasoning and Subgraph Extraction: For predictions made on knowledge graphs, explaining an outcome can involve extracting the most influential subgraph or path linking the natural product to the disease. An explanation could be: "The model predicted this marine alkaloid treats Condition X primarily due to a 3-hop path connecting it to Gene Y (a known target), which is also linked to Disease X via pathway Z." This provides a testable biological hypothesis [64].

Table 3: XAI Methodologies and Their Application to Repositioning Tasks

XAI Technique	Mechanism	Application in Natural Product Repositioning	Biological Insight Generated
SHAP / LIME [61]	Feature attribution by perturbation or game theory.	Identifies key molecular features or disease genetics driving a prediction.	Highlights critical pharmacophores or suggests a shared genetic etiology between conditions.
Counterfactual Explanations [62]	Generates minimal input changes to flip the prediction.	Probes structural or phenotypic boundaries of predicted activity.	Suggests precise chemical modifications for lead optimization or reveals model sensitivity to specific biomarkers.
Attention Visualization [8]	Maps internal model focus onto input elements.	Shows which parts of a chemical structure or disease text the model "attended to."	Correlates model attention with known functional groups or clinical disease hallmarks, building face validity.
KG Path Extraction [64]	Identifies salient connecting paths in a knowledge graph.	Extracts the chain of entities linking a natural product to a candidate disease.	Proposes a mechanistic pathway (e.g., Product→Target→Pathway→Disease) for experimental validation.

An Integrated Experimental Protocol for Validating XAI-Generated Hypotheses

An XAI explanation is only as good as the biological insight it provides and the experimental validation it enables. The following protocol outlines a闭环 (closed-loop) workflow from AI prediction to biological insight.

Step 1: AI Prediction & XAI Explanation Generation

• Input: A library of characterized natural products and a target disease (e.g., a specific oncology indication).
• Process: Run the hybrid AI repositioning model (e.g., a UKEDR-type framework). For top-ranking predictions, apply XAI techniques (e.g., SHAP, KG Path Extraction) to generate hypotheses.
• Output: 1) A ranked list of candidate natural products. 2) For each candidate, an XAI-derived hypothesis (e.g., "Compound A is predicted effective due to its similarity to known inhibitors of Target B, which is overexpressed in Disease D").

Step 2: In Silico Cross-Validation and Prioritization

• Process:
  • Molecular Docking: If the XAI hypothesis involves a specific protein target, perform molecular docking simulations of the natural product with the target's 3D structure (from PDB or AlphaFold prediction) to assess binding feasibility [60].
  • Pathway Enrichment Analysis: If the hypothesis involves a pathway, cross-reference the implicated genes/proteins with disease-specific omics data (e.g., RNA-seq from public repositories) to confirm pathway dysregulation.
• Output: A refined, prioritized shortlist of candidates with stronger in silico support.

Step 3: Targeted Experimental Validation This phase tests the specific mechanism proposed by the XAI explanation.

• Assay Design: Design experiments based directly on the XAI output.
  • If a specific target is implicated: Perform a biochemical binding assay (e.g., SPR, FRET) or a cellular target engagement assay (e.g., CETSA) to confirm direct interaction.
  • If a pathway is implicated: Use phospho-specific flow cytometry or western blotting to measure changes in key pathway nodes (phosphorylation, cleavage) after treatment with the natural product.
  • If a phenotypic effect is predicted: Conduct a cell-based viability assay (e.g., in a relevant cancer cell line) or a high-content imaging assay to capture complex phenotypic signatures [59].
• Controls: Include negative controls (structurally similar but inactive compounds) and positive controls (known modulators of the target/pathway). Crucially, test counterfactual examples suggested by the XAI (e.g., a synthetic analog lacking the key functional group highlighted by SHAP).

Step 4: Model Feedback and Iteration

• Process: The results from Step 3—both positive and negative—are formatted and fed back into the AI model's training data. This reinforces correct patterns and corrects erroneous associations, progressively closing the interpretability gap by aligning the model's reasoning with ground-truth biology.
• Output: An updated, more accurate, and more interpretable AI model for the next discovery cycle.

Diagram 2: Integrated XAI Hypothesis Validation Workflow

The Scientist's Toolkit: Essential Research Reagents and Materials

Validating XAI-driven hypotheses requires a combination of classical and modern research tools.

Table 4: Key Research Reagent Solutions for XAI Hypothesis Validation

Category / Reagent	Specific Example / Technology	Function in Validating XAI Insights
Target Engagement Assays	Cellular Thermal Shift Assay (CETSA), Surface Plasmon Resonance (SPR)	Directly tests if a natural product binds to the specific protein target implicated by an XAI KG path or counterfactual explanation.
Pathway Activity Assays	Phospho-specific flow cytometry (Cytometry by Time of Flight), Western Blot kits for key kinases/phospho-proteins.	Measures downstream signaling changes in a biological pathway (e.g., MAPK, PI3K) that an XAI model associated with the drug's mechanism.
Phenotypic Screening	High-content imaging (HCI) systems, 3D organoid or spheroid culture matrices.	Tests complex phenotypic predictions (e.g., inhibition of invasion) in a physiologically relevant model, validating holistic model outputs.
Molecular Probes & Inhibitors	Selective chemical inhibitors (positive controls), fluorescently labeled analogs of natural products.	Serves as controls in validation assays. A labeled analog can be used to visualize compound localization (e.g., microscropy), confirming target colocalization.
Omics Readouts	RNA-Seq kits, multiplexed proteomics panels (e.g., Olink), metabolomics kits.	Provides global molecular profiling to confirm that treatment with the natural product induces the expected genomic, proteomic, or metabolic changes suggested by the AI model's reasoning.
AI & XAI Software	SHAP/LIME libraries, graph database platforms (Neo4j), molecular visualization software (PyMOL).	The tools to generate and visualize the explanations themselves, and to analyze the resulting biological data for feedback into the AI model.

The future of AI-driven drug repositioning for natural products hinges on closing the interpretability gap. Emerging trends point toward several key developments:

• Inherently Interpretable Model Architectures: Research will focus on designing models that are powerful yet provide explanations by design, such as more transparent graph reasoning methods or self-explaining neural networks.
• Causal AI Integration: Moving beyond correlation, next-generation models will incorporate causal reasoning frameworks to distinguish spurious statistical associations from true cause-effect relationships, dramatically improving the biological plausibility of predictions [62].
• Standardized XAI Benchmarking: The field requires standardized benchmarks and metrics to evaluate not just an XAI method's technical performance, but the utility and verifiability of the biological insights it produces.
• Regulatory-XAI Frameworks: Collaborative development of guidelines between AI researchers, pharmaceutical scientists, and regulators (like the FDA and EMA) on the sufficient level of explainability required for AI-assisted drug development decisions [62].

In conclusion, AI presents an unprecedented opportunity to systematically mine the vast therapeutic potential of natural products for new disease indications. However, its transformative impact on drug repositioning will only be fully realized when predictions are coupled with clear, actionable biological explanations. By strategically deploying XAI methodologies—feature attribution, counterfactual analysis, and path reasoning—within a rigorous closed-loop validation workflow, researchers can transform the "black box" into a generator of testable scientific hypotheses. This synergy between computational prediction and experimental validation is the essential pathway to gaining true biological insight, accelerating the delivery of safe, effective repurposed therapies to patients.

The pursuit of new therapeutics is a high-stakes endeavor characterized by protracted timelines, exorbitant costs, and a daunting failure rate exceeding 90% between preclinical studies and market approval [67]. Drug repositioning—identifying new therapeutic uses for existing drugs or natural compounds—presents a compelling strategy to mitigate these challenges. By leveraging compounds with established safety profiles, repositioning can reduce development costs to approximately $300 million and shorten timelines to around 6 years, a fraction of the $2.3+ billion and 10–15 years required for de novo drug development [67] [68].

The integration of artificial intelligence (AI) and computational prediction with rigorous experimental validation is transforming this field. This convergence is particularly potent for natural products, which are chemically complex and historically under-explored in systematic drug discovery. AI-driven in silico methods can efficiently navigate the vast chemical and biological space of natural compounds, predicting promising targets and mechanisms. However, the ultimate measure of success remains in vitro and in vivo validation. This whitepaper provides a technical guide for researchers aiming to construct robust, reproducible pipelines that effectively bridge the gap between computational prediction and experimental validation, with a focused application on repositioning natural products.

Foundational Computational Methodologies for Prediction

The first pillar of a successful pipeline is the selection and application of robust computational methods. These approaches can be categorized based on their starting data and underlying principles.

Table 1: Core Computational Methodologies for Drug Repositioning

Methodology	Primary Principle	Key Tools/Techniques	Strengths	Key Limitations
Molecular Docking (Structure-Based)	Predicts binding pose and affinity of a ligand within a target protein's 3D structure [67] [69].	AutoDock, Glide, GROMACS (for MD) [69] [70].	High mechanistic insight; useful for novel targets.	Highly dependent on accurate protein structures; can miss allosteric sites [67].
QSAR & Pharmacophore Modeling (Ligand-Based)	Correlates molecular features with biological activity to predict new actives [67] [69].	DeepChem, OpenEye, pharmacophore mapping [69].	Effective when target structure is unknown; leverages known actives.	Requires significant bioactive compound data; limited to similar chemical space [69].
Machine Learning (ML) & Deep Learning (DL)	Learns complex patterns from multimodal data (structures, sequences, omics) to predict interactions [67] [71].	Graph Neural Networks, Transformer Models (e.g., for protein sequences), CNNs [67].	Handles high-dimensional data; can integrate diverse data types; high predictive power.	"Black box" nature; requires large, high-quality datasets; risk of overfitting [71] [72].
Network Pharmacology & Pathway Analysis	Models disease and drug action as perturbations within biological interaction networks [68].	Protein-protein interaction networks, signaling pathway databases.	Captures polypharmacology and systemic effects; good for complex diseases.	Network completeness and quality are limiting; validation is complex [68].

The evolution from early rule-based methods to contemporary AI-driven approaches is marked by a significant increase in predictive capability and scope. Modern pipelines often integrate multiple methodologies. For instance, a target-based approach might use AlphaFold to generate a protein structure [71], followed by molecular docking for virtual screening, and finally an ML model trained on ChEMBL bioactivity data to rank candidates by predicted affinity [73]. For natural products, which may have poorly characterized targets, drug-centric or network-based approaches are invaluable, as they can infer mechanism from similarity to known drugs or predicted perturbation of disease-associated pathways [68].

The Critical Step: Designing Definitive Experimental Validation

A computational prediction, regardless of its sophistication, remains a hypothesis until empirically verified. The design of the experimental validation protocol is therefore critical and must be tailored to the specific prediction.

Case Study Protocol: Validating a Natural Product as an RNA-Targeted Antiviral

The following detailed protocol is adapted from a successful study that computationally identified and experimentally validated riboflavin as a binder to conserved RNA structures in SARS-CoV-2 [74]. It serves as a template for validating predictions of natural products targeting nucleic acids or proteins.

Table 2: Experimental Protocol for In Vitro Antiviral Validation [74]

Step	Procedure & Specification	Purpose & Rationale
1. Candidate Preparation	Prepare stock solutions of the predicted natural product (e.g., riboflavin). Include a positive control (e.g., remdesivir) and a vehicle/negative control.	To ensure consistent compound bioavailability and establish a basis for efficacy comparison.
2. Cytotoxicity Assay (CC₅₀)	Seed adherent cells (e.g., Vero E6) in a 96-well plate. The next day, treat with serially diluted compound (e.g., 1 nM to 100 µM). After 48-72 hours, measure cell viability using MTT or CellTiter-Glo.	To determine the compound's cytotoxic concentration (CC₅₀) and establish a non-toxic dose range for antiviral testing.
3. Antiviral Efficacy Assay (IC₅₀)	Infect cells at a low multiplicity of infection (MOI=0.01). Simultaneously add serially diluted compound. After a set period (e.g., 48-72h), quantify viral replication via plaque assay, qRT-PCR for viral RNA, or immunofluorescence.	To determine the half-maximal inhibitory concentration (IC₅₀) and evaluate direct antiviral potency under non-cytotoxic conditions.
4. Time-of-Addition Study	Treat cells at different time points: pre-infection (e.g., -2h), during infection (0h), or post-infection (e.g., +2h). Use a single sub-cytotoxic concentration. Measure viral output.	To infer the stage of the viral life cycle inhibited (e.g., entry, replication, assembly), providing mechanistic insight.
5. Target Engagement Validation	Employ a Cellular Thermal Shift Assay (CETSA). Treat cells with the compound, heat them to denature proteins, and quantify the stabilization of the predicted target protein via western blot or mass spectrometry [70].	To confirm direct physical interaction between the compound and its predicted target in a physiologically relevant cellular environment.

Validating a Computationally Predicted Natural Product

Navigating the Challenge-Validation Gap

Despite advanced algorithms, a persistent gap exists between computational promise and clinical success. A critical analysis reveals several core challenges:

• Data Sparsity & Bias: Models are trained on existing datasets like ChEMBL (24.2 million bioactivity records) [73], which are heavily biased toward well-studied targets like kinases. Data for natural products or novel targets is sparse, leading to poor model generalizability [67] [73]. The "cold-start" problem—predicting interactions for completely new compounds or targets—remains significant.
• Physiological Relevance: Many in silico models predict affinity for an isolated target, failing to account for cellular permeability, metabolic stability, off-target effects, and the complexity of human physiology. As noted, if human-relevant responses are tested for the first time in the clinic, AI-designed drugs face the same failure rates as traditional ones [72].
• The Interpretability Black Box: Complex deep learning models often function as "black boxes," offering a prediction score without elucidating the structural or mechanistic rationale. This lack of interpretability hinders medicinal chemistry optimization and erodes trust for experimentalists and regulators [71] [72].

A Proposed Integrative Framework for Natural Product Repositioning

To bridge the gap, a systematic, iterative framework that tightly couples computation and experiment is essential. The following workflow diagram and description outline this integrative process.

An Integrative Silico-to-Vitro Workflow

Phase 1: AI-Driven Prioritization. The pipeline begins by ingesting multimodal data: the chemical structures of natural products (from libraries like Specs or in-house collections), disease-specific data (e.g., transcriptomics from patient samples), and comprehensive knowledge graphs of protein-protein and drug-target interactions [68]. An ensemble of computational methods—including network proximity analysis, structure-based docking (using AlphaFold models where needed), and ML classifiers—generates a ranked list of natural product-disease pairs with associated confidence metrics and a hypothesized mechanism of action (MOA).

Phase 2: Iterative Experimental Triage. Top predictions enter a tiered experimental funnel. Initial high-throughput in vitro phenotypic screens (e.g., in disease-relevant cell lines) confirm biological activity. Active compounds proceed to mechanistic deconvolution using techniques like CETSA for target engagement [70] or phosphoproteomics for pathway analysis. Crucially, the quantitative results from these experiments (IC₅₀, CC₅₀, target stabilization data) are fed back into the computational engine as new, high-quality labeled data. This feedback loop is the cornerstone of the framework, allowing for the continuous refinement of prediction models, turning them from static tools into adaptive learning systems that improve with every cycle.

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 3: Research Reagent Solutions for Silico-Vitro Pipelines

Tool/Reagent	Category	Primary Function in Pipeline	Key Consideration
AlphaFold/ RoseTTAFold	In Silico Structure Prediction	Provides high-accuracy 3D protein models for targets without crystal structures, enabling structure-based screening [71] [73].	Models may lack conformational dynamics or co-factor binding states important for function.
CETSA (Cellular Thermal Shift Assay)	In Vitro Target Engagement	Validates direct drug-target binding in live cells or tissues, bridging biochemical potency and cellular efficacy [70].	A gold-standard for confirming mechanism; can be coupled with mass spectrometry for proteome-wide off-target profiling.
ChEMBL / BindingDB	Bioactivity Database	Provides millions of curated bioactivity data points for training and benchmarking ML models and QSAR [73].	Data heterogeneity requires careful filtering (e.g., using confidence scores) to ensure quality for model training.
Primary Human Cells & Organoids	Physiological Model System	Offers a more physiologically relevant in vitro environment than immortalized cell lines, capturing human genetic diversity and tissue context [72].	Critical for assessing human-specific responses and translational potential early in validation.
Graph Neural Networks (GNNs)	AI/ML Algorithm	Excellently suited for modeling molecules (as graphs of atoms/bonds) and biological networks, predicting properties and interactions [67] [70].	Requires expertise in implementation; interpretability tools (e.g., attention maps) are needed to guide chemists.

Bridging the silico to vitro gap is not a one-time transaction but requires the establishment of a continuous, iterative dialogue between prediction and experiment. For the promising field of natural product repositioning, this integrated approach is paramount. Future progress hinges on several frontiers: the generation of high-quality, standardized bioactivity data for under-explored compound classes; the development of explainable AI (XAI) that provides chemically and biologically intuitive rationales for its predictions [69]; and the wider adoption of functional human data—from primary cells and organoids—in both model training and validation cascades to enhance clinical translatability [72]. By architecting pipelines where every experimental result refines the computational intelligence and every prediction is stress-tested in biologically relevant systems, researchers can systematically transform the latent potential of natural products into novel, effective therapeutics.

The pursuit of novel therapeutics from natural products (NPs) represents a cornerstone of drug discovery, yielding compounds with unparalleled structural complexity and bioactivity [75]. However, the traditional development pathway is untenable, characterized by a 13-15 year timeline, costs exceeding $2.5 billion, and a failure rate of approximately 90% for candidates entering clinical trials [76]. Drug repositioning—identifying new therapeutic uses for existing drugs—offers a strategic bypass to these hurdles, reducing development time to 3-6 years and cost to roughly $300 million by leveraging established safety and pharmacokinetic profiles [6].

Artificial Intelligence (AI) serves as the catalyst transforming this field. By integrating multi-omics data, clinical records, and vast chemical libraries, AI models can predict novel drug-disease associations with increasing accuracy [77] [76]. For natural products, this is particularly potent. NPs often exhibit polypharmacology—acting on multiple targets—which aligns perfectly with the complex pathophysiology of many diseases but also complicates mechanistic understanding and raises the risk of drug-herb interactions (DHIs) [78] [75]. AI-driven repositioning of NP-derived compounds or NP-inspired molecules can thus unlock new therapeutic value while systematically de-risking development.

This technical guide details three foundational AI optimization strategies revolutionizing this space: the development of hybrid models that combine disparate data modalities and algorithmic approaches, the implementation of privacy-preserving federated learning to overcome critical data silos, and the application of advanced feature engineering to extract maximal signal from complex NP data. These strategies are not merely incremental improvements but are redefining the feasibility and scope of NP-based drug repositioning.

Hybrid AI Models: Integrating Knowledge for Superior Prediction

Hybrid AI models synergistically combine different computational techniques—such as knowledge graphs (KGs), deep learning (DL), and recommender systems (RS)—to overcome the limitations of any single approach. Their integrated architecture is essential for modeling the multifaceted nature of natural products, which possess intrinsic chemical attributes, exist within a rich biological context, and have sparse historical use data.

The Unified Knowledge-Enhanced Deep Learning Framework (UKEDR)

A state-of-the-art example is the Unified Knowledge-Enhanced deep learning framework for Drug Repositioning (UKEDR) [8]. UKEDR is explicitly designed to tackle two major challenges: the "cold-start" problem (predicting for new entities absent from training graphs) and the integration of relational knowledge with intrinsic attribute representations.

• Architecture & Workflow: The model operates through a multi-stage pipeline. First, a knowledge graph embedding module (using methods like PairRE) learns relational representations of drugs, diseases, and their known interactions by analyzing the graph's structure. In parallel, a pre-training module generates rich attribute representations: for drugs, the CReSS model uses molecular SMILES and carbon spectral data for contrastive learning; for diseases, DisBERT (a BioBERT model fine-tuned on 400,000+ disease descriptions) processes textual data. For a novel entity, a semantic similarity-driven embedding approach finds similar nodes in the pre-trained space to map it into the KG embedding space. Finally, an Attentional Factorization Machine (AFM) recommender system integrates these relational and attribute features. Unlike a simple dot product, the AFM uses attention mechanisms to weight feature interactions, dynamically learning which combinations are most predictive of a successful drug-disease association [8].

• Performance Superiority: As shown in Table 1, UKEDR's hybrid configuration demonstrates superior performance. In a realistic simulation predicting clinical trial outcomes from approved drug data, the PairRE_AFM configuration achieved an AUC of 0.95, representing a 39.3% improvement over the next-best baseline model [8]. Systematic ablation studies confirmed that the choice of recommender system (AFM) was the critical performance driver, not the specific KG embedding method, underscoring the value of sophisticated feature interaction modeling [8].

Table 1: Performance Comparison of UKEDR Against Baseline Models in Drug Repositioning [8]

Model Category	Example Model	Key Limitation Addressed by UKEDR	AUC (Benchmark)	Key Advantage of UKEDR
Classical ML	SVM, Random Forest	Struggles to capture biological mechanisms [8].	Lower (varies)	Integrates network biology and semantic attributes.
Network-Based	MBiRW, DeepDR	Difficulty fusing multiple network representations [8].	Moderate	Unified embedding of heterogeneous graphs and node attributes.
KG with GNN	DRHGCN, KGAT	Cannot handle "out-of-graph" cold-start entities [8].	High (e.g., ~0.68 for DRHGCN)	Uses pre-trained features & similarity mapping for novel entities.
UKEDR (Ours)	PairRE_AFM	N/A	0.95 (Superior)	Synergy of KG relations, pre-trained attributes, and attentive RS.

The following diagram illustrates the integrated data flow and core components of the UKEDR hybrid architecture.

UKEDR Hybrid Model Architecture and Data Flow

Application to Natural Product Complexity

For natural products, this hybrid approach is transformative. A compound's chemical scaffold (from SMILES) and spectral fingerprint can be encoded via pre-training, while its biological context—known targets, associated pathways, side effects—resides in the knowledge graph. The model can thereby reason about a novel NP by analogy, linking its intrinsic chemistry to relational knowledge of similar compounds, effectively addressing the data sparsity common in NP research [79] [75].

Federated Learning: Enabling Collaborative Model Training on Distributed Data

A paramount obstacle in AI-driven drug discovery is data access. The most valuable datasets are often proprietary, held in silos by pharmaceutical companies or research institutions, or are personal patient data protected by strict privacy regulations [80] [76]. Federated Learning (FL) provides a paradigm-shifting solution by enabling collaborative model training without centralizing the raw data.

The FLuID Framework: Federated Learning with Information Distillation

Traditional FL involves sharing model parameter updates, which can still pose privacy risks and communication bottlenecks. A advanced variant, Federated Learning using Information Distillation (FLuID), refines this approach [80]. In FLuID, participants train local models on their private data. Instead of sharing model weights, they generate soft labels (probability distributions) for a shared, public anchor dataset. These soft labels, which represent the distilled knowledge of each local model, are aggregated to form a consensus. A global model is then trained on the anchor dataset using these consensus labels. This method enhances privacy and reduces communication costs [80].

• Experimental Protocol & Validation: The FLuID methodology was validated in two key experiments [80]:
  • Public Data Simulation: Using public bioactivity data to simulate a virtual consortium, demonstrating the technical feasibility and performance parity with centralized training.
  • Real-World Collaboration: A deployment across eight pharmaceutical companies, each holding private compound screening data. The collaborative goal was to build a superior global model for biological activity prediction without any participant exposing their confidential structure-activity relationships.

The protocol involved: (a) Anchor Dataset Curation: Selecting a public, representative set of compounds and assays. (b) Local Training: Each partner trained a model (e.g., a graph neural network) on their private data. (c) Knowledge Distillation: Each partner inferred soft labels for the anchor dataset using their local model. (d) Secure Aggregation: Soft labels were encrypted and aggregated via a secure coordinator. (e) Global Model Training: A new model was trained on the anchor dataset with the aggregated soft labels as targets [80].

Table 2: Comparison of Federated Learning Strategies for Drug Discovery [80] [81] [76]

Strategy	Data Movement	Privacy Risk	Communication Cost	Key Challenge	Suitability for NP Research
Centralized Training	Raw data to central server	Very High	Low (once)	Legal, ethical, and security barriers.	Low. Impractical for proprietary NP libraries or patient data.
Traditional FL	Model parameter updates	Medium (via inversion attacks)	High (frequent updates)	Network overhead; heterogeneous data distributions.	Moderate. Useful for multi-institution NP bioactivity databases.
FL with Distillation (FLuID)	Only soft labels on public anchor set	Low (no raw data or gradients shared)	Low (one distillation step)	Designing a representative anchor dataset; domain shift.	High. Ideal for pooling NP data from companies, hospitals, and herbariums.

The workflow for the FLuID framework, highlighting the secure exchange of distilled knowledge instead of raw data, is depicted below.

FLuID Framework: Secure Knowledge Distillation Workflow

Implications for Natural Product Research

FLuID is exceptionally suited for NP repositioning. It allows:

• Mining Ethnopharmacological Data: Hospitals or traditional medicine practitioners can contribute data on herbal remedy outcomes without exposing patient records.
• Pooling Proprietary NP Libraries: Biotech and pharma companies can collaboratively improve prediction models for NP bioactivity without revealing their prized chemical assets [80] [81].
• Addressing Data Scarcity: By uniting disparate, small datasets (e.g., rare plant compound screenings), FL creates a statistically powerful "virtual" dataset, accelerating the discovery of repositioning candidates for rare diseases [6] [76].

Advanced Feature Engineering: Representing Molecular Complexity

The predictive power of any AI model is fundamentally constrained by the quality and informativeness of its input features. For natural products, advanced feature engineering is critical to capture their unique structural complexity, 3D conformation, and polypharmacological profiles.

Techniques for Molecular Representation

Moving beyond simple fingerprints (e.g., Morgan fingerprints), state-of-the-art approaches include:

• Graph Neural Networks (GNNs): Represent a molecule as a graph where atoms are nodes and bonds are edges. GNNs natively learn features that encode topology, functional groups, and electronic properties, which are crucial for predicting biological activity and ADMET properties [77] [76].
• 3D-Conformer Aware Features: The bioactivity of NPs is often dependent on their three-dimensional shape. Features derived from molecular dynamics simulations or distance matrices capture this spatial information, improving target binding predictions [79].
• Pre-Trained Molecular Language Models: Models like ChemBERTa are trained on millions of SMILES strings to learn a fundamental "chemical language." These models can generate context-aware, dense vector representations (embeddings) for any novel NP structure, encapsulating rich semantic chemical information [8] [76].
• Multi-Modal NP-Specific Features: For NPs, engineered features often integrate data from:
  • Biosynthetic Gene Clusters (BGCs): Genomic data predicting NP scaffolds from Non-Ribosomal Peptide Synthetase (NRPS) or Polyketide Synthase (PKS) pathways [79].
  • Spectroscopic Encodings: Representations derived from NMR or mass spectrometry data, linking chemical features directly to analytical fingerprints [8].
  • Network Pharmacology Profiles: Vectors indicating the predicted or known association of an NP with multiple protein targets and biological pathways, quantifying its polypharmacology [78].

Application in Repositioning Workflows

In a repositioning pipeline like UKEDR, these advanced features feed into both the pre-training and KG components [8]. A GNN-processed molecular graph provides the intrinsic drug attribute. Concurrently, the NP's known interactions (e.g., with cytochrome P450 enzymes from a DHI study [78]) become relationships in the knowledge graph. This dual representation allows the hybrid model to reason that a novel NP with a similar GNN embedding and similar KG neighborhood to a successful drug is a strong repositioning candidate.

The Scientist's Toolkit: Essential Research Reagent Solutions

Implementing the strategies above requires a suite of computational tools and data resources. The following toolkit outlines key components for building an AI-driven NP repositioning platform.

Table 3: Research Reagent Solutions for AI-Driven NP Repositioning

Tool / Resource Category	Specific Examples & Functions	Relevance to NP Repositioning
Federated Learning Platforms	Lifebit Federated Platform, Intel OpenFL, NVIDIA Clara. Provide the secure infrastructure to train models across distributed data silos without data movement [76].	Enables collaboration on proprietary NP libraries and sensitive clinical data associated with herbal medicine use.
Knowledge Graph Databases	Hetionet, DRKG, PrimeKG. Curated biomedical KGs integrating drugs, diseases, genes, and interactions. Serve as the foundational relational database for models like UKEDR [8].	Provides structured biological context for NP entities. Can be extended with NP-specific data from resources like LOTUS.
Molecular Representation Libraries	DeepChem, DGL-LifeSci, RDKit. Open-source libraries for converting molecules into features (graphs, fingerprints, 3D conformers) and building GNNs [77] [76].	Essential for creating advanced vector representations of complex NP structures for model input.
Pre-Trained Foundation Models	ChemBERTa (chemistry), BioBERT (biomedical text), ESM-2 (proteins). Offer powerful, transferable feature extractors fine-tuned for specific tasks [8] [76].	DisBERT (derived from BioBERT) exemplifies fine-tuning for disease understanding. Similar models can be built for NP descriptions.
Specialized NP Databases	LOTUS Initiative, NPASS, CMAUP. Provide curated data on NP structures, sources, and biological activities [75].	Critical for populating knowledge graphs with NP entities and for training/testing models on NP-specific tasks.
Interaction Prediction Tools	DeepDDS, SSI-DDI, XGBoost-based DHI predictors. Specialized models for predicting drug-drug or drug-herb interactions [78].	Key for de-risking NP repositioning candidates by flagging potential adverse pharmacokinetic or pharmacodynamic interactions early.

The integration of hybrid models, federated learning, and advanced feature engineering forms a robust technological triad poised to unlock the vast repositioning potential of natural products. By combining contextual knowledge with intrinsic molecular insights, preserving privacy to mobilize siloed data, and faithfully representing chemical complexity, these strategies address the core challenges in the field.

The future trajectory points toward even tighter integration:

• Federated Hybrid Models: Deploying architectures like UKEDR within a FLuID-like framework would allow collaborative training of the most powerful models on the most distributed, sensitive datasets.
• Explainable AI (XAI) for NP Mechanisms: As models grow more complex, developing methods to interpret their predictions—uncovering why an NP is predicted to work for a new disease—will be vital for gaining biological insights and guiding experimental validation [78].
• Generative AI for NP Analogs: Beyond repositioning existing NPs, generative models can design optimized NP-derived analogs with improved properties, creating a new pipeline from AI-designed molecules to repositioning candidates [77] [76].

The convergence of these advanced AI strategies is transforming drug repositioning from a serendipitous endeavor into a systematic, data-driven engineering discipline, with natural products standing as a richly rewarding substrate for discovery.

Proving the Paradigm: Validation Frameworks, Case Studies, and Platform Comparisons

The repositioning of natural products using artificial intelligence represents a transformative strategy to accelerate therapeutic development. This guide details the construction of an integrated validation pipeline that synergizes state-of-the-art computational metrics with mechanistically grounded experimental assays. Framed within AI-driven drug discovery, the pipeline ensures that AI-predicted candidates are rigorously vetted for both predictive accuracy and translational biological relevance [5]. We outline core computational performance indicators, detail essential functional and phenotypic validation protocols, and provide a framework for their systematic integration. This approach is designed to mitigate attrition by closing the gap between in silico prediction and in vitro/in vivo efficacy, a critical step for the successful application of AI in natural product-based drug repositioning [70].

The convergence of artificial intelligence (AI) and natural product research is revitalizing drug discovery. Natural products offer unparalleled chemical diversity and bioactivity, but their traditional development is plagued by challenges such as complex mixtures, undefined mechanisms, and batch variability [5]. AI, particularly machine learning (ML) and deep learning (DL), accelerates this process by predicting bioactivity, inferring mechanisms of action, and prioritizing candidates from vast chemical and genomic datasets [77]. The paradigm of drug repositioning—finding new therapeutic uses for existing compounds—is especially well-suited to this synergy, as it leverages known safety profiles to reduce development time and risk [8].

However, AI predictions necessitate robust validation to transition from algorithmic output to credible therapeutic hypothesis. Reliance solely on computational scores is insufficient; predictions must be anchored in empirical biological evidence [70]. This guide provides a structured framework for a multidimensional validation pipeline, combining rigorous computational evaluation with sequential experimental assays. This pipeline is essential to confirm target engagement, functional activity, and phenotypic impact, thereby building a compelling case for further development of repositioned natural products [5].

Core Computational Metrics & AI Validation

The initial phase of the pipeline involves quantifying the performance and reliability of the AI models used for candidate prediction and prioritization.

Key Performance Indicators (KPIs) for AI Models

Model performance must be evaluated using robust, domain-standard metrics. The following table summarizes the core computational metrics essential for validating AI-driven repositioning predictions.

Table 1: Core Computational Metrics for AI Model Validation in Drug Repositioning

Metric	Definition	Interpretation in Repositioning Context	Benchmark Target
Area Under the ROC Curve (AUC-ROC)	Measures the model's ability to distinguish between positive (active) and negative (inactive) compounds across all classification thresholds.	Evaluates the overall ranking capability of the model for identifying true drug-disease associations. An AUC > 0.9 indicates excellent discriminatory power [8].	> 0.85
Area Under the Precision-Recall Curve (AUC-PR)	Assesses the trade-off between precision (correct positive predictions) and recall (sensitivity) for identifying true positives.	Particularly informative for imbalanced datasets where known drug-disease pairs are rare. A high AUPR is critical for real-world feasibility [8].	> 0.80
Enrichment Factor (EF)	The ratio of true positive rate within a top-ranked fraction (e.g., top 1%) to the random hit rate.	Quantifies the hit enrichment capability of virtual screening models. A high EF indicates efficient prioritization of promising candidates from large libraries [70].	EF₁% > 20
Mean Absolute Error (MAE) / Root Mean Square Error (RMSE)	Measures the average magnitude of error between predicted and experimental values (e.g., binding affinity, IC₅₀).	Gauges the accuracy of regression models predicting continuous biological activity values. Lower values indicate higher predictive precision [77].	Context-dependent

Validating Model Robustness: Beyond Standard KPIs

To ensure real-world applicability, models must be tested under challenging conditions:

• Cold-Start Evaluation: Testing the model's performance on drugs or diseases absent from the training data. This simulates the discovery of novel repositioning opportunities. Advanced frameworks like UKEDR use semantic similarity and pre-training to address this challenge [8].
• Robustness on Imbalanced Data: Natural product datasets are often small and imbalanced. Metrics like AUC-PR and stratified sampling are crucial to evaluate performance fairly [5].
• Applicability Domain Analysis: Determining the chemical/biological space where the model's predictions are reliable. This gates predictions and prevents over-extrapolation [5].

The following workflow diagram illustrates the sequential process of computational AI validation and its connection to downstream experimental triage.

Diagram 1: AI Model Validation & Candidate Prioritization Workflow (77 characters)

Essential Experimental Assays for Mechanistic Validation

Computationally prioritized candidates must undergo empirical validation. A tiered experimental strategy progresses from confirming direct target interaction to observing phenotypic outcomes in relevant biological systems.

Target Engagement & Binding Assays

This first experimental tier confirms the physical interaction between the natural product and its predicted macromolecular target.

• Cellular Thermal Shift Assay (CETSA): A cornerstone for validating target engagement in physiologically relevant environments. CETSA measures the thermal stabilization of a target protein upon ligand binding in intact cells or tissue lysates, confirming binding in a cellular context [70].
  • Protocol Outline: Cells are treated with the natural product or vehicle, heated to discrete temperatures, and lysed. Soluble protein is quantified via Western blot or mass spectrometry. A rightward shift in the protein's thermal melting curve (increased Tₘ) confirms engagement [70].
  • Recent Application: Mazur et al. (2024) applied CETSA coupled with high-resolution MS to quantitatively map drug-target engagement of DPP9 in rat tissue, demonstrating dose-dependent stabilization ex vivo [70].
• Surface Plasmon Resonance (SPR): Provides kinetic binding parameters (K_D, k_on, k_off) for purified target proteins, offering precise biophysical characterization of the interaction [77].

Functional & Pathway Modulation Assays

Once binding is confirmed, assays must verify the functional consequence on the intended pathway.

• Transcriptomic Signature Reversal: A powerful multi-omics approach. The disease state is associated with a gene expression signature. A successful therapeutic candidate should reverse this signature toward a healthy state. AI is used to map natural product-induced gene expression changes against disease signatures [5].
  • Protocol Outline: Treat disease-relevant cell models (e.g., cancer, inflammation) with the candidate. Perform RNA-seq or use a targeted gene panel. Compute a reversal score (e.g., connectivity map score) to quantify the degree of signature normalization [5].
• Reporter Gene Assays: Used for pathways with well-characterized transcriptional responses (e.g., NF-κB, STAT). Cells transfected with a reporter construct (e.g., luciferase under a response element) are treated, and pathway modulation is quantified by reporter activity [77].

Phenotypic & Therapeutic Effect Assays

The final tier assesses the ultimate biological effect in more complex systems.

• Cell Viability & Proliferation Assays: Standard oncology models (e.g., MTT, CellTiter-Glo) to determine IC₅₀ values in target cancer vs. non-target cells [77].
• High-Content Imaging & Analysis: Measures complex phenotypic endpoints (e.g., cell morphology, organelle integrity, biomarker co-localization) in a high-throughput format, providing rich mechanistic data [5].
• Ex Vivo Tissue or Microphysiological System (MPS) Models: Moving beyond monocultures, patient-derived organoids or "organ-on-a-chip" MPS models provide a more physiologically relevant context for evaluating efficacy and safety, aligning with trends toward human-relevant models [5] [77].

Table 2: Tiered Experimental Validation Assay Suite

Validation Tier	Assay	Primary Readout	Information Gained	Key Consideration for Natural Products
Target Engagement	Cellular Thermal Shift Assay (CETSA)	Thermal stabilization (ΔTₘ) of target protein.	Confirms direct binding in a physiologically relevant cellular context [70].	Accounts for compound metabolism & cellular bioavailability.
Functional Activity	Transcriptomic Signature Reversal	Gene expression reversal score.	Confirms systems-level biological activity and mechanism alignment [5].	Requires well-annotated disease signatures; handles complex mixtures well.
Functional Activity	Reporter Gene Assay	Luminescence/Fluorescence of pathway-specific reporter.	Quantifies modulation of a specific signaling pathway.	May oversimplify complex natural product mechanisms.
Phenotypic Effect	High-Content Screening (HCS)	Multiparametric image-based features (morphology, biomarkers).	Reveals complex phenotypic outcomes and potential off-target effects.	Ideal for characterizing multi-target or synergistic actions.
Translational Relevance	Microphysiological System (MPS)	Functional outputs in a tissue/organ context.	Evaluates efficacy in a human-relevant, tissue-structured environment [5].	Can model complex tissue interactions affected by natural products.

The following diagram outlines the logical flow of the experimental validation cascade.

Diagram 2: Tiered Experimental Validation Cascade (55 characters)

Integrated Validation Pipeline Framework

The full power of the validation strategy is realized through the iterative integration of computational and experimental modules. This creates a closed-loop, learning pipeline where experimental results feed back to refine AI models.

The Iterative Design-Make-Test-Analyze (DMTA) Cycle

The pipeline operates as a continuous DMTA cycle [70]:

• Design: AI models rank natural products or derivatives for repositioning.
• Make: Selected candidates are sourced or synthesized.
• Test: Candidates undergo the tiered experimental validation cascade.
• Analyze: Experimental results (both positive and negative) are analyzed and used to retrain and improve the AI models, enhancing future prediction rounds.

This integration is critical for addressing common AI challenges in natural product research, such as small datasets and domain shift, by continuously generating high-quality, mechanism-anchored training data [5].

Decision Gates and Go/No-Go Criteria

The pipeline incorporates clear decision points to ensure resource efficiency:

• Gate 1 (Computational): Does the candidate meet minimum computational performance thresholds (AUC, Enrichment Factor)? No-go leads to model refinement.
• Gate 2 (Binding/Engagement): Does the candidate demonstrate direct, dose-dependent target engagement in cells (e.g., via CETSA)? No-go may indicate a false positive prediction or prodrug requirement.
• Gate 3 (Functional/Phenotypic): Does the candidate elicit the desired functional and phenotypic effect in relevant models? Go decisions here justify progression to advanced in vivo studies.

The following diagram synthesizes the complete integrated validation pipeline.

Diagram 3: Integrated AI-Experimental Validation Pipeline (66 characters)

The Scientist's Toolkit: Essential Research Reagents & Materials

Successful execution of the validation pipeline requires access to key biological and chemical resources. The following table details essential research reagent solutions.

Table 3: Key Research Reagent Solutions for Validation Experiments

Reagent/Material	Primary Function in Validation	Application Example	Critical Considerations
Physiologically Relevant Cell Lines	Provide the cellular context for target engagement and functional assays.	Primary cells, patient-derived cells, or engineered cell lines with disease-specific phenotypes (e.g., specific oncogenes, inflammatory markers).	Ensure relevance to the disease pathology and express the putative target.
CETSA-Compatible Antibodies or MS Platforms	Detect and quantify target protein stabilization in cellular thermal shift assays.	Validated antibodies for Western blot or HR-MS setups for proteome-wide engagement screening [70].	Antibody specificity is paramount. MS offers an untargeted discovery approach.
Multi-Omics Profiling Kits	Enable transcriptomic, proteomic, or metabolomic readouts for functional signature analysis.	RNA-seq library prep kits, multiplexed protein detection (e.g., Olink, Luminex), or mass spectrometry-based metabolomics kits.	Choose platform based on required depth (discovery vs. targeted) and sample throughput.
Validated Disease Signature Gene Sets	Provide the reference for transcriptomic reversal analysis.	Publicly available signatures from databases like MSigDB or internally generated from well-controlled disease model studies.	Signature robustness and contextual relevance to the experimental model are crucial.
High-Content Imaging Reagents	Enable multiplexed, phenotypic readouts in complex assays.	Multiplex fluorescent antibody panels, viability dyes, and organelle-specific fluorescent probes.	Optimization of multiplex panels to avoid spectral overlap and cytotoxicity.
Microphysiological System (MPS) Platforms	Provide a human-relevant, tissue-structured environment for translational validation.	Commercially available organ-on-a-chip systems (e.g., for liver, tumor microenvironment, blood-brain barrier).	Model fidelity and ability to incorporate key cell types of the disease niche [5].

Drug repositioning—identifying new therapeutic applications for existing drugs or compounds—presents a strategic pathway to accelerate the availability of treatments, particularly for complex, multifactorial diseases [6]. This approach leverages established safety and pharmacokinetic profiles, significantly reducing development timelines from an average of 13 years for de novo drugs to approximately 3-6 years for repurposed candidates, while cutting costs from ~$2.6 billion to around $300 million [71] [6]. Natural products (NPs), with their unparalleled chemical diversity and proven historical success in drug discovery, are exceptionally rich yet underutilized sources for repositioning [82]. However, their complex structures and polypharmacology have traditionally made systematic analysis challenging.

Artificial Intelligence (AI) and Machine Learning (ML) have emerged as transformative technologies capable of deconvoluting this complexity [5]. By integrating and analyzing massive, multi-modal datasets—including genomics, transcriptomics, proteomics, clinical records, and vast chemical libraries—AI models can predict novel bioactivities, infer mechanisms of action, and prioritize NP candidates for experimental validation with unprecedented speed and accuracy [83] [84]. This synergy is creating a new paradigm in pharmacognosy, moving from serendipitous discovery to rational, data-driven prediction and validation.

Core AI/ML Methodologies in NP Repositioning

The AI-driven repositioning pipeline employs a suite of complementary computational techniques. Supervised ML models, such as Random Forests and Support Vector Machines, are trained on labeled datasets to predict quantitative structure-activity relationships (QSAR), bioactivity, and ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties [77] [6]. Deep Learning (DL) architectures, including Convolutional Neural Networks (CNNs) and Graph Neural Networks (GNNs), excel at processing high-dimensional data like molecular graphs, spectroscopic data, and histopathology images to extract latent features and predict complex biological interactions [5] [82].

Generative AI, particularly Generative Adversarial Networks (GANs) and Variational Autoencoders (VAEs), enables the de novo design of novel NP analogs or the optimization of lead compounds for improved potency and specificity [77]. Network-based approaches and knowledge graphs map complex relationships between diseases, biological pathways, drug targets, and compounds, identifying repositioning opportunities through topological analysis, such as network proximity mapping [5] [85]. Furthermore, Natural Language Processing (NLP) mines unstructured text from scientific literature and electronic health records (EHRs) to uncover hidden drug-disease associations and generate novel hypotheses [71] [85].

Table 1: Core AI/ML Techniques in Natural Product Repositioning

AI Category	Key Techniques	Primary Application in NP Repositioning	Example Output
Supervised ML	Random Forest, SVM, Gradient Boosting	QSAR modeling, ADMET prediction, binary activity classification	Prediction of IC50 for a NP against a new kinase target [77]
Deep Learning (DL)	CNN, GNN, RNN, Multilayer Perceptron	Image-based screening, molecular property prediction, complex pattern recognition	Identification of anti-cancer scaffolds from plant metabolite data [82]
Generative AI	GAN, VAE, Reinforcement Learning	De novo molecular design, lead optimization, scaffold hopping	Generation of novel flavonoid analogs with optimized binding affinity [77]
Network Pharmacology	Knowledge Graphs, Network Proximity, Random Walk	Polypharmacology prediction, mechanism inference, synergistic combination discovery	Proposing bumetanide for APOE4-carrier AD via transcriptomic reversal [85]
Natural Language Processing (NLP)	Transformer Models, Named Entity Recognition	Hypothesis generation from literature, cohort identification from EHRs	Identifying sildenafil as a candidate for AD via EHR mining [85]

Therapeutic Area 1: Oncology – Unlocking Targeted and Immunomodulatory Potential

Oncology drug development faces a formidable failure rate, with over 90% of candidates failing in clinical trials [83]. AI-driven repositioning of NPs is proving effective in identifying agents that target oncogenic signaling, induce immunogenic cell death, or modulate the tumor microenvironment (TME).

Case Study: Myricetin as a Dual PD-L1/IDO1 Immune Checkpoint Modulator

Myricetin, a common dietary flavonoid, was primarily known for its antioxidant properties. Through AI-powered network pharmacology and transcriptomic signature reversal, researchers identified its potential to modulate key immune evasion pathways [77]. Predictive models suggested simultaneous downregulation of PD-L1 and indoleamine 2,3-dioxygenase 1 (IDO1), two critical immunosuppressive nodes in the TME.

Experimental Validation Protocol:

• In silico Docking & Dynamics: Molecular docking simulations against the PD-L1 dimerization interface and IDO1 catalytic site predicted strong binding affinities. Molecular dynamics simulations confirmed stable interactions.
• In vitro Cell-Based Assays:
  • Culture: Human cancer cell lines (e.g., A549, MDA-MB-231) and IFN-γ-stimulated primary peripheral blood mononuclear cells (PBMCs).
  • Treatment: Cells treated with myricetin (0-100 µM) for 24-48 hours.
  • Readouts: Western blot and flow cytometry to quantify PD-L1 membrane expression. HPLC to measure kynurenine/tryptophan ratio as a proxy for IDO1 enzymatic activity. Co-culture assays of cancer cells with T-cells to measure T-cell proliferation and IFN-γ production.
• Mechanistic Confirmation: RNA-seq and phospho-protein arrays were used to validate the predicted inhibition of the JAK-STAT-IRF1 signaling axis, the upstream regulator of both PD-L1 and IDO1 [77].
• In vivo Validation: Syngeneic mouse tumor models (e.g., CT26 colon carcinoma) were treated with myricetin. Tumor growth was monitored, and flow cytometry of tumor-infiltrating lymphocytes quantified CD8+/Treg ratios, confirming restored anti-tumor immunity.

This work exemplifies how AI can reveal and validate polypharmacology, where a single NP modulates multiple synergistic targets within a disease network.

Case Study: AI-Driven Discovery of Novel STK33 Inhibitors from Natural Libraries

A separate AI-driven screen of natural compound libraries against a panel of serine/threonine kinases identified novel scaffolds inhibiting STK33, a kinase implicated in KRAS-mutant cancer survival [86]. The AI platform integrated public bioactivity data and patented chemical information to predict therapeutic patterns.

Key Experimental Workflow:

• Virtual Screening: A DL model screened over 1 million NP-like structures from the ZINC Natural Products library. Top hits were prioritized by predicted binding affinity and synthetic accessibility.
• Hit Validation: The lead compound Z29077885 (a novel NP-derived analog) demonstrated nanomolar inhibition of STK33 in enzymatic assays.
• Functional & Phenotypic Assays: In KRAS-mutant cancer cell lines, Z29077885 induced apoptosis and S-phase cell cycle arrest. Phospho-proteomics confirmed deactivation of the downstream STAT3 signaling pathway [86].
• In vivo Efficacy: In mouse xenograft models, treatment significantly reduced tumor volume and increased necrotic area within tumors, validating the AI prediction in vivo.

Table 2: Validated AI-Repurposed Natural Products in Oncology

Natural Product	Original Context / Known Activity	AI-Predicted New Indication & Target	Key Validation Results	Proposed Mechanism
Myricetin	Dietary flavonoid; antioxidant	Immune checkpoint modulation in solid tumors; PD-L1 & IDO1 [77]	↓ PD-L1 expression, ↓ IDO1 activity, ↑ T-cell proliferation in co-culture; suppressed tumor growth in vivo	Inhibition of JAK-STAT-IRF1 signaling axis
Z29077885 (NP-derived)	Novel scaffold from AI screen	KRAS-mutant cancers; STK33 kinase [86]	nM inhibition of STK33, induced apoptosis & S-phase arrest, deactivated STAT3; reduced xenograft growth	Direct ATP-competitive inhibition of STK33
Quercetin	Antioxidant, anti-inflammatory	Potentiator for chemotherapy/immunotherapy; modulates Nrf2, p53 [87]	Synergistic cytotoxicity with cisplatin in vitro; enhanced efficacy of anti-PD-1 therapy in murine models [87]	Modulation of oxidative stress and apoptosis pathways

Therapeutic Area 2: Neurodegeneration – Addressing Multifactorial Pathology

The rising prevalence of Alzheimer’s disease (AD) and other neurodegenerative disorders (NDDs), coupled with the high failure rate of novel drug candidates, has intensified the search for repurposed therapies [85]. AI excels here by connecting NPs to non-canonical, disease-relevant pathways beyond amyloid and tau.

Case Study: Bumetanide – From Diuretic to APOE4-Targeted AD Therapy

Bumetanide, a loop diuretic, was identified as a top repurposing candidate for AD through computational transcriptomic signature reversal [85]. AI models analyzed gene expression data from APOE ε4 carrier AD brains—the strongest genetic risk factor—and screened drug databases for compounds that could reverse this pathogenic signature to a healthy state.

Validation Protocol:

• Patient-Derived Cell Models: Induced pluripotent stem cell (iPSC)-derived neurons from APOE4-carrier AD patients and controls.
• Treatment & Phenotyping: Neurons treated with bumetanide at clinically relevant concentrations. Key readouts included:
  • Electrophysiology: Measures of neuronal hyperexcitability, a known APOE4 phenotype.
  • Biomarkers: ELISA for phospho-tau and secreted Aβ species.
  • Cell Viability: Assays for neurodegeneration.
• In vivo Validation: Transgenic APOE4-expressing mouse models were treated chronically with bumetanide. Behavioral tests (e.g., Morris water maze) assessed cognitive function, and post-mortem brain analysis quantified pathology and network activity.

This approach exemplifies genotype-directed repurposing, where AI pinpoints a drug effective for a specific, mechanistically defined patient subgroup.

AI-Enabled Screening of Real-World Data for Neuroprotective Agents

Network proximity mapping of large-scale biomedical knowledge graphs has linked approved drugs to NDD protein networks [85]. Concurrently, clinical trial emulation using EHRs has identified drugs associated with reduced AD incidence.

Key Methodology for EHR-Based Trial Emulation:

• Cohort Definition: Using the OneFlorida+ Clinical Research Network or similar EHR databases, researchers define a cohort of AD patients and matched controls [85].
• Exposure Definition: Identify patients with prior exposure to candidate repurposed drugs (e.g., antihypertensives, antidiabetics).
• Propensity Score Matching: To control for confounding factors (age, comorbidities, polypharmacy), patients are matched using propensity scores, simulating random assignment as in a randomized controlled trial (RCT) [85].
• Outcome Analysis: Compare the incidence or progression of AD between the matched drug-exposed and unexposed groups. This method identified telmisartan (an angiotensin receptor blocker) as disproportionately beneficial in African American populations at risk for AD [85].

Table 3: Validated AI-Repurposed Natural Products & Drugs in Neurodegeneration

Compound	Original Indication	AI-Predicted New Indication & Mechanism	Key Validation Results	Data Source / AI Method
Bumetanide	Loop diuretic (edema)	APOE4-genotype specific AD; reverses APOE4 transcriptomic signature [85]	Rescued neuronal hyperexcitability & pathology in APOE4 iPSC-neurons; improved cognition in APOE4 mouse models [85]	Transcriptomic reversal analysis
Telmisartan	Antihypertensive (ARB)	Alzheimer's disease risk reduction; neuroprotection & anti-inflammatory [85]	EHR analysis showed reduced AD incidence in exposed cohort; effect pronounced in African Americans [85]	EHR Mining & Mendelian Randomization
Sildenafil	Erectile dysfunction	Alzheimer's disease; reduces tau hyperphosphorylation [85]	Epidemiological studies from EHR data showed significant association with reduced AD incidence [85]	Large-scale EHR analysis & knowledge graphs

Therapeutic Area 3: Inflammation – Precision Immunomodulation

Chronic inflammatory diseases require precise modulation of immune pathways to avoid systemic immunosuppression. AI is identifying NPs that target specific inflammatory nodes or restore immune homeostasis.

Case Study: Epacadostat and Beyond – Targeting the IDO1-Tryptophan-Kynurenine Axis

While epacadostat (a synthetic IDO1 inhibitor) was initially developed for cancer, AI-driven multi-omics integration has highlighted its potential in autoimmune and chronic inflammatory conditions characterized by tryptophan depletion and kynurenine pathway activation [77]. AI models predicting downstream metabolic consequences of target inhibition can guide repositioning.

Experimental Validation in Inflammation Models:

• Animal Model of Autoimmunity: Use of the collagen-induced arthritis (CIA) mouse model or experimental autoimmune encephalomyelitis (EAEA) model for multiple sclerosis.
• Treatment: Oral administration of epacadostat or a NP-derived IDO1 inhibitor.
• Systemic & Local Readouts:
  • Plasma Metabolomics: LC-MS to quantify tryptophan and kynurenine levels, confirming target engagement.
  • Immune Profiling: Flow cytometry of lymph nodes/spleen to assess Th17/Treg balance.
  • Disease Scoring: Clinical arthritis scores or neurological deficit scores.
  • Histopathology: Analysis of joint or spinal cord inflammation and damage.

The Scientist's Toolkit: Essential Reagents for Validation

The experimental validation of AI predictions relies on a standardized toolkit of reagents and platforms.

Table 4: Research Reagent Solutions for Validating AI-NP Predictions

Reagent / Platform	Function in Validation Pipeline	Example Application
Patient-Derived iPSCs	Provides genetically relevant human cellular models for neurodegenerative & inflammatory diseases.	Differentiating APOE4 iPSCs into neurons to test bumetanide [85].
Phospho-Specific Antibody Panels (e.g., Phospho-kinase arrays)	Enables multiplexed profiling of signaling pathway activation to confirm AI-predicted mechanisms.	Validating STAT3 deactivation by STK33 inhibitor Z29077885 [86].
Recombinant Human Proteins & Enzymes	Essential for in vitro binding and enzymatic activity assays to confirm direct target engagement.	Testing direct inhibition of IDO1 or PD-L1/PD-1 interaction by myricetin [77].
Multiplex Cytokine/Chemokine Assays (Luminex, ELISA)	Quantifies secretome changes in immune co-cultures or treated patient cells, revealing immunomodulatory effects.	Profiling cytokine shifts in PBMC-cancer cell co-cultures treated with checkpoint modulators.
Syngeneic Mouse Tumor Models (e.g., CT26, MC38)	Immunocompetent in vivo models to study NP effects on tumor-immune system interactions.	Evaluating myricetin's effect on tumor-infiltrating lymphocytes [77].
LC-MS/MS Metabolomics Platforms	For target engagement (measuring substrate/product ratios) and discovering novel metabolic effects of NPs.	Measuring kynurenine/tryptophan ratio to confirm IDO1 inhibition [77].

Implementation Protocols: From Prediction to Bench Validation

Standardized Workflow for Experimental Validation

A rigorous, multi-tiered validation funnel is critical to translate AI predictions into credible drug candidates.

Phase 1: In silico Re-evaluation & Prioritization

• Step: Re-dock shortlisted NPs using higher-fidelity simulations (e.g., molecular dynamics). Apply ADMET prediction models to filter for drug-likeness and rule out predicted toxicity.
• Output: A final prioritized list of 3-5 lead candidates for in vitro testing.

Phase 2: In vitro Biochemical and Cellular Validation

• Step 1 – Target Engagement: Perform biochemical assays (e.g., enzymatic inhibition, binding displacement) with purified targets to confirm direct interaction and determine potency (IC50/Kd).
• Step 2 – Cellular Phenotype: Treat relevant disease cell models (primary cells or engineered lines). Measure phenotype reversal (e.g., reduced cytokine secretion, restored synaptic activity, decreased proliferation) and cell viability (CCK-8, MTT assay).
• Step 3 – Mechanism Confirmation: Use Western blot, qPCR, or RNA-seq to verify predicted changes in protein phosphorylation, gene expression, or pathway activity.

Phase 3: In vivo Proof-of-Concept

• Step: Administer lead NP to a validated animal disease model. Use pharmacokinetic analysis to guide dosing. Assess efficacy through disease-relevant behavioral, histological, or biochemical endpoints.
• Critical Control: Include a group treated with a standard-of-care drug for benchmark comparison.

Data Requirements & Curation for AI Model Training

The predictive power of AI models is fundamentally constrained by the quality, quantity, and relevance of training data. Key requirements include:

• Structured NP Databases: Databases like NuBBE and CAS Content Collection which curate chemical structures, sources, and associated bioactivities of NPs are indispensable [87].
• High-Quality Bioactivity Data: Experimental data (IC50, Ki, EC50) from peer-reviewed literature, standardized and annotated with standardized assay descriptions.
• Disease-Specific Omics Data: Public repositories like the Alzheimer's Disease Neuroimaging Initiative (ADNI) and The Cancer Genome Atlas (TCGA) provide essential genomic, transcriptomic, and proteomic data for building disease signatures [85] [84].
• Clinical and Real-World Data: De-identified EHRs and clinical trial data, accessible under ethical guidelines, are crucial for clinical outcome correlation and trial emulation studies [85].

Technical Challenges and Future Directions

Despite promising successes, significant technical hurdles remain. Data scarcity and imbalance for many rare NPs or disease subtypes limit model generalizability [5]. The "black-box" nature of complex DL models often obscures the rationale for a prediction, making mechanistic interpretation and regulatory acceptance difficult [84] [86]. Furthermore, experimental validation bottlenecks persist, as in silico predictions must still traverse the costly and time-consuming in vitro to in vivo pipeline [5].

Future progress hinges on several key advancements:

• Development of Federated Learning Frameworks: These allow AI models to be trained on distributed datasets across multiple institutions without sharing raw data, mitigating privacy concerns and aggregating larger, more diverse datasets [84].
• Adoption of Explainable AI (XAI) Techniques: Methods like SHAP (SHapley Additive exPlanations) and attention mechanisms are crucial to interpret model decisions, build trust, and generate testable biological hypotheses [5].
• Integration with Advanced Experimental Systems: Coupling AI predictions with high-content screening in organ-on-a-chip systems and 3D patient-derived organoids will provide more physiologically relevant validation platforms, improving translation predictability [5] [71].
• Prospective, Collaborative Validation Studies: The field requires more pre-competitive collaborations where AI groups prospectively predict NP activities, which are then blindly tested by independent laboratories to objectively assess performance and reproducibility [5].

The convergence of AI and natural product research is forging a powerful new engine for drug discovery. By systematically unlocking the latent therapeutic potential within nature's chemical treasury, this approach promises to deliver more effective, safer, and personalized treatments for some of medicine's most intractable diseases, from cancer and neurodegeneration to chronic inflammation.

Comparative Analysis of Leading AI Drug Discovery Platforms (e.g., Insilico Medicine, BenevolentAI, Exscientia)

The integration of artificial intelligence (AI) into pharmaceutical research has catalyzed a paradigm shift, transitioning from an experimental tool to a core driver of clinical-stage drug discovery and development [88]. Platforms developed by companies such as Insilico Medicine, BenevolentAI, and Exscientia exemplify this shift, employing distinct technological architectures—from generative chemistry and knowledge graphs to phenomics-first systems—to drastically compress development timelines and reduce costs [88] [89]. This analysis provides an in-depth, technical comparison of these leading platforms, with a specific focus on their methodologies, validated clinical outputs, and synergistic applicability to the drug repositioning of natural products. By deconstructing their core algorithms and experimental workflows, this guide aims to equip researchers and development professionals with a nuanced understanding of how AI is redefining the frontier of therapeutic discovery, offering a strategic framework for leveraging these technologies in the quest to unlock the latent therapeutic potential within natural product libraries.

The traditional drug discovery pipeline is notoriously protracted and capital-intensive, typically requiring over 10–15 years and more than $2.6 billion to bring a single new molecular entity to market, with a clinical success rate below 10% [90] [89]. AI promises to disrupt this model by augmenting human intuition with data-driven prediction and generation. The global market for AI in drug discovery, valued at approximately $1.94 billion in 2025, is projected to grow at a compound annual growth rate (CAGR) of 27%, underscoring the sector's rapid expansion and transformative potential [90].

AI-driven platforms compress the early discovery timeline from years to months. For instance, Insilico Medicine advanced a novel idiopathic pulmonary fibrosis candidate from target discovery to Phase I trials in just 18 months, a process that traditionally takes 4–6 years [88] [89]. Exscientia has reported in-silico design cycles that are ~70% faster and require tenfold fewer synthesized compounds than industry norms [88]. By 2025, AI is projected to generate between $350 billion and $410 billion annually for the pharmaceutical sector, primarily through efficiencies in discovery, development, and clinical trials [90].

• Thesis Context: Repositioning Natural Products with AI The repositioning of existing drugs and natural products presents a compelling strategy to bypass much of the early-stage risk, leveraging known safety and pharmacokinetic profiles for new therapeutic uses [6]. Natural products, with their immense structural diversity and historical validation in pharmacopeias, are a treasure trove for repositioning but are hindered by complexity, mixture variability, and incomplete mechanistic data [5]. AI is uniquely suited to overcome these barriers. Machine learning (ML) and deep learning (DL) models can predict the anticancer, anti-inflammatory, and antimicrobial activities of natural compounds, while network pharmacology models map complex herb–ingredient–target–pathway relationships to propose synergistic effects and novel indications [5]. This analysis will frame the comparative evaluation of leading AI platforms within this critical context, examining their specific utility and methodologies for unlocking the repositioning potential of natural products.

Comparative Analysis of Leading Platforms

The following table provides a high-level comparison of the core technologies, pipeline assets, and strategic approaches of three leading AI drug discovery companies, with a specific lens on their applicability to drug repositioning.

Table 1: Core Platform Comparison: Insilico Medicine, BenevolentAI, and Exscientia

Platform Feature	Insilico Medicine	BenevolentAI	Exscientia (post-Recursion merger)
Core AI Technology	End-to-end generative AI (PandaOmics, Chemistry42) [91] [92].	Proprietary Knowledge Graph & inference algorithms [88].	Centaur Chemist (Generative AI) integrated with Recursion's phenomics [88].
Primary Approach	Generative chemistry & target discovery from scratch [88].	Hypothesis generation from vast biomedical data for repositioning & novel discovery [88] [6].	Automated, patient-first precision design [88].
Key Repositioning Asset	AI-discovered novel molecules for new targets (e.g., INS018_055) [92].	Baricitinib for COVID-19 (validated repositioning) [92] [6].	AI-optimized designs of known pharmacophores for new indications.
Clinical-Stage Example	INS018_055 (IPF, Phase II); ISM3091 (solid tumors, Phase I) [88] [92].	Baricitinib (COVID-19, approved); BEN-34712 (ALS, Phase I) [88].	EXS-21546 (oncology, Phase I/II, halted); GTAEXS-617 (CDK7i, Phase I/II) [88].
Repositioning Workflow	De novo generation of novel chemical entities for AI-prioritized targets [88].	Analysis of >1B relationships in Knowledge Graph to identify non-obvious drug-disease links [92] [6].	Patient-derived tissue screening informs design/redesign for specific disease contexts [88].
Therapeutic Focus	Oncology, fibrosis, aging-related [91] [92].	Immunology, oncology, rare diseases [88].	Oncology, immunology (post-merger focus) [88].

Insilico Medicine: End-to-End Generative AI

Insilico's Pharma.AI platform is an integrated suite that connects biology (PandaOmics), chemistry (Chemistry42), and clinical trial analysis (InClinico) [91]. PandaOmics uses multi-omics data and natural language processing to identify and prioritize novel disease targets. For its lead asset, INS018_055, the platform identified a novel target regulating three fibrosis-related pathways (Wnt, YAP/TAZ, TGF-β) [92]. Chemistry42, a generative reinforcement learning system, then designs novel molecular structures optimized for the target. The platform's strength for natural product repositioning lies in its ability to generate novel, patentable molecular analogs inspired by natural product scaffolds, optimizing them for specificity and druggability.

BenevolentAI: Knowledge Graph-Driven Hypothesis Generation

BenevolentAI's platform centers on a massive, dynamically updated Knowledge Graph that encodes over a billion relationships between entities like genes, diseases, drugs, and biological pathways [92] [6]. Its flagship achievement was the repositioning of baricitinib, an approved JAK inhibitor for rheumatoid arthritis, as a treatment for hospitalized COVID-19 patients. The AI analyzed the virus's mechanism and identified baricitinib as a candidate with both anti-inflammatory and potential antiviral properties within 48 hours [92]. This network-based approach is exceptionally powerful for natural products, as it can infer mechanistic links between a product's complex polypharmacology and new disease networks, even with incomplete data.

Exscientia: Precision Design and Automated Synthesis

Exscientia pioneered the "Centaur Chemist" model, blending AI-driven generative design with human expert oversight [88]. Its platform designs molecules to meet a precise target product profile. A key differentiator is its patient-first biology approach, utilizing patient-derived tissue models to validate candidates early [88]. Following its 2024 merger with Recursion, Exscientia's automated chemistry platform is being integrated with Recursion's massive phenomic screening data—cell images analyzed by AI to detect disease-relevant morphological changes [88]. This creates a powerful closed loop for repositioning: AI can design molecular modifications to a known natural product derivative, which are then rapidly synthesized and tested for efficacy in highly specific disease models.

Methodological Workflows for AI-Driven Drug Repositioning

Knowledge Graph Construction & Analysis (BenevolentAI-like)

This protocol is foundational for generating repurposing hypotheses from existing data [88] [6].

• Data Aggregation: Ingest and harmonize structured and unstructured data from diverse sources: scientific literature (via NLP), genomics databases (e.g., GEO, TCGA), proteomics, clinical trial registries, and electronic health records.
• Entity-Relationship Modeling: Define a unified ontology. Extract entities (e.g., "curcumin," "NF-κB," "colorectal cancer") and relationships (e.g., "inhibits," "associated_with," "regulates") to build a massive, heterogeneous graph.
• Graph Mining & Inference: Apply network algorithms (e.g., random walk with restart, graph neural networks) to the Knowledge Graph. The goal is to identify non-obvious, shortest-path connections between a natural product (or its targets) and a disease module.
• Hypothesis Ranking: Score and rank predicted drug-disease pairs using metrics like network proximity, semantic similarity, and existing evidence strength. Top candidates, such as the link between baricitinib and COVID-19, proceed to validation [92].

AI-Drug Repositioning via Knowledge Graph

Generative Molecular Design & Optimization (Insilico Medicine-like)

This protocol details the generation of novel or optimized compounds for a repositioned target [88] [92].

• Target Profiling: Define the target (novel or known for new indication) and desired properties (potency, selectivity, ADMET).
• Model Initialization: Employ a generative model (e.g., a variational autoencoder or generative adversarial network) pre-trained on vast chemical libraries, potentially enriched with natural product-like scaffolds.
• Reinforcement Learning Cycle:
  • Generation: The AI proposes new molecular structures (SMILES strings).
  • Scoring: A predictor model (e.g., a random forest or graph neural network) scores the generated molecules against the target profile (e.g., binding affinity, solubility).
  • Feedback: The generator's parameters are updated via reinforcement learning to maximize the score of future proposals.
• Synthesis & Validation: Top-ranking virtual compounds are synthesized and tested in biochemical and phenotypic assays, closing the Design-Make-Test-Analyze (DMTA) loop.

Integrated Phenotypic Screening & Redesign (Exscientia/Recursion-like)

This protocol leverages high-content cellular data to validate and inform the redesign of compounds [88].

• Phenotypic Assay Development: Engineer disease-relevant cell models (e.g., patient-derived organoids, gene-edited lines).
• High-Throughput Imaging: Treat models with compounds (including natural products or libraries). Use automated microscopy to capture millions of cellular images.
• AI-Powered Phenomic Analysis: Process images with convolutional neural networks (CNNs) to extract quantitative morphological features ("phenomic fingerprints"). Train models to distinguish disease states and treatment effects.
• Hit-to-Lead Redesign: For active compounds, the AI analyzes structure-activity relationships (SAR) from the phenomic data. The generative design platform (e.g., Centaur Chemist) is used to design new analogs that enhance the desired phenotypic signature while improving chemical properties.

Phenotype-Driven AI Redesign Cycle

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 2: Key Reagent Solutions for AI-Driven Repositioning Experiments

Research Reagent / Material	Function in AI-Driven Workflow	Application Example
Curated Chemical Libraries	Provide the foundational data for training generative models and the physical compounds for validation screening.	Libraries enriched with natural product derivatives or FDA-approved drugs for repositioning screens [6].
Disease-Relevant Cell Lines & Primary Cells	Serve as the biological substrate for generating phenotypic data, the key output for training and validating AI models.	Patient-derived organoids used in Exscientia/Recursion's phenomics platform [88].
Multi-Omics Assay Kits (RNA-seq, Proteomics)	Generate the molecular profiling data used to build and validate network pharmacology models and identify novel targets.	Data input for platforms like Insilico's PandaOmics to discover disease pathways [92].
High-Content Imaging Systems	Automate the acquisition of cellular image data, which is transformed into quantitative features for phenotypic AI analysis.	Core to Recursion's platform, generating millions of images for CNN analysis [88].
Cloud Compute & Storage Infrastructure	Provides the scalable computational power required to train large AI models and store massive datasets (genomic, image, chemical).	Essential for running platforms like Lifebit's federated analysis or training large generative models [93].

Application to Natural Product Repositioning: A Strategic Framework

AI directly addresses the core challenges in natural product (NP) research: complex mixtures, elusive mechanisms, and data scarcity [5].

• From Mixtures to Mechanisms: Network pharmacology models can integrate data on an herb's multiple ingredients, predicting their combined effects on a disease-associated protein network. This helps transition from a traditional "black box" formulation to a mechanistic, polypharmacology model [5].
• Data Augmentation & Prediction: When experimental data on an NP is limited, self-supervised learning and transfer learning techniques can be used. Models pre-trained on vast synthetic chemical databases can be fine-tuned with smaller NP datasets to predict their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties and potential activity [5].
• Generating Optimized Analogs: The bioactivity of a natural compound can often be improved. Generative AI models can be used to design synthetic analogs that retain the core bioactive scaffold while optimizing for better potency, selectivity, or pharmacokinetic profiles, creating novel, patentable candidates inspired by nature [5].

Future Directions and Regulatory Considerations

The field is evolving toward more specialized, data-centric platforms. A key trend is the rise of federated learning, which allows AI models to be trained on decentralized datasets (e.g., across multiple hospitals) without moving sensitive patient data, thus addressing privacy and data sovereignty concerns [93] [94]. For natural products, this enables the secure integration of real-world clinical outcome data from traditional medicine use.

Regulatory guidance is catching up. The U.S. FDA is expected to release draft guidance on AI in drug development, emphasizing trustworthy AI, management of bias, data quality, and model validation [95]. A critical focus for researchers will be explainability—moving beyond "black box" predictions to provide transparent, evidence-based rationale for AI-generated hypotheses, which is essential for regulatory acceptance and scientific trust [94].

Intellectual property strategy remains complex, navigating between patenting novel AI-designed molecules and protecting the core AI models and training methods as trade secrets or through strategic patents [95]. As AI platforms become more integral to discovery, establishing clear governance for data, model deployment, and validation will be paramount for translating computational promise into clinical reality.

The process of discovering new therapeutic applications for existing drugs, known as drug repositioning or repurposing, represents a paradigm shift from traditional de novo drug discovery [31]. This strategy is particularly potent when applied to the vast and chemically diverse library of natural products—compounds derived from plants, microorganisms, and marine organisms—many of which have documented safety profiles from historical use but whose full therapeutic potential remains untapped [96]. Traditional repositioning methods, reliant on serendipitous clinical observation or low-throughput experimental screening, are slow and inefficient. The integration of Artificial Intelligence (AI) introduces a systematic, high-throughput capability to analyze complex biomedical data and predict novel drug-disease associations with unprecedented scale and speed [97] [6].

This whitepaper provides a rigorous, quantitative benchmarking of AI-driven methodologies against traditional approaches within the specific context of natural product repositioning. We dissect core performance metrics, detail experimental protocols for computational benchmarking, and provide a practical toolkit for researchers aiming to harness AI to unlock new value from nature's pharmacopeia.

Quantitative Performance Benchmarking

The superiority of AI-driven and computational repositioning strategies is demonstrable across key pharmaceutical development metrics: time, cost, success rate, and predictive accuracy.

Table 1: Macro-Level Benchmark: Traditional Discovery vs. Repositioning Pathways

Performance Metric	Traditional De Novo Discovery	General Drug Repositioning	AI-Accelerated Repositioning	Data Source
Average Timeline	10–15 years	6–9 years	Potentially 3–6 years [6]	[97] [31] [6]
Average Cost	~$2.6 billion	~$300 million	Significant reduction in R&D expenditure [6] [98]	[97] [6]
Clinical Success Rate	<10% from Phase I to approval	Higher, leveraging existing safety data	Enhanced by improved candidate selection [97] [31]	[97] [31]
Primary Advantage	Novel chemical entities	Reduced safety risk, known pharmacokinetics	High-throughput prediction, systematic analysis	[31] [6]
Key Challenge	High attrition, cost, time	Identifying novel mechanistic insights	Data quality, model interpretability, validation [97] [99]	[97] [99]

Table 2: Micro-Level Benchmark: Predictive Performance of Computational Platforms

Model / Platform	Core Methodology	Key Performance Metric	Reported Result	Benchmark Control	Context
CANDO v2 (Default Pipeline)	Bioanalytic docking (BANDOCK), interaction signature similarity [100]	Average Indication Accuracy (AIA) at Top10 cutoff	~12.8% (v1.5)	Random control: ~0.2% [100]	Measures accuracy in ranking known drugs for the same indication.
CANDO v2	As above	Top10 Accuracy for Melanoma (58 associated drugs)	39.6% (23/58 drugs)	Not explicitly stated	Example of indication-specific performance [100].
Network-Based Approaches	Random walks, heterogeneous graph mining [6]	Prediction accuracy for drug-disease associations	Varies by study; generally superior to random	Traditional similarity-based methods	Excels at integrating multi-omics data for novel prediction [6] [101].
Generative AI (e.g., GANs, VAEs)	De novo molecular generation & optimization [99]	Novel compound design success rate	Case study: Rentosertib (AI-designed drug reached clinical stages) [99]	Traditional medicinal chemistry	Reduces time for lead identification and optimization [99].

Table 3: Application-Specific Benchmark: Natural Product Repositioning Examples

Natural Product / Source	Original / Traditional Use	Repositioned Indication (Predicted/Validated)	AI/Computational Role	Experimental Validation & Key Metric	Source
Fuzheng Jiedu (FZJD) Granules	Traditional Chinese medicine formula	Reducing COVID-19 progression risk [96]	Computational screening identified bioactive compounds and mechanisms (e.g., NLRP3 inhibition).	Clinical observation: reduced severe illness in high-risk patients [96].	[96]
Eicosapentaenoic Acid (EPA)	Dietary supplement (Fish oil)	Broad-spectrum antiviral (Zika, Dengue, H1N1) [96]	Mechanism elucidated as viral envelope disruption.	In vitro IC50 for Zika virus: ~0.42 µM with low cytotoxicity [96].	[96]
Geraniol (Monoterpene)	Fragrance, flavoring agent	Multifunctional antifungal candidate [96]	SAR studies and computational modeling identified superior activity.	MIC against C. albicans: 1.25–5 mM; suppressed virulence factors & cytokines [96].	[96]
Marine Compounds (Naseseazine C, Wailupemycin H)	Marine natural products	Inhibiting drug-resistant Candida albicans [96]	Virtual screening & molecular docking identified Yck2 inhibition.	Low binding energies in simulation: -81.67 / -67.12 kcal/mol [96].	[96]

Methodologies and Experimental Protocols

Traditional Experimental Workflow

The conventional path for repositioning natural products begins with bioactivity-guided fractionation and in vitro screening against phenotypic or target-based assays. Hits undergo lead optimization through synthetic modification, followed by extensive in vivo pharmacokinetic and toxicology studies before clinical trials for the new indication [31]. This process, while reliable, is resource-intensive and low-throughput.

AI-Enhanced Computational Workflow

AI integrates multiple data streams to generate testable hypotheses. A standard pipeline involves: 1) Curating multi-omics data and chemical structures of natural products; 2) Using network algorithms or deep learning to predict drug-target or drug-disease associations; 3) Validating predictions via in silico docking or pathway analysis; 4) Prioritizing candidates for experimental testing [6] [101].

Protocol: Benchmarking a Repositioning Platform (CANDO v2 Example)

This protocol outlines steps to quantitatively evaluate a computational repositioning platform's performance [100].

1. Library Curation:

• Compound Library: Compile a structured database of natural products or approved drugs. Example: 2162 FDA-approved drugs from DrugBank [100].
• Protein Target Library: Assemble a non-redundant set of protein structures (e.g., 14,606 from PDB) to represent the proteome [100].
• Ground Truth Mapping: Establish known drug-indication pairs from databases like Comparative Toxicogenomics Database (CTD) as a benchmark [100].

2. Interaction Scoring & Signature Generation:

• For each compound, compute an interaction score against every protein target using a defined method (e.g., BANDOCK bioinformatic docking protocol) [100].
• Represent each compound by its proteome interaction signature—a vector of all interaction scores.

3. Similarity Calculation & Ranking:

• Calculate pairwise similarity between all compound signatures using a metric like root mean squared deviation (RMSD) or cosine distance [100].
• For each "query" compound, rank all other compounds from most to least similar based on their signature similarity.

4. Performance Evaluation (Benchmarking):

• For each indication in the ground truth:
  • Identify all associated compounds ("true set").
  • For each associated compound as the query, determine the rank of other compounds from the same true set.
  • Calculate indication accuracy: the percentage of query compounds that have at least one other true-set compound ranked above a defined cutoff (e.g., Top10, Top25).
• Compute the Average Indication Accuracy (AIA) across all indications as the primary platform performance metric [100].
• Compare AIA against a random control (empirically or theoretically modeled) to determine significance.

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Resources for AI-Driven Natural Product Repositioning

Category	Resource / Tool	Description & Function in Research	Example / Provider
Data Resources	Comparative Toxicogenomics Database (CTD)	Curates known chemical-gene-disease relationships to establish ground truth for benchmarking predictions [100].	http://ctdbase.org/
Data Resources	DrugBank	Comprehensive database containing biochemical, pharmacological, and structural information on drugs and natural products [100].	https://go.drugbank.com/
Data Resources	Protein Data Bank (PDB)	Repository of 3D structural data for proteins and nucleic acids, essential for structure-based prediction [100].	https://www.rcsb.org/
Software & Platforms	RDKit	Open-source cheminformatics toolkit for working with molecular fingerprints, descriptors, and similarity searching [100].	https://www.rdkit.org/
Software & Platforms	COACH	Meta-server for protein-ligand binding site prediction, used to guide docking simulations [100].	Integrated into computational pipelines.
Software & Platforms	AI Drug Discovery Platforms	Integrated software suites using ML/DL for target prediction, virtual screening, and de novo design.	Atomwise, BenevolentAI, Insilico Medicine [98] [102]
Computational Infrastructure	High-Performance Computing (HPC) / Cloud Computing	Essential for running large-scale molecular simulations, training deep learning models, and analyzing omics datasets [98] [99].	AWS, Google Cloud, Azure; on-premise clusters.
Validation Reagents	Pathway-Specific Cell-Based Assays	Used for in vitro validation of predicted mechanisms (e.g., anti-inflammatory, antifungal activity) [96].	Commercially available from vendors like Thermo Fisher, Abcam.
Validation Reagents	Recombinant Target Proteins	Purified proteins for in vitro binding or enzymatic activity assays to confirm predicted target engagement.	Recombinant expression or purchased from specialty biotech firms.

Regulatory and Ethical Considerations for AI-Discovered Repurposing Candidates

The integration of artificial intelligence (AI) into drug discovery represents a paradigm shift, offering a powerful strategy to overcome the notorious inefficiencies of traditional development—a process that typically requires over a decade and costs between $500 million to $2.6 billion per new chemical entity [6] [8]. Drug repositioning, the identification of new therapeutic uses for existing drugs or compounds, is particularly well-suited to AI acceleration. By leveraging known safety and pharmacokinetic profiles, repositioning can drastically reduce development timelines to an average of 6 years and lower costs to approximately $300 million [6]. Within this broader field, the repositioning of natural products presents a unique opportunity and challenge. Natural products, with their vast structural diversity and historical validation in traditional medicine, are a rich source for novel therapeutics [5]. However, their complex chemistry, mixture variability, and incomplete mechanistic data have traditionally hindered systematic exploitation [5].

AI and machine learning (ML) models are now being deployed to navigate this complexity. Techniques such as graph neural networks, knowledge graph mining, and self-supervised molecular embeddings can predict the anticancer, anti-inflammatory, and antimicrobial actions of natural compounds by analyzing multi-omics data and constructing intricate herb–ingredient–target–pathway networks [5] [8]. This AI-driven approach has successfully moved candidates from in silico prediction to in vitro validation, confirming its translational potential [5]. As of late 2024, over 75 AI-derived drug candidates have entered clinical stages, with several stemming from natural product research or repositioning efforts [88].

This transformative potential, however, is accompanied by significant regulatory and ethical complexities. Regulatory agencies worldwide are grappling with how to evaluate evidence generated by "black-box" algorithms, ensure model credibility, and govern adaptive AI systems used across the drug lifecycle [103] [104]. Ethically, the use of AI raises profound questions concerning data privacy, informed consent for data mining, algorithmic bias that may perpetuate health disparities, and the overall accountability for AI-driven decisions [105]. This whitepaper provides an in-depth analysis of these considerations, offering a technical guide for researchers and developers navigating the promising yet intricate landscape of AI-discovered repurposing candidates for natural products.

Table 1: Comparative Analysis of Traditional vs. AI-Aided Drug Repositioning

Aspect	Traditional Drug Development	AI-Aided Drug Repositioning
Average Timeline	10-15 years [6] [8]	~6 years (3 years minimum) [6]
Estimated Cost	$500M - $2.6B [6] [8]	~$300M [6]
Key Bottlenecks	High-throughput screening, serendipitous discovery, lengthy clinical trials	Data quality/availability, model interpretability, regulatory clarity [5] [6]
Success Rate	Low (<10%) [8]	Higher (leverages known safety profiles) [6]
Role of Natural Products	Challenging due to complexity and variability	Enabled by network pharmacology and multi-omics AI models [5]

Regulatory Considerations for AI-Generated Evidence

The regulatory landscape for AI in drug development is evolving rapidly, with agencies striving to balance innovation with robust oversight. A critical distinction is made between AI used for operational efficiency (e.g., drafting documents) and AI used to generate data that directly informs regulatory decisions on safety, efficacy, or quality—the latter being the focus of emerging guidelines [106] [107].

The U.S. FDA's Risk-Based Credibility Framework

In January 2025, the U.S. Food and Drug Administration (FDA) issued a draft guidance outlining a flexible, risk-based approach [106] [107]. Its core is a seven-step credibility assessment framework centered on the Context of Use (COU). The COU is a precise definition of the AI model's function in addressing a specific regulatory question (e.g., "predicting cardiac toxicity of a natural product derivative using in vitro assay data") [106] [104]. Credibility is defined as the trust in the model's output for that COU, established through evidence [107].

The framework tailors assessment stringency to model risk. Factors influencing risk include the impact of an erroneous output on patient safety or trial integrity, and the model's transparency [104]. For high-risk COUs—such as AI used as a primary endpoint in a pivotal trial or to replace a standard preclinical test—the FDA expects rigorous documentation. This includes detailed descriptions of data provenance (critical for variable natural products), model training, validation on independent datasets, and ongoing performance monitoring [106] [104]. The FDA encourages early engagement via existing pathways (e.g., IND, pre-submission meetings) to align on credibility evidence plans [107].

The European EMA's Structured, Risk-Tiered Approach

The European Medicines Agency (EMA) published a 2024 Reflection Paper advocating a more structured, tiered regulatory architecture [103]. It classifies AI applications by "high patient risk" and "high regulatory impact," applying stricter oversight to those affecting pivotal safety/efficacy decisions [103] [104].

A key EMA principle is the prohibition of continuous learning within a frozen AI model during an ongoing clinical trial to preserve evidence integrity. Model updates are permitted between studies or in the post-marketing phase but require re-validation [103]. Like the FDA, the EMA mandates comprehensive documentation, with a strong preference for interpretable models. When "black-box" models are used, sponsors must provide enhanced explainability metrics and justification [103]. The EMA offers early dialogue through its Innovation Task Force and Scientific Advice Working Party [103].

International Regulatory Perspectives

Other jurisdictions are developing nuanced approaches:

• Japan's PMDA: Introduced a Post-Approval Change Management Protocol (PACMP) for AI software. This allows predefined, validated algorithm updates post-approval without a full re-submission, facilitating continuous improvement [104].
• UK's MHRA: Operates a principles-based framework with an "AI Airlock" regulatory sandbox, allowing real-world testing of AI-as-a-Medical Device (AIaMD) under supervision to identify practical challenges [104].

These divergent approaches reflect broader institutional philosophies: the FDA's flexible, case-by-case model promotes innovation but can create uncertainty, while the EMA's structured rules offer predictability but may impose higher initial compliance burdens [103].

Table 2: Comparative Overview of Key Regulatory Frameworks

Agency	Core Document	Philosophy	Key Requirements	Unique Provisions
U.S. FDA	Draft Guidance (Jan 2025) [106] [107]	Risk-based, COU-driven, flexible	Credibility evidence tailored to model risk; Early engagement encouraged	Focus on total product lifecycle context; Seven-step assessment framework
EU EMA	Reflection Paper (2024) [103]	Structured, risk-tiered, precautionary	Data representativeness checks; Bias mitigation; Frozen models in trials	Prohibits incremental learning during a trial; Clear high-risk classification
Japan PMDA	Guidance on AI-SaMD (2023) [104]	Progressive, innovation-facilitating	Pre-specified change protocols for post-market updates	PACMP enables streamlined algorithm updates after approval
UK MHRA	Software & AI as Medical Device Framework [104]	Principles-based, pragmatic	Safety, efficacy, transparency, accountability	"AI Airlock" sandbox for controlled real-world testing

Regulatory Pathways for AI-Discovered Natural Products

For AI-discovered natural product repurposing candidates, regulatory strategy must account for two layers: the AI component and the natural product complexities. Sponsors should:

• Define the COU Early: Clearly articulate how the AI model is used (e.g., candidate prioritization, toxicity prediction) [106].
• Document Data Provenance: Given natural product batch variability, document sources, extraction methods, and chemical standardization data used to train the AI model [5].
• Plan for Explainability: Develop strategies to interpret AI predictions, which is crucial for establishing a biological rationale for repurposing a complex natural product [103] [104].
• Engage Regulators Proactively: Use qualified letter or pre-IND meetings to discuss the AI model's role and the required credibility evidence package [107].

Ethical Imperatives in AI-Driven Repositioning

The acceleration of drug discovery via AI introduces ethical challenges that must be addressed to ensure responsible innovation. An ethical framework based on autonomy, justice, non-maleficence, and beneficence provides a foundation for analysis [105].

Data Privacy, Consent, and Ownership

AI models for repositioning are trained on massive datasets, including genomic data, electronic health records, and published biomedical literature. A primary ethical concern is informed consent for data mining. Traditional broad consent forms may not cover the use of patient data for training complex AI models years later [105]. The ethical principle of autonomy requires transparent communication about how data will be used in AI systems. Instances where data sharing lacked clarity, such as certain partnerships between tech companies and health systems, have sparked controversy [105]. For natural products, this extends to the ethical sourcing and use of traditional knowledge associated with medicinal plants, requiring fair benefit-sharing frameworks [5].

Algorithmic Bias and Justice

AI models can perpetuate and amplify biases present in historical training data. If clinical trial data is predominantly from certain ethnic, gender, or age groups, the AI's predictions for drug repurposing may be less accurate or safe for underrepresented populations [103] [105]. This violates the principle of justice. Furthermore, bias can affect patient recruitment for trials of AI-predicted candidates, potentially excluding groups not well-represented in the training data [105]. Mitigating this requires proactive assessment of data representativeness, algorithmic auditing for disparate impact, and intentional diversification of training datasets [103] [105].

Transparency, Explainability, and Accountability

The "black-box" problem of some advanced AI models conflicts with the scientific and ethical need for understanding a drug's mechanism of action. The principle of non-maleficence (avoiding harm) necessitates that researchers and regulators can interrogate why an AI suggested a particular natural product for a new indication [105] [104]. Lack of explainability complicates liability assignment if a repurposed drug causes unexpected harm. Was it a flaw in the AI model, the input data, or the biological complexity? Developing explainable AI (XAI) techniques and maintaining rigorous human oversight throughout the development cycle are critical to establishing clear accountability [103] [104].

Dual-Track Validation and Safety

The drive for speed must not compromise safety. The tragic historical example of thalidomide underscores the risks of missing long-term or intergenerational toxicity [105]. An ethical dual-track verification mechanism is recommended: AI-generated predictions (e.g., of low toxicity) must be synchronously validated with traditional experimental methods, such as animal studies or advanced in vitro micro-physiological systems [105]. This hybrid approach balances the beneficence of accelerated development with the non-maleficence of thorough safety checking.

Experimental Protocols for Validating AI Predictions

Translating an AI-predicted repurposing hypothesis into a validated candidate requires a rigorous, multi-stage experimental workflow. Below is a detailed protocol inspired by leading AI platforms and recent methodological advances [88] [8].

Protocol:In SilicoPrediction and Prioritization Using a Unified Knowledge-Enhanced Framework

This protocol is based on the Unified Knowledge-Enhanced deep learning framework for Drug Repositioning (UKEDR), which integrates knowledge graphs and pre-trained models to address cold-start problems [8].

• Knowledge Graph Construction:
  • Data Curation: Integrate heterogeneous data into a knowledge graph. Entities include drugs/natural products (from databases like COCONUT, NPASS), diseases (from OMIM, MeSH), targets (from UniProt), pathways (from KEGG), and side effects (from SIDER). Relations include "binds-to," "indicates," "has-side-effect," and "associates-with" [8].
  • Entity Embedding: Use a knowledge graph embedding model (e.g., PairRE) to encode entities and relations into a continuous vector space, capturing semantic relationships [8].
• Attribute Representation Learning:
  • For Natural Products/Drugs: Employ a model like CReSS to generate feature representations from molecular SMILES strings or spectral data (e.g., carbon NMR) via contrastive learning [8].
  • For Diseases: Fine-tune a large language model (e.g., BioBERT) on a corpus of disease descriptions to create a specialized model (DisBERT) for generating deep semantic disease features [8].
• Cold-Start Handling for Novel Entities:
  • For a novel natural product not in the original graph, use its SMILES-derived attribute vector to find the k-most similar compounds in the pre-trained embedding space.
  • Map the novel entity into the knowledge graph embedding space by averaging the relational embeddings of its similar compounds [8].
• Prediction and Prioritization:
  • Integrate the relational (graph) and attribute embeddings for all drug-disease pairs.
  • Use an Attentional Factorization Machine (AFM) recommendation algorithm to model complex, non-linear interactions between the fused features and predict the probability of a therapeutic association [8].
  • Output a ranked list of repurposing candidates (e.g., Natural Product X -> Disease Y).

Protocol:In VitroandEx VivoValidation of Top Candidates

Following computational prioritization, top candidates undergo biological validation [5] [88].

• Mechanistic In Vitro Assays:
  • Target Engagement: For a predicted protein target, employ techniques like cellular thermal shift assay (CETSA) or surface plasmon resonance (SPR) to confirm direct binding of the natural product compound.
  • Functional Phenotypic Screening: Use disease-relevant cell lines (e.g., cancer, fibroblasts for fibrosis) to assess functional endpoints (e.g., cell viability, cytokine secretion, collagen production). AI platforms like Recursion use high-content imaging and automated analysis for this step [88].
  • Pathway Analysis: Treat cells with the candidate and perform RNA-seq or phospho-proteomics to verify modulation of the predicted signaling pathways [5].
• Ex Vivo Patient-Derived Models:
  • Tissue Sampling: Culture patient-derived organoids or primary cells (e.g., from tumor biopsies or diseased tissue).
  • Treatment and Readout: Expose these models to the candidate compound. Platforms like Exscientia's (acquired by Allcyte) use high-content phenotypic screening on patient-derived samples to assess efficacy in a more physiologically relevant context [88].

Protocol:In VivoPreclinical Validation with Digital Twin Component

This incorporates a "digital twin" element for experimental refinement [103].

• Traditional Animal Study Arm:
  • Conduct standard efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies in a relevant animal disease model.
  • Collect multi-omics data (transcriptomics, metabolomics) from treated versus control animals.
• Digital Twin Simulation Arm (Parallel):
  • Model Building: Develop a computational model (digital twin) of the animal physiology and disease progression, calibrated with historical control data.
  • In Silico Trial: Run virtual simulations of the treatment protocol on the digital twin cohort to predict outcomes.
  • Analysis: Compare predictions from the digital twin with results from the physical animal study. Significant discrepancies trigger model refinement and can highlight unanticipated biological effects [103].

Diagram 1: Regulatory Evaluation Workflow for an AI Model Supporting a Repositioning Candidate. This diagram outlines the key steps from model development through regulatory submission, highlighting decision points for engagement with different agencies.

The Scientist's Toolkit: Essential Research Reagents & Platforms

Table 3: Research Reagent Solutions for AI-Driven Natural Product Repositioning

Item / Resource	Function in Workflow	Key Characteristics & Examples
Knowledge Graph Databases	Provides structured, interconnected biological data for AI model training and inference.	DRKG (Drug Repurposing Knowledge Graph), Hetionet, PrimeKG. Custom graphs integrating natural product databases (NPASS, COCONUT) [8].
Pre-trained Molecular Models	Generates numerical representations (embeddings) of natural product structures for similarity search and feature input.	CReSS Model: For SMILES/spectral data [8]. ChemBERTa: Pre-trained on chemical literature.
Pre-trained Disease Models	Generates deep semantic representations of diseases from text for computational pairing with drugs.	DisBERT: BioBERT fine-tuned on disease descriptions [8].
AI Discovery Platforms	End-to-end or modular software for candidate identification, design, and prioritization.	Exscientia's Centaur Chemist: Generative design [88]. Insilico's PandaOmics: Target identification [88]. UKEDR Framework: For repositioning predictions [8].
Multi-Omics Data Suites	Provides validation data for AI predictions and feeds back into model refinement.	Transcriptomics (RNA-seq), Proteomics (mass spectrometry), Metabolomics (feature-based molecular networking) [5].
Digital Twin Software	Creates computational models of disease or trial populations for simulation and analysis.	Used in clinical trial design to simulate control arms or predict patient stratification [103].
High-Content Phenotypic Screening Systems	Validates AI predictions in biologically complex, disease-relevant cellular systems.	Recursion's Phenomics: Automated imaging and ML-based analysis of cell paintings [88]. Patient-derived organoid platforms.

The integration of AI into natural product repositioning is a powerful convergence poised to accelerate the delivery of new therapies. However, its sustainable progress hinges on navigating the intertwined regulatory and ethical landscapes. Regulators are moving toward risk-based, credibility-focused frameworks that require greater transparency and robust validation of AI-generated evidence [106] [103]. Ethically, the field must prioritize fairness, accountability, and patient autonomy by addressing data bias, ensuring explainability, and upholding rigorous dual-track safety validation [105].

Future developments will likely see increased regulatory convergence on core principles like Good Machine Learning Practice (GMLP), even as implementation details vary by region [104]. The adoption of adaptive licensing pathways and real-world evidence generated by AI-powered pharmacovigilance will further shape the lifecycle of repositioned drugs [103] [104]. For researchers, success will depend on proactive regulatory strategy, interdisciplinary collaboration (bridging data science, ethnopharmacology, and regulatory science), and a steadfast commitment to ethical principles that ensure these technological advances translate equitably into global public health benefits.

Diagram 2: Ethical Oversight Lifecycle for AI in Drug Repositioning. This diagram maps how abstract ethical principles are translated into concrete operational safeguards throughout the research and development process, culminating in the goal of responsible innovation.

Conclusion

The integration of AI with natural product research marks a paradigm shift in drug repurposing, offering a powerful strategy to rapidly identify new therapeutic uses for complex, biologically validated compounds. By leveraging methodologies from machine learning to knowledge graphs, researchers can overcome historical challenges of data scarcity and complexity. However, realizing the full translational potential requires overcoming persistent hurdles in data quality, model interpretability, and rigorous multi-stage validation. The future of this field lies in the deeper integration of multi-omics data, the adoption of explainable AI frameworks, and the development of standardized benchmarks. As AI platforms mature and generate clinical candidates, collaborative efforts between computational scientists, natural product chemists, and biologists are essential to translate in silico predictions into safe, effective, and accessible medicines, ultimately accelerating the drug development pipeline and addressing unmet medical needs[citation:1][citation:6][citation:8].

References

• 1. Plant-Derived Natural Products: A Source for Drug ... [https://www.mdpi.com/2813-2998/3/1/11]
• 2. Natural Products for Drug Discovery in the 21st Century [https://pmc.ncbi.nlm.nih.gov/articles/PMC6032166/]
• 3. Natural products in drug discovery: advances and ... [https://www.nature.com/articles/s41573-020-00114-z]
• 4. Natural products in drug discovery: advances and opportunities [https://pmc.ncbi.nlm.nih.gov/articles/PMC7841765/]
• 5. Artificial intelligence for natural product drug discovery and ... [https://www.sciencedirect.com/science/article/pii/S2666521225001206]
• 6. AΙ-Driven Drug Repurposing: Applications and Challenges [https://pmc.ncbi.nlm.nih.gov/articles/PMC12641654/]
• 7. Machine learning for drug repositioning: Recent advances ... [https://www.sciencedirect.com/science/article/pii/S2666246923000022]
• 8. A fused deep learning approach to transform drug ... [https://www.nature.com/articles/s42004-025-01712-x]
• 9. A foundation model for clinician-centered drug repurposing [https://www.nature.com/articles/s41591-024-03233-x]
• 10. Recent Advances in Drug Repurposing Using Machine ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8671152/]
• 11. The Challenge of Reproducibility and Accuracy in Nutrition ... [https://www.sciencedirect.com/science/article/pii/S2161831322006627]
• 12. Challenges of reproducible AI in biomedical data science [https://pmc.ncbi.nlm.nih.gov/articles/PMC11724458/]
• 13. Toward the future of scientific publishing through ... [https://apertureneuro.org/article/143700-toward-the-future-of-scientific-publishing-through-reproducible-research-artefacts-enabled-by-neurodesk]
• 14. Advances in machine learning for optimizing ... [https://www.sciencedirect.com/science/article/pii/S1570164625000153]
• 15. Drug Repurposing: An Overview [https://www.drugpatentwatch.com/blog/drug-repurposing-an-overview/?srsltid=AfmBOop-cMi58wVwP1PLQlDaHo62cbaiR6K6k4vpPsWeB0iIwk4mrCvO]
• 16. Drug Repositioning: One Molecule. Two Indications. Triple ... [https://www.drugpatentwatch.com/blog/drug-repositioning-mirror-patenting-surveying-mining-uncharted-territory/?srsltid=AfmBOopRUs5rZ9XJbsYu5uxUM44Y7dRTdkqhOHq8n2uVPSl7gzRmL2_F]
• 17. Therapeutic innovation in drug repurposing: Challenges ... [https://www.sciencedirect.com/science/article/pii/S1359644625001035]
• 18. From Lab to Clinic: Success Stories of Repurposed Drugs in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12535746/]
• 19. Editorial: Opportunities and challenges in drug repurposing [https://pmc.ncbi.nlm.nih.gov/articles/PMC12540431/]
• 20. Computational Drug Repurposing: Approaches and Case ... [https://www.drugpatentwatch.com/blog/computational-drug-repurposing-approaches-and-case-studies/?srsltid=AfmBOooEdoZTuqET-KO1OwjKspUv199cveaFQkR2MppqcSEIjdIeLKho]
• 21. Drug Repurposing Market Size to Hit USD 59.30 Billion ... [https://www.precedenceresearch.com/drug-repurposing-market]
• 22. Literature data-based de novo candidates for drug ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12317455/]
• 23. Empowering natural product science with AI: leveraging ... [https://pubs.rsc.org/en/content/articlehtml/2025/np/d4np00008k]
• 24. Drug Repurposing Market Size & Outlook, 2025-2033 [https://straitsresearch.com/report/drug-repurposing-market]
• 25. Drug Repurposing Market Report 2025 (Global Edition) [https://www.cognitivemarketresearch.com/drug-repurposing-market-report]
• 26. Computational Drug Repurposing: Approaches and Case ... [https://www.drugpatentwatch.com/blog/computational-drug-repurposing-approaches-and-case-studies/?srsltid=AfmBOooWUzerCv4rGj0P8iYdpmgO8yw5-nNh3kNdYnbrOA_s0iMt4FcV]
• 27. A review of computational drug repurposing - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC6989243/]
• 28. A structural perspective of drug-target-indication relationship ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7215100/]
• 29. Computational approaches streamlining drug discovery [https://www.nature.com/articles/s41586-023-05905-z]
• 30. Drug Repurposing Strategic Research Business Report 2025 [https://finance.yahoo.com/news/drug-repurposing-strategic-research-business-094900325.html]
• 31. Recent advances in drug repositioning and rediscovery for ... [https://link.springer.com/article/10.1007/s11030-025-11248-w]
• 32. Artificial intelligence for natural product drug discovery - PubMed [https://pubmed.ncbi.nlm.nih.gov/37697042/]
• 33. AI-driven drug discovery from natural products [https://www.sciencedirect.com/science/article/pii/S2773237124000522]
• 34. Repositioning Natural Products in Drug Discovery [https://www.mdpi.com/journal/molecules/special_issues/repositioning]
• 35. Drug discovery and mechanism prediction with explainable ... [https://www.nature.com/articles/s41598-024-83090-3]
• 36. Drug discovery and Graph Neural Networks (GNNs) [https://medium.com/@mulugetas/drug-discovery-and-graph-neural-networks-gnns-a-regression-example-fc738e0f11f3]
• 37. DeepDR: an integrated deep-learning model web server ... [https://arxiv.org/abs/2511.08921]
• 38. Network-based modeling of herb combinations in traditional ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8425426/]
• 39. Evaluating current status of network pharmacology for ... [https://www.sciencedirect.com/science/article/pii/S2090123224006180]
• 40. SmartGraph: a network pharmacology investigation platform [https://jcheminf.biomedcentral.com/articles/10.1186/s13321-020-0409-9]
• 41. HerbKG: Constructing a Herbal-Molecular Medicine ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9091197/]
• 42. VNP: Interactive Visual Network Pharmacology of Diseases ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4039393/]
• 43. Network pharmacology analysis and experimental ... [https://www.nature.com/articles/s41598-022-11139-2]
• 44. Network Understanding of Herb Medicine via Rapid ... [https://www.nature.com/articles/srep03719]
• 45. Strategies for Comprehensive Multi-Omics Integrative Data ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11592251/]
• 46. Multi-omics Data Integration, Interpretation, and Its Application [https://pmc.ncbi.nlm.nih.gov/articles/PMC7003173/]
• 47. Integrating Proteomics with Metabolomics: A Multi-Omics ... [https://www.metwarebio.com/integrating-proteomics-with-metabolomics-a-multi-omics-strategy-for-systems-biology/]
• 48. Metabolomics and transcriptomics based multi-omics ... [https://www.nature.com/articles/s41540-023-00305-5]
• 49. A Guide to Multi-omics Integration Strategies [https://frontlinegenomics.com/a-guide-to-multi-omics-integration-strategies/]
• 50. Approaches to Integrating Metabolomics and Multi-Omics ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8003953/]
• 51. Multi-view multi-level contrastive graph convolutional ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11789786/]
• 52. as an DeepDrug and AI driven drug repurposing... expert guided [https://pmc.ncbi.nlm.nih.gov/articles/PMC11735786/]
• 53. Best practices for solving the cold start problem in AI projects [https://xenoss.io/blog/cold-start-problem-ai-projects]
• 54. The cold-start problem in nascent AI strategy [https://www.sciencedirect.com/science/article/pii/S0148296323005957]
• 55. What is Overfitting in Deep Learning [+10 Ways to Avoid It] [https://www.v7labs.com/blog/overfitting]
• 56. Prevent overfitting and imbalanced data with Automated ML [https://learn.microsoft.com/en-us/azure/machine-learning/concept-manage-ml-pitfalls?view=azureml-api-2]
• 57. Overfitting Machine Learning: How to Protect AI Security ... [https://qohash.com/overfitting-machine-learning/]
• 58. Artificial Intelligence in Drug & Biological Product Development [https://ctti-clinicaltrials.org/2025-ai-in-drug-biological-product-development/]
• 59. The Application Prospects of AI Technology in Drug ... [https://ai.creative-biolabs.com/blog/the-application-prospects-of-ai-technology-in-drug-repurposing-and-repositioning/]
• 60. Artificial intelligence in drug discovery and development [https://link.springer.com/article/10.1007/s44395-025-00007-3]
• 61. Explainable Artificial Intelligence: A Perspective on Drug ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12472777/]
• 62. Making sense of AI: bias, trust and transparency in pharma ... [https://www.drugtargetreview.com/article/183358/making-sense-of-ai-bias-trust-and-transparency-in-pharma-rd/]
• 63. The Role of AI in Drug Discovery: Challenges, Opportunities ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10302890/]
• 64. The AI Catalyst: Transforming Drug Repurposing into a ... [https://www.drugpatentwatch.com/blog/the-role-of-artificial-intelligence-ai-and-machine-learning-ml-in-drug-repurposing/?srsltid=AfmBOor5e9IWiTCK95yDPju8RKnEUJDh_lUoPU6cbTcU1EW1fVPfAgPN]
• 65. Natural Products with Artificial Intelligence: A Revolution in ... [https://ijrpas.com/HTMLPaper.aspx?Journal=International%20Journal%20of%20Research%20in%20Pharmacy%20and%20Allied%20Science;PID=2025-4-1-5]
• 66. Artificial Intelligence-Based Methods for Drug Repurposing ... [https://www.mdpi.com/2076-3417/15/5/2798]
• 67. In silico methods for drug-target interaction prediction - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC12570315/]
• 68. Computational Drug Repurposing: Approaches and Case ... [https://www.drugpatentwatch.com/blog/computational-drug-repurposing-approaches-and-case-studies/?srsltid=AfmBOoqNdBqRJnEoPPJjp2Y_XXkjYYPieAy2xjwnVgS-WTS9CmYZf5KY]
• 69. opportunities for innovation in drug discovery - PubMed Central [https://pmc.ncbi.nlm.nih.gov/articles/PMC12641420/]
• 70. Top 5 Drug Discovery Trends 2025 Driving Breakthroughs [https://www.pelagobio.com/cetsa-drug-discovery-resources/blog/drug-discovery-trends-2025/]
• 71. Transformative Role of Artificial Intelligence in Drug ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12406033/]
• 72. The AI drug revolution needs a revolution [https://www.nature.com/articles/s44386-025-00013-6]
• 73. Navigating structure-based drug discovery with emerging ... [https://www.nature.com/articles/s44386-025-00031-4]
• 74. In silico screening and experimental validation identify ... [https://www.nature.com/articles/s41598-025-16949-8]
• 75. The latest advances with natural products in drug discovery ... [https://pubmed.ncbi.nlm.nih.gov/40391763/]
• 76. AI-Driven Drug Discovery: The Ultimate Guide 2025 [https://lifebit.ai/blog/ai-driven-drug-discovery-complete-guide/]
• 77. Integrating artificial intelligence into small molecule ... [https://www.nature.com/articles/s44386-025-00029-y]
• 78. Artificial Intelligence Models and Tools for the Assessment of Drug–Herb Interactions - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC11944892/]
• 79. Toward a unified pipeline for natural product discovery [https://pubs.rsc.org/en/content/articlelanding/2025/np/d5np00041f]
• 80. Data-driven federated learning in drug discovery with knowledge distillation | Nature Machine Intelligence [https://www.nature.com/articles/s42256-025-00991-2]
• 81. Pharma companies collaborate on secure data sharing for AI [https://www.nature.com/articles/d41591-025-00021-z]
• 82. Application of artificial intelligence in bioprospecting for ... [https://link.springer.com/article/10.1186/s44398-025-00004-7]
• 83. Exploring Artificial Intelligence's Potential to Enhance ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12582507/]
• 84. Artificial Intelligence in Cancer Drug Discovery in 2025 [https://oncodaily.com/oncolibrary/artificial-intelligence-in-cancer-drug-discovery]
• 85. Drug repurposing for Alzheimer's disease and other ... [https://www.nature.com/articles/s41467-025-56690-4]
• 86. Artificial Intelligence-Driven Innovations in Oncology Drug ... [https://www.dovepress.com/artificial-intelligence-driven-innovations-in-oncology-drug-discovery--peer-reviewed-fulltext-article-DDDT]
• 87. AI's emerging role in natural product drug discovery [https://www.cas.org/resources/cas-insights/ais-emerging-role-in-natural-product-drug-discovery]
• 88. Leading AI-Driven Drug Discovery Platforms [https://www.sciencedirect.com/science/article/abs/pii/S0031699725075118]
• 89. From Lab to Clinic: How Artificial Intelligence (AI) Is ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12298131/]
• 90. in Pharma and Biotech: Market AI and Beyond Trends 2025 [https://www.coherentsolutions.com/insights/artificial-intelligence-in-pharmaceuticals-and-biotechnology-current-trends-and-innovations]
• 91. 12 AI drug discovery companies you should know about [https://www.labiotech.eu/best-biotech/ai-drug-discovery-companies/]
• 92. Top 5 AIdesigned drugs in trials [https://www.futuremedicine.com/articles/top-5-ai-designed-drugs-in-trials]
• 93. The Complete Guide to Cloud AI Drug Discovery Platforms [https://lifebit.ai/blog/which-companies-offer-a-cloud-based-drug-discovery-platform-that-uses-artificial-intelligence/]
• 94. The State of Adopting AI in Drug in Discovery 2025 [https://chemaxon.com/blog/ai-in-drug-discovery]
• 95. in AI : Drug Outlook | Foley & Lardner LLP Discovery 2025 [https://www.foley.com/insights/publications/2024/12/ai-drug-discovery-2025-outlook/]
• 96. Natural Remedies Repositioned: Advancing Drug ... [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1655921/abstract]
• 97. Integrating artificial intelligence in drug discovery and early ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11909971/]
• 98. Artificial Intelligence in Drug Discovery Market to Hit USD ... [https://media.market.us/artificial-intelligence-in-drug-discovery-market-news-2025/]
• 99. Generative AI in Drug Discovery: Transforming Pharma R&D [https://www.delveinsight.com/blog/generative-ai-drug-discovery-market-impact]
• 100. Evaluating the performance of drug-repurposing technologies [https://pmc.ncbi.nlm.nih.gov/articles/PMC10014214/]
• 101. Application status of traditional computational methods and ... [https://www.sciencedirect.com/science/article/pii/S2950523224000149]
• 102. AI In Drug Repurposing Market Scope, Research Report ... [https://www.polarismarketresearch.com/industry-analysis/ai-in-drug-repurposing-market]
• 103. The future of AI regulation in drug development: a comparative ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12598624/]
• 104. Regulating the Use of AI in Drug Development: Legal ... [https://www.fdli.org/2025/07/regulating-the-use-of-ai-in-drug-development-legal-challenges-and-compliance-strategies/]
• 105. Exploring the ethical issues posed by AI and big data ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12581208/]
• 106. Considerations for the Use of Artificial Intelligence [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological]
• 107. Considerations for the Use of Artificial Intelligence To ... [https://www.federalregister.gov/documents/2025/01/07/2024-31542/considerations-for-the-use-of-artificial-intelligence-to-support-regulatory-decision-making-for-drug]